Heterocyclic compounds for use in the treatment of cancer - Patents.com

Heterocyclic compounds targeting Polθ inhibit microhomology-mediated end joining, addressing the challenge of cancer cell survival and therapy resistance by enhancing DNA damage sensitivity in tumors with impaired homologous recombination repair.

JP2024540912AInactive Publication Date: 2024-11-06ARTIOS PHARMA LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024523463
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-10-21
Filing Date
2022-10-21
Publication Date
2024-11-06
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current cancer treatments lack effective inhibitors for Polθ, a protein essential for the misrepair of DNA double-strand breaks in cancer cells, particularly in those with impaired homologous recombination repair, leading to increased reliance on error-prone microhomology-mediated end joining, which contributes to cancer progression and resistance to therapies.

Method used

Development of heterocyclic compounds that inhibit Polθ activity, disrupting the microhomology-mediated end joining pathway, thereby targeting and killing cancer cells with impaired homologous recombination repair.

Benefits of technology

The heterocyclic compounds effectively inhibit Polθ, sensitizing cancer cells to DNA damage, enhancing the efficacy of existing therapies and overcoming resistance, particularly in tumors with homologous recombination defects, thereby providing a novel therapeutic strategy for various cancer types.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024540912000001
    Figure 2024540912000001
  • Figure 2024540912000002
    Figure 2024540912000002
  • Figure 2024540912000003
    Figure 2024540912000003
Patent Text Reader

Abstract

The present invention relates to heterocyclic derivatives and their use in the treatment and prevention of cancer, as well as compositions containing said derivatives and methods for their preparation.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] FIELD OF THE INVENTION The present invention relates to heterocyclic derivatives and their use in the treatment and prevention of cancer, as well as compositions containing said derivatives and methods for their preparation. [Background technology]

[0002] BACKGROUND OF THE INVENTION Robust repair of DNA double-strand breaks (DSBs) is essential for maintaining genome stability and cell survival. DSBs can be repaired by one of three major pathways: homologous recombination (HR), non-homologous end joining (NHEJ), and alternative NHEJ (alt-NHEJ). Microhomology-mediated end joining (MMEJ) is the most well-characterized alt-NHEJ mechanism. HR-mediated repair is a high-fidelity mechanism essential for accurate and error-free repair, preventing genome stability that predisposes to cancer. Conversely, NHEJ and MMEJ are error-prone pathways that can leave mutational scars at the site of repair. MMEJ can function in parallel with both the HR and NHEJ pathways (Truong et al., PNAS 2013, 110(19), 7720-7725).

[0003] Unlike normal cells, the survival of cancer cells often depends on misregulation of DNA damage response (DDR) pathways. For example, increased reliance on one pathway (often mutagenic) to cope with either the inactivation of another pathway or the increased replication stress resulting from increased proliferation. Aberrant DDR can also sensitize cancer cells to specific types of DNA damage, and therefore, defective DDR can be exploited to develop targeted cancer therapies. Importantly, cancer cells with impaired or inactivated HR and NHEJ become overly dependent on MMEJ-mediated DNA repair. Genetic, cell biological, and biochemical data have identified Polθ (UniProtKB - O75417(DPOLQ_HUMAN)) as a key protein in MMEJ (Kent et al., Nature Structural & Molecular Biology (2015), 22(3), 230-237; Mateos-Gomez, Nature (2015), 518(7538), 254-257). Polθ is a multifunctional enzyme containing an N-terminal helicase domain (SF2 HEL308 type) and a C-terminal low-fidelity DNA polymerase domain (A type) (Wood and Doublie, DNA Repair (2016), 44, 22-32). Both domains have been shown to have coordinated mechanistic functions in MMEJ: the helicase domain mediates the removal of RPA proteins from the ssDNA ends and stimulates annealing, while the polymerase domain extends the ssDNA ends and fills the remaining gap.

[0004] Therefore, therapeutic inactivation of Pol θ would abolish the cellular ability to undergo MMEJ and provide a novel targeting strategy in various defined tumor contexts. First, Pol θ has been shown to be essential for the survival of HR-defective (HRD) cells (e.g., synthetic lethality due to FA / BRCA deficiency) and is upregulated in HRD tumor cell lines (Ceccaldi et al., Nature (2015), 518(7538), 258-262). In vivo studies have also shown that Pol θ is significantly overexpressed in a subset of HRD ovarian, uterine, and breast cancers and is associated with poor prognosis (Higgins et al., Oncotarget (2010), 1, 175-184; Lemee et al., PNAS (2010), 107(30), 13390-13395; Ceccaldi et al. (2015), supra). Importantly, Pol θ has been shown to be largely suppressed in normal tissues but upregulated in matched cancer samples, thus linking elevated expression with disease (Kawamura et al., International Journal of Cancer (2004), 109(1), 9-16). Second, its suppression or inhibition confers radiosensitivity in tumor cells. Finally, Pol θ inhibition may prevent the functional reversion of MMEJ-dependent BRCA2 mutations that underlie the emergence of cisplatin and PARPi resistance in tumors.

[0005] Therefore, there is a need to provide effective Pol θ inhibitors for the treatment of cancer. Summary of the Invention

[0006] (Summary of the Invention) According to a first aspect of the present invention, there is provided a compound of formula (I), or a tautomeric or stereochemically isomeric form, pharmaceutically acceptable salt, or solvate thereof: [ka] (In the formula: n represents an integer selected from 0, 1, 2, 3, or 4; R 1 is C 1-6 Alkyl, C 2-6 Alkenyl, C 1-6 Alkoxy, hydroxy, halogen, haloC 1-6 Alkyl, HaloC 1-6 Alkoxy, C 3-8 cycloalkyl, cyano, or -NR x R y represents; X is a bond or one or more C 1-6 Alkyl, NR x represents a C1-C6 alkylene group optionally substituted with an O, hydroxy, halogen, or CO group; R 2 is -ring A or -ring B -Y-ring C Does it represent a group? Or -XR 2 is -C1-C 12 Alkylene-NR x R y represents a group, wherein the alkylene group is one or more C 1-6 Alkyl, C 2-6 Alkenyl, -NR x , optionally substituted with O, hydroxy, or CO groups; ring A is -(CH2) m -CO-C 1-6 Alkyl, -(CH2) m -NHCO-C 1-6 Alkyl, -(CH2) m -CO-C 2-6 Alkenyl, -(CH2) m -NHCO-C 2-6 Alkenyl, -(CH2) m -CO-C 2-6 Alkynyl, or -(CH2) m -NHCO-C 2-6 represents a carbocyclyl, heterocyclyl, or heteroaryl requiring substituents selected from alkynyl groups, wherein the alkyl, alkenyl, or alkynyl group contains one or more (e.g., 1, 2, or 3) halogen, hydroxy, CO, or —NR x Ry and wherein the carbocyclyl, heterocyclyl, or heteroaryl group is optionally substituted by a halogen, C 1-6 Alkyl, hydroxy, C 1-6 Alkoxy, -CO-C 1-6 Alkyl, oxo, C 1-6 and optionally further substituted with one or more (e.g., one, two, or three) substituents selected from alkylamino, alkylamino, or cyano, wherein the C 1-6 The alkyl group may be optionally substituted with one or more halogen, hydroxy, or cyano groups; m represents an integer selected from 0, 1, 2, 3, or 4; ring B are each hydroxy, oxo, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, HaloC 1-6 Alkyl, -CO-C 1-6 represents carbocyclyl, heterocyclyl, or heteroaryl, which may be optionally substituted with one or more (e.g., 1, 2, or 3) substituents selected from alkyl, cyano, or halogen; ring C is a halogen, C 1-6 Alkyl, -CO-C 1-6 alkyl and / or -NR x R y optionally substituted by a -(CH2) group m -CO-C 2-6 represents heterocyclyl substituted by one or more (e.g., 1, 2, or 3) substituents selected from alkenyl; Y is a bond, -O-, -NHCO-, CO, or one or more C 1-6 Alkyl, C 2-6 Alkenyl, -NR x represents a C1-C6 alkylene group optionally substituted with an O, hydroxy, or CO group; R 3 is hydrogen or C 1-6 represents alkyl; R4 , R 5 , R 6 , and R 7 are independently hydrogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 1-6 Alkoxy, halogen, haloC 1-6 Alkyl, HaloC 1-6 Alkoxy, C 3-8 cycloalkyl, cyano, or -NR x R y represents; and R x and R y are independently hydrogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 represents alkoxy, or R x and R y are bonded together with the nitrogen atoms to which they are attached, forming one or more C 1-6 forming a nitrogen-containing heterocyclic ring which may be optionally substituted by alkyl groups). DETAILED DESCRIPTION OF THE INVENTION

[0007] (Detailed Description of the Invention) (definition) The term "halo" or "halogen" as used herein refers to fluorine, chlorine, bromine, or iodine.

[0008] The term "cyano" as used herein refers to a group in which a carbon atom is triple bonded to a nitrogen atom.

[0009] As used herein, "C" refers to a group or part of a group. 1-6 The term "alkyl" refers to a linear or branched saturated hydrocarbon group containing from 1 to 6 carbon atoms. Examples of such groups include methyl, ethyl, n-propyl, iso-propyl, butyl, iso-butyl, tert-butyl, pentyl, hexyl, and the like.

[0010] As used herein, "C" refers to a group or part of a group. 2-6The term "alkenyl" refers to a linear or branched unsaturated hydrocarbon group containing 2 to 6 carbon atoms and at least one double bond. Examples of such groups include ethenyl, propenyl, butenyl, pentenyl, hexenyl, and the like.

[0011] As used herein, "C" refers to a group or part of a group. 2-6 The term "alkynyl" refers to linear or branched hydrocarbon groups each having 2 to 6 carbon atoms and containing a carbon-carbon triple bond. Examples of such groups include C 3-4 Alkynyl or C 3-6 Alkynyl groups include, for example, ethynyl and 2-propynyl (propargyl) groups.

[0012] As used herein, "C" refers to a group or part of a group. 1-6 The term "alkoxy" refers to a C group containing an oxygen atom. 1-6 refers to an alkyl group, where C 1-6 Alkyl is as defined herein. Examples of such groups include methoxy, ethoxy, or propoxy.

[0013] As used herein, a "C-C" group or part of a group x The term "alkylene" refers to -(CH2) 1-x refers to a group. Examples of such groups include methylene, ethylene, propylene, and butylene.

[0014] As used herein, a "haloC" is a group or part of a group. 1-6 The term "alkyl" refers to a C alkyl group, as defined herein, in which one or more hydrogen atoms have been replaced with halogen. 1-6 It refers to an alkyl group. Therefore, "haloC" 1-6 The term "alkyl" refers to monohalo C 1-6 Contains alkyl and polyhalo C 1-6 There may be one, two, three or more hydrogen atoms replaced with halogen, thus the haloC 1-6Alkyl may have one, two, three or more halogens. Examples of such groups include fluoroethyl, fluoromethyl, trifluoromethyl, or trifluoroethyl.

[0015] As used herein, "C 3-8 The term "cycloalkyl" refers to a saturated monocyclic hydrocarbon ring of 3 to 8 carbon atoms. Examples of such groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, and the like.

[0016] As used herein, the term "oxo" refers to the group =O.

[0017] As used herein, the term "hydroxy" refers to the group -OH. The term "carbocyclyl" includes aromatic and non-aromatic ring systems containing only carbon and hydrogen (i.e., no heteroatoms). Carbocyclyl ring systems have 5 to 12 ring members, more usually 5 to 10 ring members. In one embodiment, carbocyclyl includes aryl rings, which refers to carbocyclyl aromatic groups including phenyl, naphthyl, indanyl, indenyl, and tetrahydronaphthyl groups. The term "aryl" encompasses polycyclic (e.g., bicyclic) ring systems in which one or more rings are non-aromatic, provided that at least one ring is aromatic. An example of a polycyclic (e.g., bicyclic) aryl group containing an aromatic ring and a non-aromatic ring is the indanyl group. In such polycyclic systems, groups may be attached by either the aromatic ring or the non-aromatic ring. One particular example of an aromatic carbocyclic ring system is phenyl.

[0018] In alternative embodiments, carbocyclyl includes non-aromatic carbocyclic groups as defined herein, such as cycloalkyl and cycloalkenyl groups, and spiro and bridged derivatives thereof. Particular examples of non-aromatic carbocyclic ring systems include cyclobutyl, cyclohexyl, 2,3-dihydro-1H-inden-2-yl, and bicyclo[1.1.1]pentan-1-yl.

[0019] The term "heteroaryl" as used herein refers to a monocyclic or bicyclic aromatic ring system containing, for example, 3 to 12 ring members. Each ring may contain up to five heteroatoms typically selected from nitrogen, sulfur, and oxygen. Specific examples of heteroaryl include imidazolyl, pyrazolyl, triazolyl, pyridinyl, pyrimidinyl, oxazolyl, and oxadiazolyl.

[0020] The term "heterocyclyl" as used herein refers to a monocyclic, bicyclic, or tricyclic non-aromatic, partially saturated, or fully saturated ring system containing, for example, 3 to 12 ring members. Each ring may contain up to five heteroatoms typically selected from nitrogen, sulfur, and oxygen. Particular examples of bicyclic or tricyclic heterocyclyls include monocyclic carbocyclic rings and monocyclic or bicyclic heterocyclic rings that can be fused to a heteroaromatic ring.

[0021] Specific examples of "heterocyclyl" include morpholine, piperidine (e.g., piperidin-1-yl, piperidin-2-yl, piperidin-3-yl, and piperidin-4-yl), piperidinone, pyrrolidine (e.g., pyrrolidin-1-yl, pyrrolidin-2-yl, and pyrrolidin-3-yl), pyrrolidone, azetidine, pyran (2H-pyran or 4H-pyran), dihydrothiophene, dihydropyran, dihydrofuran, dihydrothiazole, tetrahydrofuran, tetrahydrothiophene, dioxane, diazepane, tetrahydropyran (e.g., , tetrahydropyran-4-yl), tetrahydropyridine, imidazoline, imidazolidinone, oxazoline, thiazoline, pyrazolin-2-yl, pyrazolidine, piperazinone, piperazine, hexahydropyrrolo[3,4-b][1,4]oxazin-6(2H)-yl, octahydro-2H-pyrazino[1,2-a]pyrazin-2-yl, octahydro-2H-pyrazino[1,2-a]pyrazin-3-yl, octahydro-5H-pyrrolo[3,4-c]pyridin-5-yl, tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl, ... tetrahydropyridine, tetrahydropyridine, tetrahydropyridine, tetrahydropyridine, tetrahydropyridine, tetrahydropyridine, tetrahydropyridine, tetrahydropyridine, tetrahydropyridine, tetrahydropyridine, tetrahydropyridine, tetrahydropyridine, tetrahydropyridine, tetrahydropyridine, tetrahydropyridine, tetrahydropyr Hydro-3H-imidazo[4,5-c]pyridin-3-yl, isoindolin-1-yl, isoindolin-5-yl, tetrahydroisoquinolin-6-yl, tetrahydro-[1,2,4]triazolo[1,5-a]pyrazin-2-yl, tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3-yl, tetrahydroimidazo[1,2-a]pyrazin-2-yl, dihydro-5H-pyrrolo[3,4-b]pyrazin-2-yl, dihydro-5H-pyrrolo[3,4-b]pyridin-3-yl, dihydro-5H-pyrrolo[3,4-b]pyridine- 2-yl, dihydro-5H-pyrrolo[3,4-b]pyridin-7-yl, dihydro-5H-pyrrolo[3,4-b]pyridin-5-yl, tetrahydropyrrolo[3,4-d]imidazol-2-yl, dihydro-2H-benzo[b][1,4]oxazin-6-yl, dihydro-2H-benzo[b][1,4]oxazin-7-yl, dihydro-4H-pyrrolo[3,4-d]imidazol-1-yl, dihydro-1H-pyrrolo[3,4-c]pyridin-6-yl, dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-yl, dihydro-4H-pyrrolo[3,4-d]thiazol-2-yl, dihydro-4H-pyrrolo[3,4-d]oxazol-2-yl, tetrahydropyrrolo[3,4-c]pyrazol-3-yl, tetrahydroimidazo[1,2-a]pyridin-6-yl, tetrahydroimidazo[1,2-a]pyridin-7-yl, and tetrahydropyrazolo[1,5-a]pyrazin-2-yl.

[0022] It will be understood that the term "heterocyclyl" includes reference to spiro and bridged heterocyclic derivatives. Examples of such spiro and bridged heterocyclic derivatives include hexahydropyrrolo[2,3-c]pyrrolidinyl, diazaspiro[3.3]heptanyl, azaspiro[3.3]heptan-6-yl, diazaspiro[3.4]octanyl, diazaspiro[4.4]nonyl, oxa-azaspiro[3.4]octanyl, oxa-azaspiro[4.4]nonyl, tetrahydrofuro[3,4-c]pyrrolidinyl, oxa-azaspiro[3.3] Heptyl, diazaspiro[3.5]nonanyl, diazaspiro[4.4]nonanyl, diazaspiro[4.5]decanyl, diazaspiro[3.5]nonanyl, octahydro-naphthyridinyl, tetrahydropyrazino-oxazinyl, oxadiazaspiro[3.4]octanyl, oxadiazaspiro[3.5]nonanyl, oxadiazaspiro[4.5]decanyl, oxadiazospiro[5.5]undecanyl, triazaspiro[3.5]nonanyl Nanyl, diazabicyclo[2.2.1]heptan-2-yl, diazabicyclo[3.1.1]heptan-6-yl, diazabicyclo[3.2.1]octan-8-yl, oxabicyclo[2.2.1]heptanyl, oxa-2,8-diazaspiro[3.5]nonan-8-yl, oxa-3,7-diazabicyclo[3.3.1]nonan-3-yl, tetrahydro-1'H-spiro[azetidine-3,4'-pyrrolo[1,2-a]pyra spiro[azetidin-3,3'-imidazo[1,2-a]imidazol]-1'(2'H)-yl, and spiro[azetidin-3,5'-imidazo[1,2-a]pyrazin]-7'(8'H)-yl). As used herein, the term "optionally substituted" refers to a group that may or may not be substituted by substituents as defined herein.

[0023] (Implementation) According to one particular embodiment of the present invention that may be mentioned, there is provided a compound of formula (I) or a tautomeric or stereochemically isomeric form, a pharmaceutically acceptable salt, or a solvate thereof: [ka] (In the formula: n represents an integer selected from 0, 1, 2, 3, or 4; R 1 is C 1-6 Alkyl, C 2-6 Alkenyl, C 1-6 Alkoxy, hydroxy, halogen, haloC 1-6 Alkyl, HaloC 1-6 Alkoxy, C 3-8 cycloalkyl, cyano, or -NR x R y represents; X is a bond or one or more C 1-6 Alkyl, NR x represents a C1-C6 alkylene group optionally substituted with an O, hydroxy, or CO group; R 2 is -ring A or -ring B -Y-ring C Does it represent a group? Or -XR 2 is -C1-C 12 Alkylene-NR x R y represents a group, wherein the alkylene group is one or more C 1-6 Alkyl, C 2-6 Alkenyl, -NR x , optionally substituted with O, hydroxy, or CO groups; ring A is -(CH2) m -CO-C 1-6 Alkyl, -(CH2) m -NHCO-C 1-6 Alkyl, -(CH2) m -CO-C 2-6 Alkenyl, -(CH2) m -NHCO-C 2-6 Alkenyl, -(CH2)m -CO-C 2-6 Alkynyl, or -(CH2) m -NHCO-C 2-6 represents a carbocyclyl, heterocyclyl, or heteroaryl requiring substituents selected from alkynyl groups, wherein the alkyl, alkenyl, or alkynyl group contains one or more (e.g., 1, 2, or 3) halogen, hydroxy, CO, or —NR x R y and wherein the carbocyclyl, heterocyclyl, or heteroaryl group is optionally substituted by a halogen, C 1-6 Alkyl, hydroxy, C 1-6 Alkoxy, -CO-C 1-6 Alkyl, oxo, C 1-6 optionally further substituted with one or more (e.g., 1, 2, or 3) substituents selected from alkylamino, or cyano; m represents an integer selected from 0, 1, 2, 3, or 4; ring B are each hydroxy, oxo, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, HaloC 1-6 Alkyl, -CO-C 1-6 represents carbocyclyl, heterocyclyl, or heteroaryl, which may be optionally substituted with one or more (e.g., 1, 2, or 3) substituents selected from alkyl, cyano, or halogen; ring C is C 1-6 Alkyl (e.g., methyl) and / or -NR x R y optionally substituted by a -(CH2) group m -CO-C 2-6 represents heterocyclyl substituted by one or more (e.g., 1, 2, or 3) substituents selected from alkenyl; Y is a bond, —O—, CO, or one or more C 1-6 Alkyl, C 2-6 Alkenyl, -NR xrepresents a C1-C6 alkylene group optionally substituted with an O, hydroxy, or CO group; R 3 is hydrogen or C 1-6 represents alkyl; R 4 , R 5 , R 6 , and R 7 are independently hydrogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 1-6 Alkoxy, halogen, haloC 1-6 Alkyl, HaloC 1-6 Alkoxy, C 3-8 cycloalkyl, cyano, or -NR x R y represents; and R x and R y are independently hydrogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 represents alkoxy, or R x and R y are bonded together with the nitrogen atoms to which they are attached, forming one or more C 1-6 forming a nitrogen-containing heterocyclic ring which may be optionally substituted by alkyl groups).

[0024] In one embodiment, n represents 0, 1, 2, or 3.

[0025] In one embodiment, R 1 is C 1-6 alkyl (e.g., methyl), halogen (e.g., fluorine or chlorine), or C 3-8 In a further embodiment, R represents cycloalkyl (e.g., cyclopropyl). 1 is C 1-6 represents alkyl (e.g., methyl) or halogen (e.g., fluorine or chlorine). 1 represents a halogen (e.g., fluorine or chlorine). In an alternative embodiment, R 1 is C 1-6In a further embodiment, R 1 represents methyl.

[0026] In a further embodiment, n represents 0.

[0027] In a further embodiment, n represents 1. In yet a further embodiment, n represents 1 and R 1 is C 1-6 In yet a further embodiment, n represents 1 and R 1 represents methyl, fluorine, or chlorine. In still further embodiments, n represents 1 and R 1 is C 1-6 In still yet further embodiments, n represents 1 and R 1 represents methyl.

[0028] In an alternative embodiment, n represents 2. In yet a further embodiment, n represents 2 and R 1 is C 1-6 alkyl (e.g., methyl), halogen (e.g., fluorine or chlorine), or C 3-8 In yet a further embodiment, n represents 2 and R 1 represents methyl, fluorine, chlorine, or cyclopropyl. In still yet a further embodiment, n represents 2: R 1 the groups are both halogens (e.g., both represent fluorine, or one represents fluorine and the other represents chlorine); or One R 1 The group represents a halogen (i.e., fluorine) and the other is C 1-6 represents alkyl (e.g., methyl); or One R 1 The group represents a halogen (i.e., fluorine) and the other is C 3-8 It represents cycloalkyl (eg cyclopropyl).

[0029] In an alternative embodiment, n represents 3. In yet a further embodiment, n represents 3 and R 1 represents halogen (e.g., fluorine or chlorine). In still further embodiments, n represents 3 and R 1 represents fluorine or chlorine. In still yet a further embodiment, n represents 3 and two R 1 The group represents fluorine, and one R 1 The group represents chlorine.

[0030] In one embodiment, R 2 is -ring A Represents.

[0031] In one embodiment, the ring A teeth, -(CH2) optionally substituted with halogen groups m -CO-C 2-6 alkyl (e.g., -CO-CH2-Cl); One or more halogen, hydroxy, CO, or -NR x R y optionally substituted by a -(CH2) group m -CO-C 2-6 Alkenyl (e.g. -COCH=CH2, -CO-C(=CH2)-Me, -CO-CH=CH-CH2-N(Me)2, -CO-C(=CH2)-CH2-N(Me)2, -CO-C(=CH-Me)-CH2-N(Me)2, -CO-C(=CH2)- CH2-N(Me)2, -CO-C(Cl)=CH-CH2-N(Me)2, -CO-C(=CH2)-CH2-OH, -CO-C(=CH2)-CH2-OC(=O)-Me), -CO-CH=CH-CHF2, -CO-C(=CH2)-CH2-NEt2; -NR x R y optionally substituted by a -(CH2) group m -NHCO-C 2-6Alkenyl (e.g. -NH-CO-CH=CH2, -NH-CO-C(=CH2)-CH2-N(Me)2, -NH-CO-C(=CH-Me)-CH2-N(Me)2, -NH-CO-CH=CH -CH2-N(Me)2, -CH2-NH-CO-CH=CH2-, -CH2-NH-CO-CH=CH-CH2-N(Me)2, -CH2-NH-CO-C(=CH2)-CH2-N(Me)2); -(CH2) m -CO-C 2-6 Alkynyl (e.g., -CO-ethynyl or -CO-ethynyl-Me); or -(CH2) m -NHCO-C 2-6 Alkynyl groups (e.g., -NH-CO-ethynyl) carbocyclyl (e.g., phenyl, cyclobutyl, 2,3-dihydro-1H-inden-2-yl, or bicyclo[1.1.1]pentan-1-yl), heterocyclyl ring (e.g., azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, isoindolin-1-yl, isoindolin-5-yl, tetrahydroisoquinolin-6-yl, diazaspiro[3.4]octan-6-yl, octahydro-2H-pyrazino[1,2-a]pyrazin-2-yl, octahydro-5H-pyrrolo[3,4-c]pyridin-5-yl, 5-oxa-2,8-diazaspiro[3.5]nonan-8-yl, 2,6-diazaspiro[3.4]octane, 9-oxa-3,7-diazabicyclo[3.3.1]nonan-3-yl, tetrahydro -1H-Imidazo[4,5-c]pyridin-1-yl, tetrahydro-1'H-spiro[azetidine-3,4'-pyrrolo[1,2-a]pyrazin]-2'(3'H)-yl, tetrahydro-1'H-spiro[azetidine-3,6'-pyrazino[2,1-c][1,4]oxazin]-8'(7'H)-yl, tetrahydro-3H-imidazo[4,5-c]pyridin-3-yl, tetrahydro-1 ...imidazo[4,5-c]pyridin-1-yl, tetrahydro-1H-spiro[azetidine-3,4'-pyrrolo[1,2-a]pyrazin]-2'(3'H)-yl, tetrahydro-1H-spiro[azetidine-3,6'-pyrazino[2,1-c][1,4]oxazin]-8'(7'H)-yl rahydro-[1,2,4]triazolo[1,5-a]pyrazin-2-yl, tetrahydroimidazo[1,2-a]pyrazin-2-yl, tetrahydropyrazolo[1,5-a]pyrazin-2-yl, octahydro-2H-pyrazino[1,2-a]pyrazin-3-yl, tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3-yl, 2,5,8-triazaspiro[3.5]nonan-8-yl, spiro[azetidin-3,3'-imidazo[1,2-a]imidazol]-1'(2'H)-yl, dihydro-5H-pyrrolo[3,4-b]pyrazin-2-yl, dihydro-5H-pyrrolo[3,4-b]pyridin-3-yl, dihydro-5H-pyrrolo[3,4-b]pyridin-2-yl, dihydro-5H-pyrrolo[3,4-b]pyridin-7-yl, dihydro 5H-pyrrolo[3,4-b]pyridin-5-yl, tetrahydropyrrolo[3,4-d]imidazol-2-yl, dihydro-2H-benzo[b][1,4]oxazin-6-yl, dihydro-2H-benzo[b][1,4]oxazin-7-yl, dihydro-4H-pyrrolo[3,4-d]imidazol-1-yl, diazabicyclo[3.1.1]heptan-6-yl, diazabicyclo[3.1.1]heptan-6-yl, diazabicyclo[3.1.1]heptan-6-yl, diazabicyclo[3.1.1]heptan-7-yl, dihydro-5H-pyrrolo[3,4-b]pyridin-5-yl, tetrahydropyrrolo[3,4-d]imidazol-2-yl, dihydro-2H-benzo[b][1,4]oxazin-6-yl, dihydro-2H-benzo[b][1,4]oxazin-7-yl, dihydro-4H-pyrrolo[3,4-d]imidazol-1-yl, diazabicyclo[3.1.1]heptan-6-yl, diazabicyclo[3.1.1]heptan-7 ... Cyclo[3.2.1]octan-8-yl, diazabicyclo[2.2.1]heptan-2-yl, dihydro-1H-pyrrolo[3,4-c]pyridin-6-yl, dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-yl, dihydro-4H-pyrrolo[3,4-d]thiazol-2-yl, dihydro-4H-pyrrolo[3,4-d]oxazo-2-yl, tetrahydropyrrolo[3,4 -c]pyrazol-3-yl, diazaspiro[3.3]heptan-6-yl, tetrahydroimidazo[1,2-a]pyridin-6-yl, tetrahydroimidazo[1,2-a]pyridin-7-yl, or spiro[azetidin-3,5'-imidazo[1,2-a]pyrazin]-7'(8'H)-yl), or a heteroaryl ring (e.g., pyridyl or pyrimidinyl). wherein the carbocyclyl, heterocyclyl, or heteroaryl group is selected from the group consisting of halogen (e.g., fluorine); C optionally substituted by one or more halogen (e.g., —CF3 or —CHF2), hydroxy (e.g., —CH2—OH), or cyano (e.g., —CH2—CN) groups. 1-6 Alkyl (e.g., methyl or ethyl); hydroxy; C 1-6 Alkoxy (e.g., methoxy and -CH2-OMe); -CO-C 1-6 Alkyl (e.g., -CO-Me); oxo; C 1-6alkylamino (e.g., —N(Me)—(CH)—N(Me)); or cyano).

[0032] In a further embodiment, the ring A teeth, -(CH2) optionally substituted with halogen groups m -CO-C 2-6 alkyl (e.g., -CO-CH2-Cl); One or more halogen, hydroxy, CO, or -NR x R y optionally substituted by a -(CH2) group m -CO-C 2-6 Alkenyl (e.g. -COCH=CH2, -CO-C(=CH2)-Me, -CO-CH=CH-CH2-N(Me)2, -CO-C(=CH2)-CH2-N(Me)2, -CO-C(=CH-Me)-CH2-N (Me)2, -CO-C(=CH2)-CH2-N(Me)2, -CO-C(Cl)=CH-CH2-N(Me)2, -CO-C(=CH2)-CH2-OH, -CO-C(=CH2)-CH2-OC(=O)-Me); -NR x R y optionally substituted by a -(CH2) group m -NHCO-C 2-6 Alkenyl (e.g. -NH-CO-CH=CH2, -NH-CO-C(=CH2)-CH2-N(Me)2, -NH-CO-C(=CH-Me)-CH2-N(Me)2, -NH-CO-CH=CH -CH2-N(Me)2, -CH2-NH-CO-CH=CH2-, -CH2-NH-CO-CH=CH-CH2-N(Me)2, -CH2-NH-CO-C(=CH2)-CH2-N(Me)2); -(CH2) m -CO-C 2-6 Alkynyl (e.g., -CO-ethynyl or -CO-ethynyl-Me); or -(CH2) m -NHCO-C 2-6 Alkynyl groups (e.g., -NH-CO-ethynyl) carbocyclyl (e.g., phenyl or bicyclo[1.1.1]pentan-1-yl), heterocyclyl rings (e.g., azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, isoindolin-5-yl, tetrahydroisoquinolin-6-yl, diazaspiro[3.4]octan-6-yl, octahydro-2H-pyrazino[1,2-a]pyrazin-2-yl, octahydro-5H-pyrro 1'H-pyro[azetidin-3,4'-pyrrolo[1,2-a]pyrazine]-2'(3'H)-yl, tetrahydro-2,8-diazabicyclo[3.5]nonan-5-yl, 5-oxa-2,8-diazaspiro[3.5]nonan-8-yl, 2,6-diazaspiro[3.4]octane, 9-oxa-3,7-diazabicyclo[3.3.1]nonan-3-yl, tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl, tetrahydro-1'H-spiro[azetidin-3,4'-pyrrolo[1,2-a]pyrazine]-2'(3'H)-yl, tetrahydro- 1'H-spiro[azetidine-3,6'-pyrazino[2,1-c][1,4]oxazin]-8'(7'H)-yl, tetrahydro-3H-imidazo[4,5-c]pyridin-3-yl, tetrahydro-[1,2,4]triazolo[1,5-a]pyrazin-2-yl, tetrahydroimidazo[1,2-a]pyrazin-2-yl, tetrahydropyrazolo[1,5-a]pyrazin-2-yl, octahydro-2H-pyrazino[1,2 -a]pyrazin-3-yl, tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3-yl, 2,5,8-triazaspiro[3.5]nonan-8-yl, spiro[azetidin-3,3'-imidazo[1,2-a]imidazol]-1'(2'H)-yl, or spiro[azetidin-3,5'-imidazo[1,2-a]pyrazin]-7'(8'H)-yl) or a heteroaryl ring (e.g., pyridyl), wherein the carbocyclyl, heterocyclyl, or heteroaryl group is selected from the group consisting of halogen (e.g., fluorine), C 1-6 Alkyl (e.g., methyl or ethyl), hydroxy, C 1-6 Alkoxy (e.g., methoxy and -CH2-OMe), -CO-C 1-6 Alkyl (e.g., -CO-Me), oxo, C 1-6and optionally substituted by one or more (e.g., one, two, or three) further substituents selected from alkylamino (e.g., —N(Me)—(CH)—N(Me)—, or cyano).

[0033] In a further embodiment, the ring A teeth, -(CH2) optionally substituted with halogen groups m -CO-C 2-6 alkyl (e.g., -CO-CH2-Cl); One or more halogen, hydroxy, CO, or -NR x R y optionally substituted by a -(CH2) group m -CO-C 2-6 Alkenyl (e.g. -COCH=CH2, -CO-C(=CH2)-Me, -CO-CH=CH-CH2-N(Me)2, -CO-C(=CH2)-CH2-N(Me)2, -CO-C(=CH-Me)-CH2-N(Me)2, -CO-C(=CH2)- CH2-N(Me)2, -CO-C(Cl)=CH-CH2-N(Me)2, -CO-C(=CH2)-CH2-OH, -CO-C(=CH2)-CH2-OC(=O)-Me), -CO-CH=CH-CHF2, -CO-C(=CH2)-CH2-NEt2; -NR x R y optionally substituted by a -(CH2) group m -NHCO-C 2-6 Alkenyl (e.g. -NH-CO-CH=CH2, -NH-CO-C(=CH2)-CH2-N(Me)2, -NH-CO-C(=CH-Me)-CH2-N(Me)2, -NH-CO-CH=CH -CH2-N(Me)2, -CH2-NH-CO-CH=CH2-, -CH2-NH-CO-CH=CH-CH2-N(Me)2, -CH2-NH-CO-C(=CH2)-CH2-N(Me)2); -(CH2) m -CO-C 2-6 Alkynyl (e.g., -CO-ethynyl or -CO-ethynyl-Me); or -(CH2) m -NHCO-C2-6 Alkynyl groups (e.g., -NH-CO-ethynyl) heterocyclyl rings (e.g., azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, isoindolin-1-yl, isoindolin-5-yl, tetrahydroisoquinolin-6-yl, diazaspiro[3.4]octan-6-yl, octahydro-2H-pyrazino[1,2-a]pyrazin-2-yl, octahydro-5H-pyrrolo[3,4-c]pyridin-5-yl, 5-oxa-2,8-diazaspiro[3.5]nonan-8-yl, 2,6-diazaspiro[3.4]octane, 9-oxa-3,7-diazabis(2-methyl-2-oxo-1,2-dioxo-2,6-di ... chloro[3.3.1]nonan-3-yl, tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl, tetrahydro-1'H-spiro[azetidine-3,4'-pyrrolo[1,2-a]pyrazine]-2'(3'H)-yl, tetrahydro-1'H-spiro[azetidine-3,6'-pyrazino[2,1-c][1,4]oxazine]-8'(7'H)-yl, tetrahydro-3H-imidazo[4,5-c]pyridin-3-yl, tetrahydro-[1,2,4]triazolo[1,5-a]pyrazin-2-yl, tetrahydroimidazo[1,2-a]pi 2,5,8-triazaspiro[3.5]nonan-8-yl, spiro[azetidin-3,3'-imidazo[1,2-a]imidazol]-1'(2'H)-yl, dihydro-5H-pyrrolo[3,4-b]pyrazin-2-yl, dihydro-5H-pyrrolo[3,4-b]pyridin-3-yl, dihydro-5H-pyrrolo[3,4 -b]pyridin-2-yl, dihydro-5H-pyrrolo[3,4-b]pyridin-7-yl, dihydro-5H-pyrrolo[3,4-b]pyridin-5-yl, tetrahydropyrrolo[3,4-d]imidazol-2-yl, dihydro-2H-benzo[b][1,4]oxazin-6-yl, dihydro-2H-benzo[b][1,4]oxazin-7-yl, dihydro-4H-pyrrolo[3,4-d]imidazol-1-yl, diazabicyclo[3.1.1]heptan-6-yl, diazabicyclo[3.2.1]octan-8-yl, diazabicyclo[2.2.1]octan-8-yl.1]heptan-2-yl, dihydro-1H-pyrrolo[3,4-c]pyridin-6-yl, dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-yl, dihydro-4H-pyrrolo[3,4-d]thiazol-2-yl, dihydro-4H-pyrrolo[3,4-d]oxazo-2-yl, tetrahydropyrrolo[3,4-c]pyrazol-3-yl, diazaspiro[3.3]heptan-6-yl, tetrahydroimidazo[1,2-a]pyridin-6-yl, tetrahydroimidazo[1,2-a]pyridin-7-yl, or spiro[azetidin-3,5'-imidazo[1,2-a]pyrazin]-7'(8'H)-yl). wherein the heterocyclyl or heteroaryl group is selected from the group consisting of halogen (e.g., fluorine); C optionally substituted with one or more halogen (e.g., —CF3 or —CHF2), hydroxy (e.g., —CH2—OH), cyano (e.g., —CH2—CN) groups. 1-6 Alkyl (e.g., methyl or ethyl); hydroxy; C 1-6 Alkoxy (e.g., methoxy and -CH2-OMe); -CO-C 1-6 Alkyl (e.g., -CO-Me); oxo; C 1-6 and optionally substituted by one or more (e.g., one, two, or three) further substituents selected from: alkylamino (e.g., —N(Me)—(CH)—N(Me)); or cyano.

[0034] In a further embodiment, the ring A teeth, one or more halogen, hydroxy, CO, or -NR x R y optionally substituted by a -(CH2) group m -CO-C 2-6Alkenyl (e.g. -COCH=CH2, -CO-C(=CH2)-Me, -CO-CH=CH-CH2-N(Me)2, -CO-C(=CH2)-CH2-N(Me)2, -CO-C(=CH-Me)-CH2-N(Me)2, -CO-C(=CH2)- CH2-N(Me)2, -CO-C(Cl)=CH-CH2-N(Me)2, -CO-C(=CH2)-CH2-OH, -CO-C(=CH2)-CH2-OC(=O)-Me), -CO-CH=CH-CHF2, -CO-C(=CH2)-CH2-NEt2 dihydro-5H-pyrrolo[3,4-b]pyridinyl, for example dihydro-5H-pyrrolo[3,4-b]pyridin-3-yl, dihydro-5H-pyrrolo[3,4-b]pyridin-2-yl, dihydro-5H-pyrrolo[3,4-b]pyridin-7-yl, or dihydro-5H-pyrrolo[3,4-b]pyridin-5-yl, each of which is substituted by wherein the heterocyclyl group is selected from the group consisting of halogen (e.g., fluorine); C optionally substituted by one or more halogen (e.g., —CF3 or —CHF2), hydroxy (e.g., —CH2—OH), or cyano (e.g., —CH2—CN) groups. 1-6 Alkyl (e.g., methyl or ethyl); hydroxy; C 1-6 Alkoxy (e.g., methoxy and -CH2-OMe); -CO-C 1-6 Alkyl (e.g., -CO-Me); oxo; C 1-6 alkylamino (e.g., —N(Me)—(CH)—N(Me)); or cyano).

[0035] In still further embodiments, the ring A represents dihydro-5H-pyrrolo[3,4-b]pyridinyl, for example dihydro-5H-pyrrolo[3,4-b]pyridin-3-yl, dihydro-5H-pyrrolo[3,4-b]pyridin-2-yl, dihydro-5H-pyrrolo[3,4-b]pyridin-7-yl, or dihydro-5H-pyrrolo[3,4-b]pyridin-5-yl, each of which is substituted by —COCH═CH.

[0036] In still yet further embodiments, the ring A represents dihydro-5H-pyrrolo[3,4-b]pyridin-2-yl substituted by -COCH=CH2.

[0037] In still yet further embodiments, the ring A represents 6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-2-yl substituted by -COCH=CH2.

[0038] In an alternative embodiment, R 2 is -ring B -Y-ring C Represents.

[0039] In one embodiment, the ring B are each hydroxy, oxo, C 1-6 Alkyl (e.g., methyl), haloC 1-6 represents carbocyclyl (e.g., cyclohexyl or phenyl), heterocyclyl (e.g., azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, diazepanyl, or hexahydropyrrolo[3,4-b][1,4]oxazin-6(2H)-yl), or heteroaryl (e.g., imidazolyl, pyrazolyl, triazolyl, pyridinyl, pyrimidinyl, oxazolyl, or oxadiazolyl), which may be optionally substituted by one or more (e.g., 1, 2, or 3) substituents selected from alkyl (e.g., —CH—F), cyano, or halogen (e.g., fluorine).

[0040] In a further embodiment, the ring Brepresents cyclohexyl, phenyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, diazepanyl, hexahydropyrrolo[3,4-b][1,4]oxazin-6(2H)-yl, imidazolyl, pyrazolyl, triazolyl, pyridinyl, pyrimidinyl, oxazolyl, or oxadiazolyl, each of which may be optionally substituted with one or more (e.g., one, two, or three) substituents selected from hydroxy, oxo, methyl, —CH—F, cyano, or fluorine.

[0041] In a further embodiment, the ring B are each hydroxy, oxo, C 1-6 Alkyl (e.g., methyl), haloC 1-6 represents carbocyclyl (e.g., cyclohexyl or phenyl), heterocyclyl (e.g., azetidinyl, pyrrolidinyl, piperazinyl, diazepanyl, or hexahydropyrrolo[3,4-b][1,4]oxazin-6(2H)-yl), or heteroaryl (e.g., imidazolyl, pyrazolyl, triazolyl, pyridinyl, pyrimidinyl, oxazolyl, or oxadiazolyl), which may be optionally substituted by one or more (e.g., 1, 2, or 3) substituents selected from alkyl (e.g., —CH—F), cyano, or halogen (e.g., fluorine).

[0042] In one embodiment, Y is a bond, —O—, —NHCO—, CO, or one or more C 1-6 Alkyl, C 2-6 Alkenyl, -NR x In a further embodiment, Y represents a C1-C6 alkylene group optionally substituted with an O, hydroxy, or CO group (e.g., -CO-C(=CH2)-CH2- or -NHCO-CH=CH-CH2-). In a further embodiment, Y represents a bond, -O-, -NHCO-, CO, or one or more C 1-6 Alkyl, C 2-6 Alkenyl, -NR x represents a C1-C6 alkylene group optionally substituted with an O, hydroxy, or CO group (e.g., -CO-C(=CH2)-CH2-).

[0043] In a further embodiment, Y represents a bond.In an alternative embodiment, Y represents -O-.

[0044] In one embodiment, the ring C represents a monocyclic heterocyclyl ring having at least one nitrogen atom. C each of which is a halogen (e.g., fluorine), C 1-6 Alkyl (e.g., methyl), -CO-C 1-6 alkyl (e.g., —CO-methyl), and / or —NR x R y optionally substituted by a -(CH2) group m -CO-C 2-6 It represents azetidinyl, pyrrolidinyl, piperazinyl, piperidinyl, morpholinyl, or tetrahydropyridinyl substituted by alkenyl (e.g., -COCH=CH2, -CO-C(=CH2)-CH2-N(Me)2, -CO-C(=CH-Me)-CH2-N(Me)2, or -CO-CH=CH-CH2-N(Me)2).

[0045] In a further embodiment, the ring C represents azetidinyl, pyrrolidinyl, piperazinyl, piperidinyl, morpholinyl, or tetrahydropyridinyl, each of which is substituted by fluorine, methyl, —CO-methyl, and / or —COCH═CH, —CO—C(═CH)—CH—N(Me), —CO—C(═CH-Me)—CH—N(Me) or —CO—CH═CH—CH—N(Me).

[0046] In a further embodiment, the ring C Each of them is one methyl group; or one -CO-methyl group; or one -COCH=CH group; or one -CO-C(=CH2)-CH2-N(Me)2 group; or one -CO-C(=CH-Me)-CH2-N(Me)2 group; or one -CO-CH=CH-CH2-N(Me)2 group; or one methyl group and one -COCH=CH group; or One fluorine group and one -COCH=CH2 group : represents azetidinyl, pyrrolidinyl, piperazinyl, piperidinyl, morpholinyl, or tetrahydropyridinyl substituted by:

[0047] In a further embodiment, the ring C Each of them is C 1-6 Alkyl (e.g., methyl) and / or -NR x R y optionally substituted by a -(CH2) group m -CO-C 2-6 It represents azetidinyl, pyrrolidinyl, piperazinyl, or tetrahydropyridinyl substituted by alkenyl (e.g., -COCH=CH2, -CO-C(=CH2)-CH2-N(Me)2, -CO-C(=CH-Me)-CH2-N(Me)2, or -CO-CH=CH-CH2-N(Me)2).

[0048] In one embodiment, X is a bond or one or more C 1-6 Alkyl (e.g., methyl), -NR x (e.g., -NH or -N-methyl), O, hydroxy, halogen (e.g., fluorine), or CO group.

[0049] In further embodiments, X is a bond or one or more C 1-6 Alkyl (e.g., methyl), -NR x (e.g., -NH or -N-methyl), O, hydroxy, or CO groups.

[0050] In a further embodiment, X represents a bond.

[0051] In an alternative embodiment, X is one or more C 1-6alkyl (e.g., —(CH2)—C(Me)—), O (e.g., —(CH2)2—O—, —(CH2)3—O—, or —(CH2)2—O—CH2—), or CO (e.g., —(CH2)—CO— or —(CH2)2—CO—), —NR x (e.g., —(CH2)2—NH—, —(CH2)3—NH—, —(CH2)2—N(Me)—, or —(CH2)3—N(Me)—) groups, or CO and —NR x groups (e.g., —(CH2)2—N(Me)—CO—), or hydroxy and —NR x represents a C-C alkylene group (e.g., -CH-, -(CH)-, -(CH)-, -(CH)-, or -(CH)-) optionally substituted with a group (e.g., -(CH)-CH(OH)-CH-N(Me)-, or a halogen (e.g., -(CH)-CHF-, -(CH)-CHF-CH-, or -CH-CHF-(CH)-).

[0052] In further embodiments, X is one or more C 1-6 alkyl (e.g., —(CH2)—C(Me)—), O (e.g., —(CH2)2—O—, —(CH2)3—O—, or —(CH2)2—O—CH2—), or CO (e.g., —(CH2)—CO— or —(CH2)2—CO—), —NR x (e.g., —(CH2)2—NH—, —(CH2)3—NH—, —(CH2)2—N(Me)—, or —(CH2)3—N(Me)—) groups, or CO and —NR x groups (e.g., —(CH2)2—N(Me)—CO—), or hydroxy and —NR x represents a C1-C4 alkylene group (e.g., —CH2—, —(CH2)2—, —(CH2)3—, or —(CH2)4—) substituted by a group (e.g., —(CH2)—CH(OH)—CH2—N(Me)—).

[0053] In still further embodiments, X represents a bond, —CH—, —(CH)—, —(CH)—, —(CH)—, —(CH)—C(Me)—, —(CH)—O—, —(CH)—O—, —(CH)—O—CH—, —(CH)—CO—, —(CH)—CO—, —(CH)—NH—, —(CH)—NH—, —(CH)—N(Me)—, —(CH)—N(Me)—, —(CH)—N(Me)—CO—, —(CH)—CH(OH)—CH—N(Me)—, —(CH)—CHF—, —(CH)—CHF—CH—, or —CH—CHF—(CH)—.

[0054] In still further embodiments, X represents a bond, —CH—, —(CH)—, —(CH)—, —(CH)—, —(CH)—C(Me)—, —(CH)—O—, —(CH)—O—, —(CH)—O—CH—, —(CH)—CO—, —(CH)—CO—, —(CH)—NH—, —(CH)—NH—, —(CH)—N(Me)—, —(CH)—N(Me)—, —(CH)—N(Me)—CO—, or —(CH)—CH(OH)—CH—N(Me)—.

[0055] In a still yet further embodiment, X represents -CH2-.

[0056] In one embodiment, -XR 2 is -C1-C 10 Alkylene-NR x R y group, wherein the alkylene group is one or more C 2-6 Alkenyl, NR x , O, or CO groups), for example, —(CH2)2—O—(CH2)2—NH—CO—C(═CH2)—CH2—N(Me)2, —(CH2)5—NH—CO—CH═CH—CH2—N(Me)2, —(CH2)5—NH—CO—C(═CH2)—CH2—N(Me)2, —(CH2)4—NHCOCH═CH—CH2—NMe2, or —CH2—CHF—(CH2) 3-It represents NHCO-CH=CHCH2NMe2, -(CH2)3-CHF-CH2NHCO-CH=CHCH2NMe2, or -(CH2)3-CF2-CH2NHCO-CH=CHCH2NMe2.

[0057] In a further embodiment, -XR 2 is -C1-C 10 Alkylene-NR x R y group, wherein the alkylene group is one or more C 2-6 Alkenyl, NR x , O, or CO group), for example, —(CH)—O—(CH)—NH—CO—C(═CH)—CH—N(Me)—, —(CH)—NH—CO—CH═CH—CH—N(Me)—, or —(CH)—NH—CO—C(═CH)—CH—N(Me)—.

[0058] In one embodiment, R 3 is hydrogen or C 1-6 In a further embodiment, R represents alkyl (e.g., methyl or ethyl). 3 is hydrogen or C 1-6 In still further embodiments, R 3 represents hydrogen or methyl. In still further embodiments, R 3 is C 1-6 In still yet further embodiments, R 3 represents methyl.

[0059] In one embodiment, R 4 teeth, hydrogen; C 1-6 alkyl (e.g., methyl or ethyl); C 2-6 Alkenyl (e.g., ethenyl); C 1-6 alkoxy (e.g., methoxy); halogens (e.g., chlorine); or -NR x R y(e.g., -N(Me)2 or -N(Me)(Et)) : represents.

[0060] In a further embodiment, R 4 is C 1-6 In still further embodiments, R 4 represents methyl.

[0061] In one embodiment, R 5 teeth, hydrogen; halogens (e.g., chlorine); or C 1-6 Alkyl (e.g., methyl) : represents.

[0062] In one embodiment, R 5 represents hydrogen.

[0063] In one embodiment, R 6 teeth, C 1-6 alkyl (e.g., methyl, ethyl, or isopropyl); C 2-6 alkenyl (e.g., -C(=CH2)(Me)); halogens (e.g., bromine); Haro C 1-6 alkyl (e.g., trifluoromethyl or -C(H)(Me)-CF3); or Haro C 1-6 Alkoxy (e.g., difluoromethoxy) : represents.

[0064] In a further embodiment, R 6 is Haro C 1-6 In still further embodiments, R 6 represents trifluoromethyl.

[0065] In one embodiment, R 7 teeth, hydrogen; or Cyano : represents.

[0066] In a further embodiment, R 7 represents hydrogen.

[0067] In one particular embodiment, R 4 represents methyl, and R 5 represents hydrogen, and R 6 represents trifluoromethyl, and R 7 represents hydrogen. Thus, in one embodiment, the compound of formula (I) a or a tautomeric or stereochemically isomeric form, pharmaceutically acceptable salt, or solvate thereof: [ka] (where n, R 1 , X, R 2 , and R 3 are as defined herein) is.

[0068] In one embodiment, R x and R y are independently hydrogen or C 1-6 In a further embodiment, R represents alkyl (e.g., methyl or ethyl). x and R y are independently, C 1-6 In a further embodiment, R x and R y are both C 1-6 It represents alkyl (eg, methyl).

[0069] In one embodiment, the present invention provides a compound of formula (I) that is the free base of a compound of Examples 1 to 332, or a pharmaceutically acceptable salt or solvate thereof.

[0070] In a further embodiment, the present invention provides a compound of formula (I) which is the free base of the compounds of Examples 1 to 227, or a pharmaceutically acceptable salt or solvate thereof.

[0071] References to compounds of formula (I) and sub-groups thereof also include ionic forms, salts, solvates, isomers (including geometric and stereochemical isomers), tautomers, N-oxides, esters, prodrugs, isotopes and protected forms thereof, for example, as discussed below; preferably, salts or tautomers or isomers or N-oxides or solvates thereof; and more preferably, salts or tautomers or N-oxides or solvates thereof, even more preferably, salts or tautomers or solvates thereof. Hereinafter, compounds defined in any aspect of the invention and their ionic forms, salts, solvates, isomers (including geometric and stereochemical isomers), tautomers, N-oxides, esters, prodrugs, isotopes and protected forms (excluding intermediate compounds in chemical processes) are referred to as "compounds of the invention".

[0072] (salt) Certain compounds of formula (I) can exist in the form of salts, for example, acid addition salts or, in some cases, salts of organic and inorganic bases such as carboxylates, sulfonates, and phosphates. All such salts are within the scope of the present invention, and references to compounds of formula (I) include the salt forms of the compounds.

[0073] The salts of the present invention can be synthesized from the parent compound containing a basic or acidic moiety by conventional chemical methods, such as those described in "Pharmaceutical Salts: Properties, Selection, and Use," P. Heinrich Stahl (ed.), Camille G. Wermuth (ed.), ISBN: 3-90639-026-8, Hardcover, 388 pages, August 2002. Typically, such salts can be prepared by reacting the free acid or base form of these compounds with the appropriate base or acid in water or an organic solvent, or a mixture of the two; non-aqueous media such as ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are typically used.

[0074] Acid addition salts (monosalts or disalts) can be formed with a wide variety of acids, both inorganic and organic. Examples of acid addition salts include acetic acid, 2,2-dichloroacetic acid, adipic acid, alginic acid, ascorbic acid (e.g., L-ascorbic acid), L-aspartic acid, benzenesulfonic acid, benzoic acid, 4-acetamidobenzoic acid, butanoic acid, (+) camphoric acid, camphorsulfonic acid, (+)-(1S)-camphor-10-sulfonic acid, capric acid, caproic acid, caprylic acid, cinnamic acid, citric acid, cyclohexane ... Laminic acid, dodecyl sulfate, ethane-1,2-disulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, D-gluconic acid, glucuronic acid (e.g., D-glucuronic acid), glutamic acid (e.g., L-glutamic acid), α-oxoglutaric acid, glycolic acid, hippuric acid, hydrohalic acids (e.g., hydrobromic acid, hydrochloric acid), acid, hydroiodic acid), isethionic acid, lactic acid (e.g., (+)-L-lactic acid, (±)-DL-lactic acid), lactobionic acid, maleic acid, malic acid, (-)-L-malic acid, malonic acid, (±)-DL-mandelic acid, methanesulfonic acid, naphthalene-2-sulfonic acid, naphthalene-1,5-disulfonic acid, 1-hydroxy-2-naphthoic acid, nicotinic acid, nitric acid, oleic acid, orotic acid, oxalic acid, palmitic acid Included are mono- or di-salts formed with acids selected from the group consisting of pamoic, phosphoric, propionic, pyruvic, L-pyroglutamic, salicylic, 4-amino-salicylic, sebacic, stearic, succinic, sulfuric, tannic, (+)-L-tartaric, thiocyanic, p-toluenesulfonic, undecylenic, and valeric acids, as well as acylated amino acids and cation exchange resins.

[0075] One particular group of salts consists of salts formed from acetic acid, hydrochloric acid, hydroiodic acid, phosphoric acid, nitric acid, sulfuric acid, citric acid, lactic acid, succinic acid, maleic acid, malic acid, isethionic acid, fumaric acid, benzenesulfonic acid, toluenesulfonic acid, methanesulfonic acid (mesylate), ethanesulfonic acid, naphthalenesulfonic acid, valeric acid, acetic acid, propanoic acid, butanoic acid, malonic acid, glucuronic acid, and lactobionic acid. One particular salt is the hydrochloride salt.

[0076] When a compound of formula (I) contains an amine functionality, it can form a quaternary ammonium salt, for example, by reaction with an alkylating agent by methods well known to those skilled in the art. Such quaternary ammonium compounds are within the scope of formula (I).

[0077] The compounds of the present invention have a pK of the acid with which the salt is formed. a Depending on the compound, it may exist as a mono- or di-salt.

[0078] It will be understood that for use in medicine, salts of compounds of formula (I) should be pharmaceutically acceptable. Suitable pharmaceutically acceptable salts will be apparent to those skilled in the art. Pharmaceutically acceptable salts include those described in Berge, Bighley, and Monkhouse, J. Pharm. Sci. 1977, 66, pp. 1-19. Such pharmaceutically acceptable salts include acid addition salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, or phosphoric acid, and organic acids such as succinic acid, maleic acid, acetic acid, fumaric acid, citric acid, tartaric acid, benzoic acid, p-toluenesulfonic acid, methanesulfonic acid, or naphthalenesulfonic acid. Other salts, such as oxalates or formates, can be used, for example, in the isolation of compounds of formula (I) and are within the scope of the present invention. However, non-pharmaceutically acceptable salts can also be prepared as intermediate forms that can be subsequently converted to pharmaceutically acceptable salts. Such non-pharmaceutically acceptable salts forms, which may be useful, for example, in the purification or separation of the compounds of the invention, also form part of the invention.

[0079] Some of the compounds of formula (I) may form acid addition salts with one or more equivalents of the acid. The present invention includes within its scope all possible stoichiometric and non-stoichiometric forms.

[0080] (Solvate) Those skilled in the art of organic chemistry will understand that many organic compounds can form complexes with solvents in which they are reacted or from which they are precipitated or crystallized. These complexes are known as "solvates." For example, a complex with water is known as a "hydrate." Pharmaceutically acceptable solvates of the compounds of the present invention are within the scope of the present invention. In one embodiment, the pharmaceutically acceptable solvates of the compounds of the present invention include hydrates thereof.

[0081] In one embodiment, the crystalline form of the compound of formula (I) is a co-crystal or co-former. Such co-crystals or co-formers can be prepared with water-soluble molecules such as saccharin, caffeine, nicotinamide, or carboxylic acid. Co-formers can be prepared as described in Emami S et al. (2018) BioImpacts 8(4), 305-320, the technique of which is incorporated herein by reference.

[0082] It will be understood that the present invention includes pharmaceutically acceptable derivatives of compounds of formula (I) and these are included within the scope of the present invention.

[0083] As used herein, "pharmaceutically acceptable derivative" includes any pharmaceutically acceptable ester of a compound of formula (I), or a salt of such an ester, which, upon administration to a recipient, is capable of providing (directly or indirectly) a compound of formula (I) or an active metabolite or residue thereof.

[0084] (N-oxide) Compounds of formula (I) that contain an amine function may also form N-oxides, and a reference herein to a compound of formula (I) that contains an amine function also includes the N-oxide.

[0085] If the compound contains several amine functions, one or more nitrogen atoms may be oxidized to form N-oxides. Particular examples of N-oxides are the N-oxides of tertiary amines or the N-oxides of nitrogen atoms of nitrogen-containing heterocycles.

[0086] N-oxides can be formed by treatment of the corresponding amine with an oxidizing agent, such as hydrogen peroxide or a peracid (e.g., a percarboxylic acid); see, for example, "Advanced Organic Chemistry," Jerry March, 4th Edition, Wiley Interscience. More particularly, N-oxides can be made by the procedure of L.W. Deady (Syn. Commun. 1977, 7, 509-514), in which an amine compound is reacted with m-chloroperbenzoic acid (mCPBA) in an inert solvent such as dichloromethane.

[0087] (prodrug) Those skilled in the art will appreciate that certain protected derivatives of compounds of formula (I) that may be prepared prior to the final deprotection step may not possess pharmacological activity per se, but may, in some cases, be administered orally or parenterally and subsequently metabolized in the body to form pharmacologically active compounds of the present invention. Therefore, such derivatives may be described as "prodrugs." All such prodrugs of the compounds of the present invention are included within the scope of the present invention. Examples of prodrug functional groups suitable for the compounds of the present invention are described in Drugs of Today, Vol. 19, No. 9, 1983, pp. 499-538 and Topics in Chemistry, Chapter 31, pp. 306-316, and "Design of Prodrugs," by H. Bundgaard, Elsevier, 1985, Chapter 1 (the disclosures of which are incorporated herein by reference). It will further be appreciated by those skilled in the art that certain moieties known to those skilled in the art as "promoieties," for example, as described by H. Bundgaard in "Design of Prodrugs," the disclosure of which is incorporated herein by reference, can be placed on appropriate functional groups, if such groups are present in the compounds of the invention.

[0088] Also included within the scope of the compounds and various salts of the present invention are polymorphs thereof.

[0089] (enantiomers) Where chiral centers are present in compounds of formula (I), the present invention includes within its scope all possible enantiomers and diastereoisomers, including mixtures thereof. The different isomeric forms may be separated or resolved one from the other by conventional methods, or any given isomer may be obtained by conventional synthetic methods or by stereospecific or asymmetric syntheses. The invention also extends to any tautomeric forms or mixtures thereof.

[0090] (Isotopes) The present invention also includes all pharmaceutically acceptable isotopically labeled compounds which are identical to those set forth in formula (I) except for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number most commonly found in nature.

[0091] Examples of isotopes suitable for inclusion in compounds of the invention include isotopes of hydrogen, e.g., 2 H(D) and 3 H(T), an isotope of carbon, e.g. 11 C. 13 C, and 14 C, an isotope of chlorine, e.g. 36 Cl, isotopes of fluorine, e.g. 18 F, an isotope of iodine, e.g. 123 I, 125 I, and 131 I, isotopes of nitrogen, e.g. 13 N and 15 N, isotopes of oxygen, e.g. 15 O. 17 O, and 18 O, isotopes of phosphorus, e.g. 32 P, as well as sulfur isotopes, e.g., 35 Includes S.

[0092] Certain isotopically labeled compounds of formula (I), for example, those incorporating a radioisotope, are useful in drug and / or substrate tissue distribution studies. Compounds of formula (I) can also have valuable diagnostic properties in that they can be used to detect or identify the formation of complexes between the labeled compound and other molecules, peptides, proteins, enzymes, or receptors. Detection or identification methods can use compounds labeled with labeling agents such as radioisotopes, enzymes, fluorescent substances, luminescent substances (e.g., luminol, luminol derivatives, luciferin, aequorin, and luciferase). The radioisotope tritium, i.e., 3 H(T), and carbon-14, i.e., 14 C is particularly useful for this purpose given its ease of incorporation and ready means of detection.

[0093] Deuterium, i.e., 2 Substitution with heavier isotopes, such as H(D), may confer certain therapeutic advantages due to greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements, and therefore may be preferable in certain circumstances.

[0094] 11 C. 18 F, 15 O, and 13 Substitution with positron emitting isotopes, such as N, can be useful in Positron Emission Topography (PET) studies for examining target occupancy.

[0095] Isotopically labeled compounds of formula (I) can generally be prepared by conventional techniques known to those skilled in the art, or by processes analogous to those described in the accompanying examples and preparations, substituting an appropriate isotopically labeled reagent for the previously utilized non-labeled reagent.

[0096] (purity) It will be readily appreciated that, since the compounds of formula (I) are intended for use in pharmaceutical compositions, they are each preferably provided in substantially pure form, e.g., at least 60% pure, more suitably at least 75% pure, and preferably at least 85%, especially at least 98% pure (percentages given weight to weight). Impure preparations of the compounds may be used to prepare the purer forms used in the pharmaceutical compositions.

[0097] (method) According to a further aspect of the present invention, there is provided a method for preparing the compound of formula (I) and its derivatives. The following schemes are examples of synthetic schemes that can be used to synthesize the compounds of the present invention. In the following schemes, reactive groups can be protected and deprotected with protecting groups by well-established techniques.

[0098] According to a further aspect of the present invention there is provided a process for preparing a compound of formula (I) as defined herein, comprising the steps of: (a) a compound of formula (II); [ka] (In the formula, R 1 , n, X, R 3 , R 4 , R 5 , R 6 , R 7 ,ring A , and ring C is as defined herein, and P 1 represents a suitable protecting group, e.g., Boc) Deprotection of; (b) a compound of formula (III): [ka] (In the formula, R 1 ,n,R 3 , R 4 , R 5 , R 6 , and R 7 is as defined herein) into a compound of formula L 1 -XR 2 wherein X and R 2 is as defined herein, and L 1 represents a suitable leaving group, for example a halogen (i.e., chlorine) or a hydroxy group; (c) deprotecting the protected derivative of the compound of formula (I); (d) interconversion of a compound of formula (I) or a protected derivative thereof to a further compound of formula (I) or a protected derivative thereof; and (e) the optional formation of a pharmaceutically acceptable salt of a compound of formula (I). A method is provided that includes:

[0099] Process (a) typically involves a deprotection reaction to prepare a compound of formula (I). For example, P 1When represents Boc, process (a) usually involves the use of an acid, for example TFA.

[0100] Process (b) typically involves converting a compound of formula (II) to a compound of formula L in a suitable solvent, such as DCM, in the presence of suitable reagents, such as HATU and DIPEA. 1 -XR 2 This involves reacting the compound with

[0101] The compounds of formula (II) and (III) can be prepared according to the procedures described herein. For example, the compound of formula (II) can be prepared according to the experimental procedures described in Example 1, and the compound of formula (III) can be prepared according to the experimental procedures described in Example 27.

[0102] formula L 1 -XR 2 Compounds of formula (I) are either known or can be prepared according to known procedures.

[0103] A wide variety of well-known functional group interconversions for process (d) to convert precursor compounds to compounds of formula (I) are known to those skilled in the art and are described in "Advanced Organic Chemistry," Jerry March, 4th Edition, John Wiley & Sons, 1992. For example, possible metal-catalyzed functionalizations using organotin reagents (Stille reaction), Grignard reagents, and reactions with nitrogen nucleophiles are described in "Palladium Reagents and Catalysts" [Jiro Tsuji, Wiley, ISBN 0-470-85032-9] and "Handbook of OrganoPalladium Chemistry for Organic Synthesis" [Vol. 1, Ei-ichi Negishi, ed., Wiley, ISBN 0-471-31506-0].

[0104] Where appropriate, the reactions described herein may be preceded or followed by one or more reactions known to those skilled in the art, and carried out in an appropriate order to achieve the necessary substitutions for each of the variables defined herein, to give other compounds of formula (I). Non-limiting examples of such reactions, the conditions for which can be found in the literature, include: Protection of reactive functional groups, Deprotection of reactive functional groups, Halogenation, Dehalogenation, Dealkylation, Alkylation of amines, anilines, alcohols, and phenols, Mitsunobu reaction on hydroxyl groups, Cycloaddition reactions to suitable groups, Reduction of nitro, ester, cyano, aldehyde, transition metal-catalyzed coupling reactions, acylation, Sulfonylation / introduction of sulfonyl groups, Saponification / hydrolysis of ester groups, amidation or transesterification of ester groups, esterification or amidation of carboxyl groups, Halogen exchange, nucleophilic substitution by amines, thiols, or alcohols; reductive amination, Oxime formation on carbonyl and hydroxylamine groups, S-oxidation, N-oxidation, chloride : are listed.

[0105] It is recognized that the sequence of reactions involving the aryl coupling and reduction may be varied. It is also recognized that a wide range of palladium-based catalysts are suitable for carrying out the aryl coupling reaction.

[0106] It will also be appreciated that isomer separation can be carried out at any suitable stage in the synthetic sequence. It should be emphasized that such chiral separations form an important aspect of the present invention and that such separations can be carried out according to the methods described herein or according to known methods. It will also be appreciated that it may be advantageous to temporarily form protected derivatives of intermediates in the synthesis, such as Boc-protected amines or SEM-protected amides, to facilitate chromatographic separations, chiral resolutions, or to obtain improved solubility or yields at certain steps.

[0107] In many of the above reactions, it may be necessary to protect one or more groups to prevent reaction from occurring at an undesirable location on the molecule. Examples of protecting groups and methods for protecting and deprotecting functional groups can be found in "Protective Groups in Organic Synthesis" (T. Green and P. Wuts; 4th ed.; John Wiley and Sons, 2007).

[0108] Hydroxy groups can be protected, for example, as ethers (-OR) or esters (-OC(=O)R), such as tert-butyl ethers; tetrahydropyranyl (THP) ethers; benzyl, benzhydryl (diphenylmethyl), or trityl (triphenylmethyl) ethers; trimethylsilyl or tert-butyldimethylsilyl ethers; or acetyl esters (-OC(=O)CH).

[0109] Amine groups can be, for example, as amides (-NRCO-R) or carbamates (-NRCO-OR), such as: methylamide (-NHCO-CH); benzyl carbamate (-NHCO-OCH2C6H5, -NH-Cbz, or NH-Z); tert-butyl carbamate (-NHCOOC(CH3)3, NH-Boc); It can be protected as 2-biphenyl-2-propyl carbamate (-NHCO-OC(CH)CHCH, NH-Boc), as 9-fluorenylmethyl carbamate (-NH-Fmoc), as 6-nitroveratryl carbamate (-NH-Nvoc), as 2-trimethylsilylethyl carbamate (-NH-Teoc), as 2,2,2-trichloroethyl carbamate (-NH-Troc), as allyl carbamate (-NH-Alloc), or as 2(-phenylsulfonyl)ethyl carbamate (-NH-Psec).

[0110] Other protecting groups for amines, such as cyclic amines and heterocyclic NH groups, include toluenesulfonyl (tosyl) and methanesulfonyl (mesyl) groups, benzyl groups, such as para-methoxybenzyl (PMB), and tetrahydropyranyl (THP) groups.

[0111] Carboxylic acid groups can be used as esters, for example: 1-7 Alkyl esters (e.g., methyl esters; tert-butyl esters); C 1-7 Haloalkyl esters (e.g., C 1-7 Trihaloalkyl ester); Tri C 1-7 Alkylsilyl-C 1-7 Alkyl ester; or C 5-20 Aryl-C 1-7 It may be protected as an alkyl ester (e.g., benzyl ester; nitrobenzyl ester; para-methoxybenzyl ester).

[0112] It will be appreciated by those skilled in the art that certain compounds of the invention can be converted to other compounds of the invention according to standard chemical methods.

[0113] Pharmaceutically acceptable salts may be prepared in a conventional manner by reaction with the appropriate acid or acid derivative.

[0114] (therapeutic utility) The compounds of the present invention, subgroups and examples thereof, are inhibitors of Pol θ polymerase activity, which may be useful in preventing or treating the disease states or disorders described herein. Furthermore, the compounds of the present invention and subgroups thereof are useful in preventing or treating diseases or conditions mediated by Pol θ. Reference to preventing or methods of prophylaxis or treatment of a disease state or disorder, such as cancer, includes within its scope alleviating or reducing the incidence of cancer.

[0115] Thus, for example, it is envisaged that the compounds of the invention will be useful in alleviating or reducing the incidence of cancer.

[0116] The compounds of the invention may be useful in treating the adult population. The compounds of the invention may be useful in treating the pediatric population.

[0117] As a result of their inhibition of Pol θ, the compounds are useful in providing a means of neutralizing the ability of cells to undergo MMEJ. It is therefore expected that the compounds may prove useful in treating or preventing proliferative disorders such as cancer. Furthermore, the compounds of the present invention may be useful in treating diseases in which disorders associated with cell accumulation exist.

[0118] Without being bound by theory, the Pol θ inhibitors of the invention are expected to exhibit particular properties that make them particularly useful in the therapeutic treatment of certain cancers. For example, in one embodiment, the Pol θ inhibitors of the invention are preferably lethal in BRCA1- and BRCA2-deficient primary and secondary solid tumors, including those of the breast, ovary, prostate, and pancreas.

[0119] In further embodiments, the Pol θ inhibitors of the present invention are preferably lethal in a variety of primary and secondary solid tumors that undergo HRD through mechanisms other than BRCA deficiency, such as those involving promoter hypermethylation. In these tumors, where DSB repair pathways may not be fully downregulated, the Pol θ i can be administered together with another DDR modulator, such as a PARP inhibitor, a DNA-PK inhibitor, an ATR inhibitor, an ATM inhibitor, a wee1 inhibitor, or a CHK1 inhibitor.

[0120] In further embodiments, the Pol θ inhibitors of the present invention are preferably lethal in primary and secondary breast, ovarian, prostate, and pancreatic tumors that retain a BRCA1 deficiency but are resistant to PARPi treatment, with or without exposure to PARPi drug treatment.

[0121] In further embodiments, the Pol θ inhibitors of the present invention, preferably when given in conjunction with a PARPi therapeutic program, increase ORR, including CRR, delay the onset of PARPi resistance, increase time to recurrence and DFS, and increase OS in HRD (BRCA1 / 2-deficient and other HRD mechanisms) primary and secondary tumors (breast, ovarian, prostate, and pancreatic).

[0122] In a further embodiment, the Pol θ inhibitors of the present invention preferably inhibit the loss of ATM activity (ATM), particularly in the context of WT p53. - / - (2014) demonstrate synthetic sickness and / or synthetic lethality in various tumors associated with CLL. This tumor type, along with CLL, comprises approximately 10% of all solid tumors, including gastric, lung, breast, and CRC. Co-treatment with another DDR modulator, such as a DNA-PK inhibitor, a PARP inhibitor, or an ATR inhibitor, can further enhance such activity. Pol theta inhibitors resensitize CLL to classical chemotherapy and chemoimmunotherapy in which drug resistance has emerged. Thus, according to a further embodiment, the pharmaceutical composition of the present invention further comprises a DNA-PK inhibitor, a PARP inhibitor, or an ATR inhibitor.

[0123] In further embodiments, the Pol θ inhibitors of the present invention preferably exhibit synthetic disease and / or synthetic lethality in various tumors defective in the non-homologous end joining (NHEJ-D) DNA double-strand break repair process. These tumor types comprise approximately 2-10% of all solid tumors, including those of the prostate, pancreas, cervix, breast, lung, bladder, and esophagus. Co-treatment with another DDR modulator, such as a PARP inhibitor, ATM inhibitor, wee1 inhibitor, CHK inhibitor, or ATR inhibitor, can further enhance such activity. Pol θ inhibitors further sensitize NHEJD cancer cells to DNA DSB-inducing chemotherapy and ionizing radiation-based therapy. Thus, according to further embodiments, the pharmaceutical compositions of the present invention further comprise a PARP inhibitor, ATM inhibitor, wee1 inhibitor, CHK inhibitor, or ATR inhibitor.

[0124] In a further embodiment, the Pol θ inhibitors of the present invention preferably reduce the DNA replication stress response during chemotherapy of HR-competent tumors, such as ovarian, NSCL, and breast tumors, that overexpress Pol θ. This increases ORR to treatment and increases OS. Such effects are particularly likely with cytarabine (Ara-C) and hydroxyurea, which are used in a wide variety of leukemias, including CML, and in the management of squamous cell carcinoma.

[0125] In further embodiments, the Pol θ inhibitors of the present invention selectively sensitize solid tumors to radiation therapy, including EBRT and brachytherapy, preferably with little or no sensitization of normal tissues. In the fractionated, curative-intent setting, this increases locoregional control, promoting increased survival. This is particularly evident in the management of NSCLC, SCCH&N, colorectal cancer, prostate cancer, and pancreatic cancer.

[0126] In further embodiments, the Pol θ inhibitors of the present invention, preferably with or without co-drug treatment with a PARPi, exhibit synthetic disease and / or synthetic lethality in PTEN-deficient tumors such as CaP. Furthermore, such tumors exhibit profound sensitivity to radiotherapy due to both PTEN deletion and Pol θ inhibitor-induced radiosensitivity.

[0127] In further embodiments, the Pol θ inhibitors of the present invention preferably inhibit TLS polymerase activity and not only sensitize primary and secondary solid tumors (e.g., breast, lung, ovarian, CRC) to drugs (e.g., cisplatin, mitomycin, and cyclophosphamide), but also reduce the acquisition of drug-induced mutations implicated in tumor resistance, resulting in prolonged remission and increased TTR.

[0128] In further embodiments, Pol θ inhibitors of the present invention preferably resensitize BCR-ABL-positive CML that has developed resistance to imatinib, as well as other solid tumors with elevated levels of ligase IIIα, decreased levels of ligase IV, and increased dependency on altEJ DSB repair.

[0129] In a further embodiment, Pol θ inhibitors of the present invention suitably treat aromatase inhibitor-resistant ER tumors, which again exhibit elevated ligase IIIα levels, reduced ligase IV levels, and increased dependency on altEJ DSB repair. - It exhibits synthetic disease and / or synthetic lethality in primary and secondary breast cancer.

[0130] According to a further aspect of the present invention there is provided a compound of formula (I) as defined herein for use in the treatment of a tumour characterised by homologous recombination deficiency (HRD).

[0131] Reference herein to "homologous recombination deficiency (HRD)" will be understood to refer to any genetic variation that results in the deficiency or loss of function of a homologous recombination gene. Examples of such genetic variations include mutations (e.g., point mutations), substitutions, deletions, single nucleotide polymorphisms (SNPs), haplotypes, chromosomal abnormalities, copy number variations (CNVs), epigenetics, DNA inversions, reduced expression, and mislocalization.

[0132] In one embodiment, the homologous recombination gene is selected from any of: ATM, ATR, BRCA1, BRCA2, BARD1, RAD51C, RAD50, CHEK1, CHEK2, FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, PALB2 (FANCN), FANCP (BTBD12), ERCC4 (FANCQ), PTEN, CDK12, MRE11, NBS1, NBN, CLASPIN, BLM, WRN, SMARCA2, SMARCA4, LIG1, RPA1, RPA2, BRIP1, and PTEN.

[0133] Reference herein to "non-homologous end joining deficiency (NHEJD)" will be understood to refer to any genetic variation that results in the deficiency or loss of function of the homologous recombination gene. Examples of such genetic variations include mutations (e.g., point mutations), substitutions, deletions, single nucleotide polymorphisms (SNPs), haplotypes, chromosomal abnormalities, copy number variations (CNVs), epigenetics, DNA inversions, reduced expression, and mislocalization.

[0134] In one embodiment, the non-homologous end joining gene is selected from any one or more of: LIG4, NHEJ1, POLL, POLM, PRKDC, XRCC4, XRCC5, XRCC6, and DCLRE1C.

[0135] According to a further aspect of the present invention there is provided a compound of formula (I) as defined herein for use in the treatment of tumours which overexpress Pol Theta.

[0136] According to a further aspect of the present invention there is provided a compound of formula (I) as defined herein for use in the treatment of tumours with elevated levels of ligase IIIα, decreased levels of ligase IV and increased dependency on altEJ DSB repair.

[0137] Examples of cancers (and their benign counterparts) that may be treated (or inhibited) include tumors of epithelial origin (various types of adenomas and carcinomas, including adenocarcinoma, squamous cell carcinoma, transitional cell carcinoma, and other carcinomas), such as tumors of the bladder and urinary tract, breast, gastrointestinal tract (including esophagus, stomach (gastric), small intestine, colon, rectum, and anus), liver (hepatocellular carcinoma), gallbladder and biliary system, exocrine pancreas, kidney, lung (e.g., adenocarcinoma, small cell lung carcinoma, non-small cell lung carcinoma, bronchioloalveolar carcinoma, and mesothelioma), head and neck (e.g., tongue, buccal cavity, larynx, pharynx, nasopharynx, tonsils, salivary glands, nasal passages, and rectum), and ... such as bladder and urinary tract, breast, gastrointestinal tract (including esophagus, stomach (gastric), small in carcinomas of the ovaries, fallopian tubes, peritoneum, vagina, vulva, penis, cervix, uterine muscle, endometrium, thyroid gland (e.g., follicular thyroid carcinoma), adrenal gland, prostate, skin, and adnexa (e.g., melanoma, basal cell carcinoma, squamous cell carcinoma, keratoacanthoma, dysplastic nevi); hematologic malignancies and related conditions of lymphoid lineage (e.g., acute lymphocytic leukemia [ALL], chronic lymphocytic leukemia [CLL], B-cell lymphomas, e.g., diffuse large B-cell lymphoma [DLBCL], follicular lymphoma, Burkitt's lymphoma, mantle cell lymphoma, MAL) T lymphomas, T-cell lymphomas, and leukemias, natural killer [NK] cell lymphoma, Hodgkin's lymphoma, hairy cell leukemia, monoclonal gammopathy of undetermined significance, plasmacytoma, multiple myeloma, and post-transplant lymphoproliferative disorders), and hematological malignancies and related conditions of the myeloid lineage (e.g., acute myeloid leukemia [AML], chronic myeloid leukemia [CML], chronic myelomonocytic leukemia [CMML], hypereosinophilic syndromes, myeloproliferative disorders such as polycythemia vera, essential thrombocythemia, and primary myelofibrosis, myeloproliferative syndromes, myelodysplasia hematological malignancies (i.e., leukemias, lymphomas) and premalignant blood disorders and borderline malignant disorders, including leukemia, leukemia syndrome, and promyelocytic leukemia; tumors of mesenchymal origin, e.g., sarcomas of soft tissue, bone, or cartilage, e.g., osteosarcoma, fibrosarcoma, chondrosarcoma, rhabdomyosarcoma, leiomyosarcoma, liposarcoma, angiosarcoma, Kaposi's sarcoma, Ewing's sarcoma, synovial sarcoma, epithelioid sarcoma, gastrointestinal stromal tumors, benign and malignant histiocytomas, and dermatofibrosarcoma protuberans; tumors of the central or peripheral nervous system (e.g., astrocytoma, glioma and glioblastoma, meningioma, ependymoma, pineal tumor, and schwannoma);These include, but are not limited to, endocrine tumors (e.g., pituitary tumors, adrenal tumors, islet cell tumors, parathyroid tumors, carcinoid tumors, and medullary thyroid carcinoma); ocular and adnexal tumors (e.g., retinoblastoma); germ cell and trophoblastic tumors (e.g., teratomas, seminomas, dysgerminomas, hydatidiform moles, and choriomas); and pediatric and embryonal tumors (e.g., medulloblastomas, neuroblastomas, Wilms' tumors, and primitive neuroectodermal tumors); or congenital or other syndromes that predispose a patient to malignancies (e.g., xeroderma pigmentosum);

[0138] Many diseases are characterized by persistent and uncontrolled angiogenesis. Chronic proliferative diseases are often accompanied by significant angiogenesis, which can contribute to or maintain inflammatory and / or proliferative conditions, or cause tissue destruction through the infiltrative proliferation of blood vessels. Tumor growth and metastasis are known to be angiogenesis-dependent. Therefore, the compounds of the present invention may be useful for preventing and inhibiting the initiation of tumor angiogenesis. In particular, the compounds of the present invention may be useful for the treatment of metastasis and metastatic cancer.

[0139] Metastasis or metastatic disease is the spread of disease from one organ or part to another, non-adjacent organ or part. Cancers that can be treated with the compounds of the present invention include primary tumors (i.e., cancer cells at the site of origin), local invasion (cancer cells that invade and invade surrounding normal tissues within a local area), and metastatic (or secondary) tumors, i.e., tumors formed from malignant cells that have circulated through the bloodstream (hematogenous spread), or via lymphatic vessels, or across body cavities (transcatheteric spread) to other sites and tissues in the body.

[0140] Particular cancers include hepatocellular carcinoma, melanoma, esophageal, renal, colon, colorectal, lung, eg, mesothelioma or lung adenocarcinoma, breast, bladder, gastrointestinal, ovarian, and prostate cancer.

[0141] A further aspect provides the use of a compound for the manufacture of a medicament for the treatment of a disease or condition described herein, in particular cancer.

[0142] The compounds may also be useful in the treatment of tumor growth, pathogenesis, resistance to chemotherapy and radiotherapy by sensitizing cells to chemotherapy, and as anti-metastatic agents.

[0143] The potency of the compounds of the invention as inhibitors of Pol θ can be measured using the biological and biophysical assays described in the Examples herein, and the level of affinity exhibited by a given compound is expressed as the IC 50 Certain compounds of the invention have an IC value of less than 1 μM, more particularly less than 0.1 μM. 50 It is a compound having a value.

[0144] The role of Pol θ loss in enhancing the effectiveness of CRISPR-mediated gene editing is described in WO2017 / 062754.Therefore, Pol θ inhibitory compounds are likely to be useful for enhancing the efficiency of CRISPR-based editing methods and / or CRISPR-based editing therapies.In addition, compound-mediated Pol θ inhibition is likely to reduce the frequency of random integration events, thus providing a way to improve any safety concerns of CRISPR-mediated techniques.Therefore, according to a further aspect of the present invention, there is provided the use of a compound of formula (I) as defined herein in CRISPR-based editing methods and / or CRISPR-based editing therapies, such as enhancing the efficiency of CRISPR-based editing methods and / or CRISPR-based editing therapies.

[0145] (Pharmaceutical composition) While it is possible for the active compound to be administered alone, it is preferable to present it as a pharmaceutical composition (e.g., a formulation), hi one embodiment, this is a sterile pharmaceutical composition.

[0146] Accordingly, the present invention further provides pharmaceutical compositions as defined above, and methods for making pharmaceutical compositions comprising (e.g., in admixture with) at least one compound of formula (I) (and subgroups thereof as defined herein) together with one or more pharmaceutically acceptable excipients as described herein and, optionally, other therapeutic or prophylactic agents.

[0147] Pharmaceutically acceptable excipients can be selected from, for example, carriers (e.g., solid, liquid, or semi-solid carriers), adjuvants, diluents, fillers or extenders, granulating agents, coating agents, release-controlling agents, binders, disintegrants, lubricants, preservatives, antioxidants, buffers, suspending agents, thickeners, flavoring agents, sweeteners, taste-masking agents, stabilizers, or any other excipients customarily used in pharmaceutical compositions. Examples of excipients for various types of pharmaceutical compositions are described in more detail below.

[0148] The term "pharmaceutically acceptable," as used herein, refers to compounds, materials, compositions, and / or dosage forms that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of a subject (e.g., a human) without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio. Each carrier, excipient, etc. must also be "acceptable" in the sense of being compatible with the other ingredients of the formulation.

[0149] Pharmaceutical compositions containing compounds of formula (I) can be formulated according to known techniques, see, for example, Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, PA, USA.

[0150] The pharmaceutical composition can be in any form suitable for oral, parenteral, topical, intranasal, intrabronchial, sublingual, ophthalmic, intraaural, rectal, vaginal, or transdermal administration. If the composition is intended for parenteral administration, it can be formulated for intravenous, intramuscular, intraperitoneal, subcutaneous administration, or for direct delivery into the target organ or tissue by injection, infusion, or other delivery means. Delivery can be by bolus injection, short-term infusion, or longer-term infusion, and can be by passive delivery or by use of a suitable infusion pump or syringe driver.

[0151] Pharmaceutical formulations adapted for parenteral administration include aqueous and non-aqueous sterile injection solutions that may contain antioxidants, buffers, bacteriostats, cosolvents, surfactants, organic solvent mixtures, cyclodextrin complexing agents, emulsifiers (to form and stabilize emulsion formulations), liposome components for forming liposomes, gellable polymers for forming polymer gels, lyoprotectants, and, in particular, combinations of agents for stabilizing the active ingredient in soluble form and making the formulation isotonic with the blood of the intended recipient. Pharmaceutical formulations for parenteral administration can also take the form of aqueous and non-aqueous sterile suspensions that may contain suspending agents and thickening agents (RG Strickly, "Solubilizing Excipients in Oral and Injectable Formulations," Pharmaceutical Research, Vol. 21(2) 2004, p. 201-230).

[0152] The formulations can be presented in single-dose or multi-dose containers, for example, sealed ampoules, vials, and pre-filled syringes, and can be stored in a freeze-dried (lyophilized) state, requiring only the addition of a sterile liquid carrier, for example, water for injection, immediately prior to use. In one embodiment, the formulation is provided as an active pharmaceutical ingredient in a bottle for subsequent reconstitution with a suitable diluent.

[0153] Pharmaceutical formulations can be prepared by lyophilizing the compounds of formula (I) or any subgroup thereof. Lyophilization refers to the procedure of freeze-drying a composition. Thus, freeze-drying and lyophilization are used synonymously herein.

[0154] Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules, and tablets.

[0155] Pharmaceutical compositions of the present invention for parenteral injection may also comprise pharmaceutically acceptable sterile aqueous or non-aqueous solutions, dispersions, suspensions, or emulsions, as well as sterile powders for reconstitution into sterile injectable solutions or dispersions immediately before use.

[0156] Examples of suitable aqueous and non-aqueous carriers, diluents, solvents, or vehicles include water, ethanol, polyols (e.g., glycerol, propylene glycol, polyethylene glycol, etc.), carboxymethylcellulose, and suitable mixtures thereof, vegetable oils (e.g., sunflower oil, safflower oil, corn oil, or olive oil), and injectable organic esters, such as ethyl oleate. Proper fluidity can be maintained, for example, by using thickening or coating materials such as lecithin, by maintaining the required particle size in the case of dispersions, and by using surfactants.

[0157] The compositions of the present invention may also contain adjuvants such as preservatives, wetting agents, emulsifying agents, and dispersing agents. Prevention of microbial action can be ensured by the inclusion of various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, etc. It may also be desirable to include agents for adjusting osmotic pressure, such as sugars and sodium chloride. Prolonged absorption of injectable pharmaceutical forms can be brought about by the inclusion of agents delaying absorption, such as aluminum monostearate and gelatin.

[0158] In one particular embodiment of the invention, the pharmaceutical composition is in a form suitable for iv administration, for example, by injection or infusion. For intravenous administration, the solution can be administered as is or can be injected into an infusion bag (containing a pharmaceutically acceptable excipient, for example, 0.9% saline or 5% glucose) before administration.

[0159] In another particular embodiment, the pharmaceutical composition is in a form suitable for subcutaneous (sc) administration.

[0160] Pharmaceutical dosage forms suitable for oral administration include tablets (coated or uncoated), capsules (hard or soft shell), caplets, pills, lozenges, syrups, solutions, powders, granules, elixirs, and suspensions, sublingual tablets, wafers, or patches, e.g., buccal patches.

[0161] Thus, tablet compositions can contain a unit dosage of the active compound together with an inert diluent or carrier, such as a sugar or sugar alcohol, for example, lactose, sucrose, sorbitol, or mannitol; and / or a non-sugar-derived diluent, for example, sodium carbonate, calcium phosphate, calcium carbonate, or cellulose or its derivatives, for example, microcrystalline cellulose (MCC), methylcellulose, ethylcellulose, hydroxypropylmethylcellulose, and starch, for example, corn starch. Tablets can also contain standard ingredients such as binders and granulating agents, such as polyvinylpyrrolidone, disintegrants (e.g., swellable cross-linked polymers, such as cross-linked carboxymethylcellulose), lubricants (e.g., stearates), preservatives (e.g., parabens), antioxidants (e.g., BHT), buffers (e.g., phosphate or citrate buffers), and effervescent agents, such as citrate / bicarbonate mixtures. Such excipients are well known and need not be discussed in detail here.

[0162] Tablets can be designed to release the drug upon contact with gastric fluids (immediate-release tablets) or to release over an extended period of time or in a controlled manner in specific regions of the gastrointestinal tract (controlled-release tablets). Capsule formulations can be of the hard or soft gelatin variety and can contain the active ingredient in solid, semi-solid, or liquid form. Gelatin capsules can be formed from animal gelatin or its synthetic or plant-derived equivalents.

[0163] Solid dosage forms (e.g., tablets, capsules, etc.) can be coated or uncoated. Coatings can act either as protective films (e.g., polymers, waxes, or varnishes) or as mechanisms for controlling drug release or for aesthetic or identification purposes. Coatings (e.g., Eudragit™-type polymers) can be designed to release the active ingredient at a desired site in the gastrointestinal tract. Thus, coatings can be selected to degrade under specific pH conditions in the gastrointestinal tract, thereby selectively releasing the compound in the stomach or in the ileum, duodenum, jejunum, or colon.

[0164] Instead of or in addition to a coating, the drug can be presented in a solid matrix containing a release-controlling agent, e.g., a release-retardant agent, which can be adapted to release the compound in a controlled manner in the gastrointestinal tract. Alternatively, the drug can be presented in a polymer coating, e.g., a polymethacrylate polymer coating, which can be adapted to selectively release the compound in the gastrointestinal tract under conditions of varying acidity or alkalinity. Alternatively, the matrix material or release-retarding coating can take the form of an erodible polymer (e.g., maleic anhydride polymer) that erodes substantially continuously as the dosage form passes through the gastrointestinal tract. In another option, the coating can be designed to disintegrate under microbial action in the gastrointestinal tract. As a further option, the active compound can be formulated in a delivery system that provides osmotic control of the release of the compound. Osmotic release and other delayed- or sustained-release formulations (e.g., formulations based on ion exchange resins) can be prepared according to methods well known to those skilled in the art.

[0165] The compound of formula (I) can be formulated with a carrier and administered in the form of nanoparticles, the increased surface area of ​​which aids their absorption. Furthermore, nanoparticles offer the possibility of direct penetration into cells. Nanoparticle drug delivery systems are described in "Nanoparticle Technology for Drug Delivery," edited by Ram B. Gupta and Uday B. Kompella, published by Informa Healthcare, ISBN 9781574448573, March 13, 2006. Nanoparticles for drug delivery are also described in J. Control. Release, 2003, 91(1-2), 167-172 and Sinha et al., Mol. Cancer Ther. August 1, (2006) 5, 1909.

[0166] Pharmaceutical compositions typically contain about 1% (w / w) to about 95% (w / w) of the active ingredient and 99% (w / w) to 5% (w / w) of a pharmaceutically acceptable excipient or combination of excipients. In particular, the compositions contain about 20% (w / w) to about 90%,% (w / w) of the active ingredient and 80% (w / w) to 10% of a pharmaceutically acceptable excipient or combination of excipients. Pharmaceutical compositions contain about 1% to about 95%, in particular about 20% to about 90%, of the active ingredient. Pharmaceutical compositions according to the present invention may be, for example, in unit dose form, such as in the form of ampoules, vials, suppositories, pre-filled syringes, dragees, tablets, or capsules.

[0167] Pharmaceutically acceptable excipients can be selected according to the desired physical form of the formulation and can be selected from, for example, diluents (e.g., solid diluents such as fillers or bulking agents; and liquid diluents such as solvents and cosolvents), disintegrants, buffers, lubricants, flow aids, release-controlling (e.g., release-retarding or delaying polymers or waxes) agents, binders, granulating agents, pigments, plasticizers, antioxidants, preservatives, flavors, taste-masking agents, tonicity adjusters, and coating agents.

[0168] Those skilled in the art will have the expertise to select appropriate amounts of ingredients for use in a formulation. For example, tablets and capsules typically contain 0-20% disintegrant, 0-5% lubricant, 0-5% flow aid, and / or 0-99% (w / w) filler or bulking agent (depending on drug dose). They may also contain 0-10% (w / w) polymer binder, 0-5% (w / w) antioxidant, and 0-5% (w / w) pigment. Extended-release tablets will additionally contain 0-99% (w / w) release-controlling (e.g., retarding) polymer (depending on dose). The film coat of a tablet or capsule typically contains 0-10% (w / w) polymer, 0-3% (w / w) pigment, and / or 0-2% (w / w) plasticizer.

[0169] Parenteral formulations typically contain 0-20% (w / w) buffer, 0-50% (w / w) cosolvent, and / or 0-99% (w / w) water for injection (WFI) (depending on the dose and when freeze-dried). Formulations for intramuscular depots may also contain 0-99% (w / w) oil.

[0170] Pharmaceutical compositions for oral administration can be obtained by combining the active ingredient with a solid carrier, granulating the resulting mixture if desired, and processing the mixture into tablets, dragee cores, or capsules after adding suitable excipients if desired or necessary. They can also be incorporated into a polymer or waxy matrix that allows the active ingredient to diffuse or be released in measured amounts.

[0171] The compounds of the present invention can also be formulated as solid dispersions. A solid dispersion is a homogeneous, extremely finely dispersed phase of two or more solids. Solid solutions (molecular dispersions), a type of solid dispersion, are well known for their use in pharmaceutical technology (see Chiou and Riegelman, J. Pharm. Sci., 60, 1281-1300 (1971)), and are useful for increasing the dissolution rate and bioavailability of poorly water-soluble drugs.

[0172] The present invention also provides solid dosage forms containing the above-described solid solutions. Solid dosage forms include tablets, capsules, chewable tablets, and dispersible or effervescent tablets. Known excipients can be mixed with the solid solutions to provide the desired dosage form. For example, capsules can contain the solid solutions mixed with (a) a disintegrant and a lubricant, or (b) a disintegrant, a lubricant, and a surfactant. Additionally, capsules can contain a filler such as lactose or microcrystalline cellulose. Tablets can contain the solid solutions mixed with at least one disintegrant, a lubricant, a surfactant, a filler, and a glidant. Chewable tablets can contain the solid solutions mixed with a filler, a lubricant, and, if desired, an additional sweetener (e.g., an artificial sweetener), and a suitable flavoring. Solid solutions can be formed by spraying a solution of the drug and a suitable polymer onto the surface of an inert carrier, such as sugar beads ("nonpareils"). These beads can then be filled into capsules or compressed into tablets.

[0173] Pharmaceutical formulations can be presented to patients in "patient packs" that contain the entire course of treatment in a single package, usually a blister pack. Patient packs have an advantage over traditional prescriptions, in which a pharmacist separates a patient supply of medication from a bulk supply, in that the patient always has access to the package insert contained in the patient pack, which is typically absent from the patient's prescription. The inclusion of the package insert has been shown to improve patient compliance with physician instructions.

[0174] Compositions for topical use and nasal delivery include ointments, creams, sprays, patches, gels, drops, and inserts (e.g., intraocular inserts). Such compositions can be formulated according to known methods.

[0175] Examples of preparations for rectal or vaginal administration include pessaries and suppositories, which may be formed, for example, from a shaped plastic or waxy material containing the active compound. Solutions of the active compound can also be used for rectal administration.

[0176] Compositions for administration by inhalation can take the form of inhalable powder compositions or liquid or powder sprays, and can be administered in standard forms using powder inhaler devices or aerosol dispensing devices. Such devices are well known. For administration by inhalation, powdered formulations usually contain the active compound together with an inert solid powdered diluent such as lactose.

[0177] The compounds of formula (I) are typically provided in unit dosage form and, as such, typically contain sufficient compound to provide a desired level of biological activity. For example, a formulation may contain 1 nanogram to 2 grams of active ingredient, e.g., 1 nanogram to 2 milligrams of active ingredient. Within these ranges, particular subranges of compound are 0.1 milligram to 2 grams of active ingredient (more typically, 10 milligrams to 1 gram, e.g., 50 milligrams to 500 milligrams), or 1 microgram to 20 milligrams (e.g., 1 microgram to 10 milligrams, e.g., 0.1 milligram to 2 milligrams of active ingredient).

[0178] For oral compositions, a unit dosage form may contain from 1 milligram to 2 grams, more typically from 10 milligrams to 1 gram, for example, 50 milligrams to 1 gram, for example, 100 milligrams to 1 gram of active compound.

[0179] The active compound is administered to a patient in need thereof (eg, a human or animal patient) in an amount sufficient to achieve the desired therapeutic effect.

[0180] (Treatment method) The compounds of formula (I) and subgroups defined herein may be useful in the prevention or treatment of various disease states or disorders mediated by Pol θ. Thus, according to a further aspect of the present invention, there is provided a method of treating a disease state or disorder mediated by Pol θ (e.g., cancer), comprising administering to a subject in need thereof a compound of formula (I) as described herein. Examples of such disease states and disorders are set forth above and include, in particular, cancer.

[0181] The compounds are typically administered to a subject in need of such administration, such as a human or animal patient, particularly a human.

[0182] The compound is usually administered in an amount that is therapeutically or prophylactically useful and generally non-toxic. However, in certain situations (e.g., in the case of life-threatening diseases), the benefits of administering a compound of formula (I) may outweigh the disadvantages of any toxic or side effects, and in such cases it may be deemed desirable to administer the compound in an amount associated with some toxicity.

[0183] The compound can be administered over a long period of time to maintain beneficial therapeutic effects, or it can be administered for a short period of time, or it can be administered in a continuous or intermittent manner (e.g., in a pulsatile manner) to provide administration.

[0184] Typical daily doses of a compound of formula (I) can range from 100 picograms to 100 milligrams per kilogram of body weight, more typically from 5 nanograms to 25 milligrams per kilogram of body weight, and more usually from 10 nanograms to 15 milligrams per kilogram (e.g., 10 nanograms to 10 milligrams, more typically from 1 microgram per kilogram to 20 milligrams per kilogram of body weight, e.g., 1 microgram to 10 milligrams per kilogram), although higher or lower doses can be administered if needed. The compound of formula (I) can be administered daily, or repeatedly, for example, every 2, or 3, or 4, or 5, or 6, or 7, or 10, or 14, or 21, or 28 days.

[0185] The compounds of the present invention can be orally administered in dosage ranges of, for example, 1 to 1500 mg, 2 to 800 mg, or 5 to 500 mg, e.g., 2 to 200 mg or 10 to 1000 mg; specific examples of dosages include 10, 20, 50, and 80 mg. The compounds can be administered one or more times daily. The compounds can be administered continuously (i.e., taken every day without interruption for the duration of the treatment regimen). Alternatively, the compounds can be administered intermittently (i.e., taken continuously for a given period, such as one week, throughout the duration of the treatment regimen, followed by a break for a period, such as one week, followed by another period, such as one week). Examples of treatment regimens involving intermittent administration include regimens in which administration is cycled 1 week on, 1 week off; or 2 weeks on, 1 week off; or 3 weeks on, 1 week off; or 2 weeks on, 2 weeks off; or 4 weeks on, 2 weeks off; or 1 week on, 3 weeks off, for one or more cycles, e.g., 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more cycles.

[0186] In one particular dosing schedule, a patient receives an infusion of a compound of formula (I) for one hour daily for up to 10 days, particularly up to five days per week, with treatment repeated at desired intervals, such as every 2 to 4 weeks, particularly every 3 weeks.

[0187] More particularly, patients receive a one hour daily infusion of a compound of formula (I) for five days, with treatment repeated every three weeks.

[0188] In another particular administration schedule, the patient receives an infusion over 30 minutes to 1 hour, followed by a maintenance infusion of variable duration, eg, 1 to 5 hours, eg, 3 hours.

[0189] In a more particular dosing schedule, the patient receives a continuous infusion for a period of 12 hours to 5 days, particularly a continuous infusion for a period of 24 hours to 72 hours.

[0190] In another particular dosing schedule, patients receive oral administration of the compound once a week.

[0191] In another particular dosing schedule, the patient is administered the compound orally once daily for 7 to 28 days, for example, 7, 14, or 28 days.

[0192] In another particular dosing schedule, patients are administered the compound orally once daily for 1, 2, 3, 5, or 1 week, followed by the necessary number of days off to complete a 1- or 2-week cycle.

[0193] In another particular dosing schedule, patients receive the compound orally once daily for two weeks, followed by two weeks off the drug.

[0194] In another particular dosing schedule, patients receive the compound orally once daily for two weeks, followed by a one-week break.

[0195] In another particular dosing schedule, patients receive the compound orally once daily for one week, followed by one week off the drug.

[0196] Ultimately, however, the amount of compound administered and the type of composition used will be appropriate to the nature of the disease or physiological condition being treated and will be at the discretion of the physician.

[0197] It will be appreciated that Pol theta inhibitors can be used as single agents or in combination with other anticancer agents. Combination studies can be performed, for example, as described in Chou TC, Talalay P., "Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors," Adv Enzyme Regulat 1984;22:27-55.

[0198] The compounds defined herein can be administered as the sole therapeutic agent, or they can be administered in combination therapy with one of many other compounds (or therapies) for the treatment of a particular disease state, for example, a neoplastic disease such as cancer, as defined herein above. For the treatment of the above diseases, the compounds of the present invention can be advantageously utilized in cancer therapy in combination with one or more other drugs, more particularly, other anti-cancer drugs or adjuvants (supporting agents in therapy). Examples of other therapeutic agents or treatments that can be administered together with the compounds of formula (I) (whether simultaneously or at different time intervals) include: Topoisomerase I inhibitors; ·Antimetabolites; ·Tubulin-targeting agents; DNA binders and topoisomerase II inhibitors; · Alkylating agents; · Monoclonal antibodies; ·Antihormones; Signal transduction inhibitors; · Proteasome inhibitors; DNA methyltransferase inhibitors; · Cytokines and retinoids; · Chromatin-targeted therapy; Radiation therapy; and Other therapeutic or preventive agents These include, but are not limited to:

[0199] Specific examples of anti-cancer agents or adjuvants (or salts thereof) include, but are not limited to, any of the agents selected from the following groups (i) to (xlvi), and optionally group (xlvii): (i) platinum compounds, such as cisplatin (optionally in combination with amifostine), carboplatin, or oxaliplatin; (ii) a taxane compound, such as paclitaxel, paclitaxel protein-bound particles (Abraxane™), docetaxel, cabazitaxel, or larotaxel; (iii) a topoisomerase I inhibitor, for example, a camptothecin compound, such as camptothecin, irinotecan (CPT11), SN-38, or topotecan; (iv) topoisomerase II inhibitors, such as antitumor epipodophyllotoxins or podophyllotoxin derivatives, such as etoposide or teniposide; (v) vinca alkaloids, such as vinblastine, vincristine, liposomal vincristine (Onco-TCS), vinorelbine, vindesine, vinflunine, or vinbecil; (vi) nucleoside derivatives, such as 5-fluorouracil (5-FU, optionally in combination with leucovorin), gemcitabine, capecitabine, tegafur, UFT, S1, cladribine, cytarabine (Ara-C, cytosine arabinoside), fludarabine, clofarabine, or nelarabine; (vii) antimetabolites, e.g., clofarabine, aminopterin, or methotrexate, azacitidine, cytarabine, floxuridine, pentostatin, thioguanine, thiopurine, 6-mercaptopurine, or hydroxyurea (hydroxycarbamide); (viii) alkylating agents, such as nitrogen mustards or nitrosoureas, e.g., cyclophosphamide, chlorambucil, carmustine (BCNU), bendamustine, thiotepa, melphalan, treosulfan, lomustine (CCNU), altretamine, busulfan, dacarbazine, estramustine, fotemustine, ifosfamide (optionally in combination with mesna), pipobroman, procarbazine, streptozocin, temozolomide, uracil, mechlorethamine, methylcyclohexylchloroethylnitrosourea, or nimustine (ACNU); (ix) anthracyclines, anthracenediones, and related drugs, such as daunorubicin, doxorubicin (optionally in combination with dexrazoxane), liposomal formulations of doxorubicin (e.g., Caelyx™, Myocet™, Doxil™), idarubicin, mitoxantrone, epirubicin, amsacrine, or valrubicin; (x) Epothilones, such as ixabepilone, patupilone, BMS-310705, KOS-862, and ZK-EPO, epothilone A, epothilone B, desoxyepothilone B (also known as epothilone D or KOS-862), aza-epothilone B (also known as BMS-247550), aulimalide, isolaulimalide, or lueterobin; (xi) DNA methyltransferase inhibitors, such as temozolomide, azacitidine or decitabine, or SGI-110; (xii) antifolates, such as methotrexate, pemetrexed disodium, or raltitrexed; (xiii) cytotoxic antibiotics, such as antinomycin D, bleomycin, mitomycin C, dactinomycin, carminomycin, daunomycin, levamisole, plicamycin, or mithramycin; (xiv) tubulin-binding agents, such as combrestatin, colchicine, or nocodazole; (xv) signal transduction inhibitors, for example, kinase inhibitors (e.g., EGFR (epidermal growth factor receptor) inhibitors, VEGFR (vascular endothelial growth factor receptor) inhibitors, PDGFR (platelet-derived growth factor receptor) inhibitors, MTKI (multi-targeted kinase inhibitors), Raf inhibitors, mTOR inhibitors, for example, imatinib mesylate, erlotinib, gefitinib, dasatinib, lapatinib, dovotinib, axitinib, nilotinib, vandetanib, vatalinib, pazopanib, sorafenib, sunitinib, temsirolimus, everolimus (RAD 001), vemurafenib (PLX4032 / RG7204), dabrafenib, encorafenib, or IκB kinase inhibitors such as SAR-113945, bardoxolone, BMS-066, BMS-345541, IMD-0354, IMD-2560, or IMD-1041, or MEK inhibitors such as selumetinib (AZD6244) and trametinib (GSK121120212); (xvi) Aurora kinase inhibitors, such as AT9283, barasertib (AZD1152), TAK-901, MK0457 (VX680), cenisertib (R-763), danusertib (PHA-739358), alisertib (MLN-8237), or MP-470; (xvii) CDK inhibitors, such as AT7519, roscovitine, seliciclib, alvocidib (flavopiridol), dinaciclib (SCH-727965), 7-hydroxystaurosporine (UCN-01), JNJ-7706621, BMS-387032 (also known as SNS-032), PHA533533, PD332991, ZK-304709, or AZD-5438; (xviii) PKA / B inhibitors and PKB (akt) pathway inhibitors, for example, AKT inhibitors, such as KRX-0401 (Perifosine / NSC 639966), ipatasertib (GDC-0068; RG-7440), afuresertib (GSK-2110183; 2110183), MK-2206, MK-8156, AT13148, AZD-5363, triciribine phosphate (VQD-002; triciribine phosphate monohydrate (API-2; TCN-P; TCN-PM; VD-0002), RX-0201, NL-71-101, SR-13668, PX-316, AT13148, AZ-5363, Semaphore, SF1126, or enzastaurin HCl (LY317615), or MTOR inhibitors, for example, rapamycin analogs, for example, RAD 001 (everolimus), CCI 779 (temsirolemus), AP23573, and ridaforolimus, sirolimus (originally known as rapamycin), AP23841, and AP23573, calmodulin inhibitors, for example, CBP-501 (forkhead translocation inhibitor), enzastaurin HCl (LY317615), or PI3K inhibitors, for example, dactolisib (BEZ235), bupallisib (BKM-120; NVP-BKM-120), BYL719, copanlisib (BAY-80-6946), ZSTK-474, CUDC-907, apitolisib (GDC-0980; RG-7422), pictilisib (pictorelisib, GDC-0941, RG-7321), GDC-0032, GDC-0068, GSK-2636771, idelalisib (formerly CAL-101, GS 1101, GS-1101), MLN1117 (INK1117), MLN0128 (INK128), IPI-145 (INK1197), LY-3023414, ipatasertib, afuresertib, MK-2206, MK-8156, LY-3023414, LY294002, SF1126 or PI-103, or sonolisib (PX-866); (xix) Hsp90 inhibitors, such as AT13387, herbimycin, geldanamycin (GA), 17-allylamino-17-desmethoxygeldanamycin (17-AAG), such as NSC-330507, Kos-953, and CNF-1010, 17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride (17-DMAG), such as NSC-707545 and Kos-1022, NVP-AUY922 (VER-52296), NVP-BEP800, CNF-2024 (BIIB-021, oral purine), ganetespib (STA-9090), SNX-5422 (SC-102112), or IPI-504; (xx) Monoclonal antibodies (unconjugated or conjugated to radioisotopes, toxins, or other agents), antibody derivatives and related agents, such as anti-CD, anti-VEGFR, anti-HER2, anti-CTLA4, anti-PD-1, or anti-EGFR antibodies, e.g., Rituximab (CD20), ofatumumab (CD20), ibritumomab tiuxetan (CD20), GA101 (CD20), tositumomab (CD20), epratuzumab (CD22), lintuzumab (CD33), gemtuzumab ozogamicin (CD33), alemtuzumab (CD52), galiximab (CD80), trastuzumab (HER2 antibody), pertuzumab (HER2) , trastuzumab-DM1 (HER2), ertumaxomab (HER2 and CD3), cetuximab (EGFR), panitumumab (EGFR), necitumumab (EGFR), nimotuzumab (EGFR), bevacizumab (VEGF), catumaxomab (EpCAM and CD3), abagovomab (CA125), farletuzumab (folate receptor), elotuzumab (CS1), denosumab (RA) NK ligand), figitumumab (IGF1R), CP751,871 (IGF1R), mapatuzumab (TRAIL receptor), metMAB (met), mitumomab (GD3 ganglioside), naptumomab estafenatox (5T4), siltuximab (IL6), or immunomodulatory agents, such as CTLA-4 blocking antibodies and / or PD-1 or PD-L1 and / or PD- Antibodies against L2, such as ipilimumab (CTLA4), MK-3475 (pembrolizumab, formerly lambrolizumab, anti-PD-1), nivolumab (anti-PD-1), BMS-936559 (anti-PD-L1), MPDL320A, AMP-514 or MEDI4736 (anti-PD-L1), or tremelimumab (formerly ticilimumab, CP-675,206, anti-CTLA-4); (xxi) estrogen receptor antagonists or selective estrogen receptor modulators (SERMs) or inhibitors of estrogen synthesis, such as tamoxifen, fulvestrant, toremifene, droloxifene, faslodex, or raloxifene; (xxii) aromatase inhibitors and related drugs, such as exemestane, anastrozole, letrazole, testolactone aminoglutethimide, mitotane, or vorozole; (xxiii) antiandrogens (i.e., androgen receptor antagonists) and related agents, such as bicalutamide, nilutamide, flutamide, cyproterone, or ketoconazole; (xxiv) Hormones and their analogues, such as medroxyprogesterone, diethylstilbestrol (also known as diethylstilboestrol) or octreotide; (xxv) steroids, such as dromostanolone propionate, megestrol acetate, nandrolone (decanoate, fenpropionate), fluoxymestron, or gossypol; (xxvi) steroidal cytochrome P450, 17α-hydroxylase-17,20-lyase inhibitors (CYP17), such as abiraterone; (xxvii) gonadotropin-releasing hormone agonists or antagonists (GnRAs), such as abarelix, goserelin acetate, histrelin acetate, leuprolide acetate, triptorelin, buserelin, or deslorelin; (xxviii) Glucocorticoids, such as prednisone, prednisolone, dexamethasone; (xxix) differentiation inducers, such as retinoids, rexinoids, vitamin D, or retinoic acid, and retinoic acid metabolism blockers (RAMBAs), such as Accutane, alitretinoin, bexarotene, or tretinoin; (xxx) farnesyltransferase inhibitors, for example, tipifarnib; (xxxi) chromatin-targeted therapy, for example, histone deacetylase (HDAC) inhibitors, such as panobinostat, resminostat, abexinostat, vorinostat, romidepsin, belinostat, entinostat, xinostat, pracinostat, tefinostat, mocetinostat, gibinostat, CUDC-907, CUDC-101, ACY-1215, MGCD-290, EVP-0334, RG-2833, 4SC-202, romidepsin, AR-42 (Ohio State University), CG-200745, valproic acid, CKD-581, sodium butyrate, suberoylanilide hydroxamic acid (SAHA), depsipeptide (FR 901228), dacinostat (NVP-LAQ824), R306465 / JNJ-16241199, JNJ-26481585, trichostatin A, chlamydocin, A-173, JNJ-MGCD-0103, PXD-101, or apicidin; (xxxii) proteasome inhibitors, such as bortezomib, carfilzomib, delanzomib (CEP-18770), ixazomib (MLN-9708), oprozomib (ONX-0912), or marizomib; (xxxiii) photodynamic drugs, such as porfimer sodium or temoporfin; (xxxiv) Anticancer agents derived from marine organisms, such as trabectidin; (xxxv) Radiolabeled drugs for radioimmunotherapy, for example, using beta particle-emitting isotopes (e.g., iodine-131, yttrium-90) or alpha particle-emitting isotopes (e.g., bismuth-213 or actinium-225), such as ibritumomab or iodine-tositumomab; (xxxvi) telomerase inhibitors, for example, telomestatin; (xxxvii) matrix metalloproteinase inhibitors, such as batimastat, marimastat, prinostat, or metastat; (xxxviii) recombinant interferons (e.g., interferon-gamma and interferon-alpha) and interleukins (e.g., interleukin-2), such as aldesleukin, denileukin diftitox, interferon-alpha-2a, interferon-alpha-2b, or pegylated interferon-alpha-2b; (xxxix) selective immune response modulators, such as thalidomide or lenalidomide; (xl) therapeutic vaccines, such as sipuleucel-T (Provenge) or OncoVex; (xli) cytokine activators, including picibanil, romurtide, sizofiran, virulidin, or thymosin; (xlii) arsenic trioxide; (xliii) inhibitors of G protein-coupled receptors (GPCRs), for example, atrasentan; (xliv) an enzyme, such as L-asparaginase, pegaspargase, rasburicase, or pegademase; (xlv) DNA repair inhibitors, e.g., PARP inhibitors, e.g., olaparib, velaparib, iniparib, rucaparib (AG-014699 or PF-01367338), talazoparib, or AG-014699; (xlvi) DNA damage response inhibitors, for example, ATM inhibitors AZD0156, MS3541, ATR inhibitors AZD6738, M4344, M6620 wee1 inhibitor AZD1775; (xlvii) Agonists of death receptors (e.g., TNF-related apoptosis-inducing ligand (TRAIL) receptors), such as mapatuzumab (formerly HGS-ETR1), conatumumab (formerly AMG 655), PRO95780, lexatumumab, dulanermin, CS-1008, apomab, or recombinant TRAIL ligands, such as recombinant human TRAIL / Apo2 ligand; (xlviii) prophylactic (adjuvant) agents; i.e., agents that reduce or alleviate some of the side effects associated with chemotherapeutic agents, e.g. -Anti-emetics, - agents that prevent or reduce the duration of chemotherapy-related neutropenia and prevent complications resulting from decreased levels of platelets, red blood cells, or white blood cells, such as interleukin-11 (e.g., oprelvekin), erythropoietin (EPO) and its analogs (e.g., darbepoetin alfa), colony-stimulating factor analogs, such as granulocyte-macrophage-colony-stimulating factor (GM-CSF) (e.g., sargramostim), and granulocyte-colony-stimulating factor (G-CSF) and its analogs (e.g., filgrastim, pegfilgrastim), - drugs that inhibit bone resorption, such as denosumab or bisphosphonates, such as zoledronate, zoledronic acid, pamidronate, and ibandronate; - drugs that suppress the inflammatory response, such as dexamethasone, prednisone, and prednisolone; - drugs used to lower blood levels of growth hormone and IGF-I (and other hormones) in patients with acromegaly or other rare hormone-producing tumors, such as synthetic forms of the hormone somatostatin, e.g., octreotide acetate; antidotes to drugs that decrease folic acid levels, e.g., leucovorin or folinic acid; medications for pain, such as opiates, e.g., morphine, diamorphine, and fentanyl; nonsteroidal anti-inflammatory drugs (NSAIDs), such as COX-2 inhibitors, for example celecoxib, etoricoxib, and lumiracoxib; - Medications for mucositis, e.g., Palifermin, - Medications for the treatment of side effects including anorexia, cachexia, edema, or thromboembolic attacks, such as megestrol acetate.

[0200] In one embodiment, the anti-cancer agent is a recombinant interferon (e.g., interferon-γ and interferon-α) and an interleukin (e.g., interleukin 2), such as aldesleukin, denileukin diftitox, interferon α2a, interferon α2b, or pegylated interferon α2b; interferon-α2 (500 μg / ml), particularly interferon-β; and a signal transduction inhibitor, such as a kinase inhibitor (e.g., For example, EGFR (epidermal growth factor receptor) inhibitors, VEGFR (vascular endothelial growth factor receptor) inhibitors, PDGFR (platelet-derived growth factor receptor) inhibitors, MTKI (multi-targeted kinase inhibitors), Raf inhibitors, mTOR inhibitors, for example, imatinib mesylate, erlotinib, gefitinib, dasatinib, lapatinib, dovotinib, axitinib, nilotinib, vandetanib, vatalinib, pazopanib, sorafenib, sunitinib, temsirolimus, everolimus (RAD 001), vemurafenib (PLX4032 / RG7204), dabrafenib, encorafenib, or IκB kinase inhibitors such as SAR-113945, bardoxolone, BMS-066, BMS-345541, IMD-0354, IMD-2560, or IMD-1041, or MEK inhibitors such as selumetinib (AZD6244) and trametinib (GSK121120212), in particular Raf inhibitors (e.g., vemurafenib) or MEK inhibitors (e.g., trametinib).

[0201] Each of the compounds present in the combination of the present invention can be administered by different routes and with different dosage schedules. Therefore, the dosage regimen of each of the two or more drugs may be different; each may be administered simultaneously or at different times. Those skilled in the art will know the dosage regimen and combination therapy to be used based on their common general knowledge. For example, the compound of the present invention can be used in combination with one or more other drugs administered according to existing combination regimens. Examples of standard combination regimens are provided below.

[0202] Taxane compounds are administered at a dose of 50 to 400 mg per square meter of body surface area (mg / m) per treatment course. 2 ), e.g., 75-250 mg / m 2 In particular, for paclitaxel, the dosage is about 175-250 mg / m 2 and for docetaxel, about 75-150 mg / m 2 It is advantageously administered at

[0203] Camptothecin compounds are administered at a dose of 0.1 to 400 mg per square meter of body surface area (mg / m) per treatment course. 2 ) dosage, for example, 1 to 300 mg / m 2 , especially for irinotecan, about 100 to 350 mg / m 2 and for topotecan, about 1-2 mg / m 2 It is advantageously administered at

[0204] The antitumor podophyllotoxin derivative is administered at a dose of 30 to 300 mg per square meter of body surface area (mg / m) per treatment course. 2 ), e.g., 50-250 mg / m 2 In particular, for etoposide, the dosage is about 35-100 mg / m 2 and for teniposide, approximately 50-250 mg / m 2 It is advantageously administered at

[0205] Antitumor vinca alkaloids are administered at a dose of 2 to 30 mg per square meter of body surface area (mg / m) per treatment course. 2 ) dosage, especially for vinblastine, about 3-12 mg / m 2 For vincristine, the dosage is approximately 1-2 mg / m 2 and for vinorelbine, about 10-30 mg / m 2 is advantageously administered in a dosage of

[0206] Antitumor nucleoside derivatives are administered at a dose of 200 to 2500 mg per square meter of body surface area (mg / m) per treatment course. 2), e.g., 700-1500 mg / m 2 In particular, for 5-FU, the dosage is 200-500 mg / m 2 For gemcitabine, the dosage is approximately 800-1200 mg / m 2 and for capecitabine, approximately 1000-2500 mg / m 2 It is advantageously administered at

[0207] Alkylating agents such as nitrogen mustard or nitrosoureas should be administered at a dose of 100 to 500 mg per square meter of body surface area (mg / m) per treatment course. 2 ), e.g., 120-200 mg / m 2 In particular, for cyclophosphamide, the dosage is about 100-500 mg / m 2 For chlorambucil, the dosage is about 0.1-0.2 mg / kg, and for carmustine, the dosage is about 150-200 mg / m 2 and for lomustine, about 100-150 mg / m 2 is advantageously administered in a dosage of

[0208] Antitumor anthracycline derivatives are administered at a dose of 10 to 75 mg per square meter of body surface area (mg / m) per treatment course. 2 ), e.g., 15-60 mg / m 2 In particular, for doxorubicin, the dosage is about 40-75 mg / m 2 and for daunorubicin, approximately 25-45 mg / m 2 and for idarubicin, about 10-15 mg / m 2 is advantageously administered in a dosage of

[0209] Antiestrogens are advantageously administered in a daily dosage of about 1 to 100 mg, depending on the particular agent and the condition being treated. Tamoxifen is advantageously administered orally in a dosage of 5 to 50 mg, particularly 10 to 20 mg, twice daily, with the therapy being continued for a time sufficient to achieve and maintain a therapeutic effect. Toremifene is advantageously administered orally in a dosage of about 60 mg once daily, with the therapy being continued for a time sufficient to achieve and maintain a therapeutic effect. Anastrozole is advantageously administered orally in a dosage of about 1 mg once daily. Droloxifene is advantageously administered orally in a dosage of about 20 to 100 mg once daily. Raloxifene is advantageously administered orally in a dosage of about 60 mg once daily. Exemestane is advantageously administered orally in a dosage of about 25 mg once daily.

[0210] Antibodies are released at a rate of approximately 1-5 mg per square meter of body surface area (mg / m 2 Trastuzumab is advantageously administered at a dosage of 1 to 5 mg per square meter of body surface area (mg / m) per course of treatment, or at dosages known in the art if different. 2 ), especially 2-4 mg / m 2 is advantageously administered in a dosage of

[0211] When a compound of formula (I) is administered in combination therapy with one, two, three, four, or more other therapeutic agents (particularly one or two, more particularly one), the compounds can be administered simultaneously or sequentially. In the latter case, the two or more compounds are administered within a period, and in amounts and manner sufficient to ensure that a beneficial or synergistic effect is achieved. When administered sequentially, the compounds can be administered at closely spaced intervals (e.g., within a 5-10 minute period) or at longer intervals (e.g., 1, 2, 3, 4, or more hours apart, or even longer periods if needed), with the precise dosing regimen being appropriate to the nature of the therapeutic agents. These doses can be administered, for example, once, twice, or more per course of treatment, which can be repeated, for example, every 7, 14, 21, or 28 days.

[0212] In one embodiment, provided is a compound of Formula (I) for the manufacture of a medicament for use in therapy, wherein the compound is used in combination with one, two, three, or four other therapeutic agents. In another embodiment, provided is a medicament for treating cancer comprising a compound of Formula (I), wherein the medicament is used in combination with one, two, three, or four other therapeutic agents. The present invention further provides the use of a compound of Formula (I) for the manufacture of a medicament for enhancing or potentiating the response rate in a patient suffering from cancer, wherein the patient is being treated with one, two, three, or four other therapeutic agents.

[0213] It will be understood that the particular method and sequence of administration, as well as the respective dosage amounts and regimens of each component of the combination, will depend on the particular other drugs and compounds of the invention being administered, their routes of administration, the particular tumor being treated, and the particular host being treated. The optimal method and sequence of administration, as well as the dosage amounts and regimens, can be readily determined by one of ordinary skill in the art using conventional methods and in view of the information provided herein.

[0214] The weight ratio of the compound of the present invention to one or more other anticancer agents when administered as a combination can be determined by one skilled in the art. As is well known to those skilled in the art, the ratio and the exact dosage and frequency of administration depend on the specific compound of the present invention and other anticancer agents used, the specific disease being treated, the severity of the disease being treated, the age, weight, sex, diet, time of administration, and the general health of the particular patient, the mode of administration, and other drugs the individual may be taking. Furthermore, it will be apparent that the effective daily amount may be lowered or increased depending on the response of the treated subject and / or the evaluation of the physician prescribing the compound of the present invention. The specific weight ratio of the compound of formula (I) to another anticancer agent may range from 1 / 10 to 10 / 1, more particularly from 1 / 5 to 5 / 1, and even more particularly from 1 / 3 to 3 / 1.

[0215] The compounds of the invention may also be administered in conjunction with non-chemotherapeutic treatments such as radiation therapy, photodynamic therapy, gene therapy; surgery, and dietary restrictions.

[0216] The compounds of the present invention also have therapeutic applications in sensitizing tumor cells for radiation therapy and chemotherapy. Thus, the compounds of the present invention can be used as "radiosensitizers" and / or "chemosensitizers" or can be administered in combination with another "radiosensitizer" and / or "chemosensitizer." In one embodiment, the compounds of the present invention are for use as chemosensitizers.

[0217] The term "radiosensitizer" is defined as a molecule that is administered to a patient in a therapeutically effective amount to increase the sensitivity of cells to ionizing radiation and / or to facilitate treatment of diseases treatable with ionizing radiation.

[0218] The term "chemosensitizer" is defined as a molecule that is administered to a patient in a therapeutically effective amount to increase the sensitivity of cells to chemotherapy and / or to facilitate treatment of a disease that is treatable with a chemotherapeutic agent.

[0219] In one embodiment, the compound of the invention is administered in combination with a "radiosensitizer" and / or a "chemosensitizer." In one embodiment, the compound of the invention is administered in combination with an "immunosensitizer."

[0220] The term "immunosensitizer" is defined as a molecule that is administered to a patient in a therapeutically effective amount to increase the sensitivity of cells to Pol theta inhibitors.

[0221] Many cancer treatment protocols currently utilize radiosensitizers in conjunction with x-ray radiation. Examples of x-ray activated radiosensitizers include, but are not limited to, metronidazole, misonidazole, desmethylmisonidazole, pimonidazole, etanidazole, nimorazole, mitomycin C, RSU 1069, SR 4233, EO9, RB 6145, nicotinamide, 5-bromodeoxyuridine (BUdR), 5-iododeoxyuridine (IUdR), bromodeoxycytidine, fluorodeoxyuridine (FudR), hydroxyurea, cisplatin, and therapeutically effective analogs and derivatives thereof.

[0222] Photodynamic therapy (PDT) of cancer utilizes visible light as a radioactivator of sensitizers. Examples of photodynamic radiosensitizers include, but are not limited to, hematoporphyrin derivatives, Photofrin, benzoporphyrin derivatives, tin etioporphyrin, pheobolbide-a, bacteriochlorophyll-a, naphthalocyanines, phthalocyanines, zinc phthalocyanines, and their therapeutically effective analogs and derivatives.

[0223] The radiosensitizer may be administered in combination with a therapeutically effective amount of one or more other compounds, including, but not limited to: a compound of the present invention; a compound that promotes incorporation of the radiosensitizer into target cells; a compound that controls the flow of therapeutic agents, nutrients, and / or oxygen to target cells; a chemotherapeutic agent that acts on tumors with or without additional radiation; or another therapeutically effective compound for treating cancer or other diseases.

[0224] The chemotherapy sensitizer may be administered in combination with a therapeutically effective amount of one or more other compounds, including, but not limited to: a compound of the present invention; a compound that promotes the incorporation of the chemotherapy sensitizer into target cells; a compound that controls the flow of therapeutic agents, nutrients, and / or oxygen to target cells; a chemotherapy agent that acts on a tumor, or other therapeutically effective compound for treating cancer or other diseases. Calcium antagonists, such as verapamil, have been found to be useful in combination with anti-neoplastic agents to establish chemotherapy sensitivity in tumor cells resistant to accepted chemotherapy agents and to enhance the effectiveness of such compounds in drug-sensitive malignancies.

[0225] Examples of immunosensitizers include, but are not limited to, immunomodulators, e.g., monoclonal antibodies, e.g., immune checkpoint antibodies (e.g., CTLA-4 blocking antibodies and / or antibodies against PD-1 and PD-L1 and / or PD-L2, e.g., ipilimumab (CTLA4), MK-3475 (pembrolizumab, formerly lambrolizumab, anti-PD-1), nivolumab (anti-PD-1), BMS-936559 (anti-PD-L1), MPDL320A, AMP-514, or MEDI4736 (anti-PD-L1), or tremelimumab (formerly ticilimumab, CP-675,206, anti-CTLA-4)]; or signal transduction inhibitors; or cytokines (e.g., recombinant interferons); or oncolytic viruses; or immune adjuvants (e.g., BCG).

[0226] The immunosensitizer may be administered in combination with a therapeutically effective amount of one or more other compounds, including, but not limited to: a compound of the present invention; a compound that promotes incorporation of the immunosensitizer into target cells; a compound that controls the flow of therapeutic agents, nutrients, and / or oxygen to target cells; a therapeutic agent that acts on tumors, or other therapeutically effective compounds for treating cancer or other diseases.

[0227] For use in combination therapy with another chemotherapeutic agent, the compound of formula (I) and one, two, three, four, or more other therapeutic agents can be formulated together, for example, in a dosage form containing two, three, four, or more therapeutic agents, i.e., in a single pharmaceutical composition containing all agents. In an alternative embodiment, the individual therapeutic agents can be formulated separately and presented together in the form of a kit, optionally including instructions for their use.

[0228] In one embodiment, provided is a combination of a compound of Formula (I) with one or more (e.g., one or two) other therapeutic agents (e.g., the anticancer agents described above). In a further embodiment, provided is a combination of a Pol Theta inhibitor described herein with a PI3K / AKT pathway inhibitor selected from apitolisib, bupalisib, copanlisib, pictilisib, ZSTK-474, CUDC-907, GSK-2636771, LY-3023414, ipatasertib, afuresertib, MK-2206, MK-8156, idelalisib, BEZ235 (dactolisib), BYL719, GDC-0980, GDC-0941, GDC-0032, and GDC-0068.

[0229] In another embodiment, provided is a compound of Formula (I) in combination with one or more (e.g., one or two) other therapeutic agents (e.g., anti-cancer agents) for use in therapy, e.g., in the prevention or treatment of cancer.

[0230] In one embodiment, a pharmaceutical composition comprises a compound of Formula (I) together with a pharmaceutically acceptable carrier and, optionally, one or more therapeutic agents.

[0231] In another embodiment, the present invention relates to the use of a combination according to the invention in the manufacture of a pharmaceutical composition for inhibiting the growth of tumor cells.

[0232] In a further embodiment, the present invention relates to a product containing a compound of formula (I) and one or more anti-cancer agents as a combined preparation for simultaneous, separate or sequential use in the treatment of patients suffering from cancer. [Example]

[0233] (Example) The present invention will now be described with reference to specific embodiments described in the following examples, but the invention is not limited thereto.

[0234] (abbreviation) [Table 1] TIFF2024540912000007.tif237170

[0235] (Typical preparative HPLC method) For sample purification by HPLC, the following columns were typically used: SunFire C18, Xtimate C18, Phenomenex Gemini, Phenomenex Synergi C18, Phenomenex Luna, Waters Xbridge C18, Boston Prime C18, and Shim-pack C18. Typical mobile phases used were water and MeCN with either acidic or basic additives, such as formic acid (0.1% v / v) or ammonium hydroxide (0.05% v / v). A typical method started with 95% water:5% MeCN, and the polarity ratio of water to MeCN was gradually decreased over 5-12 minutes at a typical flow rate of 25 mL / min.

[0236] Intermediate 1: 2-(tert-butyl) 3-methyl(2S,3S)-5-oxopyrrolidine-2,3-dicarboxylate [ka] Step a. To a solution of tert-butyl 2-((diphenylmethylene)amino)acetate (CAS: 81477-94-3; 100 g, 339 mmol) and dimethyl fumarate (CAS: 624-49-7; 73.2 g, 508 mmol) in EtOAc (1 L) was added (S)-2-((2,3-bis(dicyclohexylamino)cycloprop-2-en-1-ylidene)amino)propan-1-ol (CAS: 1808186-23-3, prepared as described in J.S. Bander et al., Chem. Sci. 2015, 6, 1537; 18.5 g, 33.9 mmol). The reaction mixture was stirred at room temperature for 48 hours. After completion, the reaction mixture was evaporated and the crude product was purified by column chromatography (hexane / EtOAc=4 / 1) to give 1-(tert-butyl) 2,3-dimethyl(1S,2S)-1-((diphenylmethylene)amino)propane-1,2,3-tricarboxylate as a colorless oil (140 g, 94% yield).

[0237] Step b. To a solution of 1-(tert-butyl) 2,3-dimethyl(1S,2S)-1-((diphenylmethylene)amino)propane-1,2,3-tricarboxylate (140 g, 318.5 mmol) in THF (1.4 L) was added 15% w / w aqueous citric acid (1.4 L). The reaction mixture was stirred at rt for 48 h. Upon completion, the reaction was quenched with saturated aqueous NaHCO and extracted with EtOAc (3 × 1 L). The combined organic layers were dried over NaSO and evaporated. The crude product was purified by column chromatography (hexane / EtOAc = 3 / 7) to give the title compound as a white solid (70 g, 90% yield). [ka]

[0238] Intermediate 2a: tert-butyl(2-fluoro-6-(methylamino)phenyl)carbamate [ka] Step a. To a solution of 2-fluoro-6-nitroaniline (CAS: 17809-36-8; 100 g, 641 mmol) in DCM (500 mL) was added di-tert-butyl dicarbonate (308 g, 1.41 mol), TEA (130 g, 1.28 mol), and DMAP (7.83 g, 64.1 mmol). The mixture was stirred at 40 °C for 12 h. After completion, the reaction mixture was quenched with saturated aqueous NH4Cl (500 mL) at 25 °C, diluted with water (500 mL), and extracted with DCM (3 × 1 L). The combined organic layer was washed with brine (3 × 500 mL), dried over Na2SO4, and evaporated. The crude product was triturated (PE / EtOAc=20 / 1, 500 mL) to give tert-butyl (tert-butoxycarbonyl)(2-fluoro-6-nitrophenyl)carbamate (210 g, 92% yield) as a yellow solid. [ka]

[0239] Step b. To a solution of tert-butyl (tert-butoxycarbonyl)(2-fluoro-6-nitrophenyl)carbamate (210 g, 589 mmol) in DCM (2.1 L) was added TFA (87.4 g, 766 mmol), and the mixture was stirred at 25 °C for 12 hours. After completion, the reaction mixture was quenched with saturated aqueous Na2CO3 (500 mL), diluted with water (500 mL), and extracted with DCM (3 × 1 L). The combined organic layers were washed with brine (3 × 500 mL), dried over Na2SO4, and evaporated to give tert-butyl (2-fluoro-6-nitrophenyl)carbamate (145 g, 96% yield) as a yellow solid. [ka]

[0240] Step c. To a solution of tert-butyl (2-fluoro-6-nitrophenyl)carbamate (145 g, 567 mmol) in MeOH (2 L) was added 10% Pd / C (15 g), and the mixture was stirred under a H atmosphere (15 psi) at 25° C. for 12 h. Upon completion, the reaction mixture was filtered and evaporated to give tert-butyl (2-amino-6-fluorophenyl)carbamate (128 g, 99% yield) as an off-white solid. [ka]

[0241] Step d. To a solution of tert-butyl (2-amino-6-fluorophenyl)carbamate (128 g, 566 mmol) in MeOH (1.5 L) was added paraformaldehyde (25.5 g, 849 mmol) and sodium methoxide (306 g, 5.66 mol). The reaction mixture was stirred at 25 °C for 12 h, and then NaBH CN (107 g, 2.83 mol) was slowly added and stirred at 25 °C for 12 h. Upon completion, the reaction mixture was quenched with saturated aqueous NH CI (500 mL), diluted with water (500 mL), and extracted with EtOAc (3 × 1 L). The combined organic layers were washed with brine (3 × 500 mL), dried over Na SO , and evaporated. The crude product was purified by column chromatography (PE / EtOAc = 10 / 1) to afford the title compound (56 g, 41% yield) as a yellow solid. [ka]

[0242] Intermediate 2b: tert-butyl (2-chloro-6-(methylamino)phenyl)carbamate [ka] The title compound was prepared in a similar manner to intermediate 2a using 2-chloro-6-nitroaniline (CAS: 769-11-9) in step a. [ka]

[0243] Intermediate 2c: tert-butyl(4-fluoro-2-(methylamino)phenyl)carbamate [ka] The title compound was prepared in a similar manner to intermediate 2a using 4-fluoro-2-nitroaniline (CAS: 364-78-3) in step a. [ka]

[0244] Intermediate 2d: tert-butyl(2,4-difluoro-6-(methylamino)phenyl)carbamate [ka] The title compound was prepared in a similar manner to intermediate 2a using 2,4-difluoro-6-nitroaniline (CAS: 364-30-7) in step a. [ka]

[0245] Intermediate 3: tert-butyl (2-chloro-4-fluoro-6-(methylamino)phenyl)carbamate [ka] Step a. To a solution of 4-fluoro-2-nitroaniline (16.5 g, 106 mmol) in DMF (330 mL) was added N-chlorosuccinimide (15.5 g, 116 mmol) in DMF (330 mL), and the mixture was stirred at 40 °C for 12 hours. After completion, the reaction mixture was quenched with saturated aqueous NH Cl (100 mL) at 25 °C, diluted with water (300 mL), and extracted with EtOAc (3 × 300 mL). The combined organic layers were washed with brine (3 × 200 mL), dried over Na SO , and evaporated. The crude product was purified by column chromatography (PE / EtOAc = 50 / 1) to give 2-chloro-4-fluoro-6-nitroaniline (17 g, 84% yield) as a brown solid. [ka]

[0246] Steps b to e. These four steps were carried out in the same manner as steps a to d of intermediate 2a. [ka]

[0247] Intermediate 4: tert-butyl (6-chloro-3,4-difluoro-2-(methylamino)phenyl)carbamate [ka] Step a. To a solution of 2-chloro-4,5-difluoroaniline (CAS: 2613-32-3; 19.0 g, 116 mmol) in EtOAc (400 mL) was added DIPEA (30.0 g, 232 mmol) and acetic anhydride (17.8 g, 174 mmol) dropwise. The mixture was stirred at 50 °C for 16 h. Upon completion, the reaction mixture was washed with water (4 × 100 mL), dried over NaSO, and evaporated to give N-(2-chloro-4,5-difluorophenyl)acetamide (23 g, crude) as a brown solid. [ka]

[0248] Step b. To a solution of N-(2-chloro-4,5-difluorophenyl)acetamide (23.0 g, 112 mmol) in concentrated HSO (200 mL) was added 80% HNO (32.2 g, 409 mmol) at 0 °C. The mixture was allowed to warm to 25 °C over 1 h. After completion, the reaction mixture was poured into ice water (600 mL) and extracted with EtOAc (3 × 200 mL). The combined organic layers were washed with brine (3 × 200 mL), dried over NaSO, and evaporated. The crude product was purified by column chromatography (PE / EtOAc = 3 / 1) to give N-(6-chloro-3,4-difluoro-2-nitrophenyl)acetamide (26.0 g, 92% yield) as a yellow solid. [ka]

[0249] Step c. To a solution of N-(6-chloro-3,4-difluoro-2-nitrophenyl)acetamide (26.0 g, 104 mmol) in 1,4-dioxane (250 mL) was added 12 M aqueous hydrochloric acid (17 mL). The mixture was stirred at 80 °C for 18 hours. After completion, the reaction mixture was diluted with water (60 mL) and extracted with EtOAc (2 × 40 mL). The combined organic layers were dried over Na SO and evaporated to give 6-chloro-3,4-difluoro-2-nitroaniline (22 g, crude) as a yellow solid, which was used directly in the next step.

[0250] Steps d-g: These four steps were carried out in the same manner as steps a-d of intermediate 2a. [ka]

[0251] Intermediate 5a: (3aR,11aS)-6-fluoro-10-methyl-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-1,3a,4,5,10,11a-hexahydro-2H-benzo[b]pyrrolo[2,3-f][1,4]diazocine-2,11(3H)-dione [ka] Step a. A mixture of Intermediate 1 (40.0 g, 164 mmol) and TFA (250 mL) was stirred under a N atmosphere at 25 °C for 12 hours. After completion, the reaction mixture was evaporated. The residue was triturated with PE / EtOAc (10 / 1) for 60 minutes. The suspension was filtered to give (2S,3S)-3-(methoxycarbonyl)-5-oxopyrrolidine-2-carboxylic acid (27.0 g, 87% yield) as a white solid. [ka]

[0252] Step b. To a solution of (2S,3S)-3-(methoxycarbonyl)-5-oxopyrrolidine-2-carboxylic acid (5 g, 26.7 mmol) in MeCN (50 mL) was added Ghosez reagent (CAS: 26189-59-3; 3.93 g, 29.3 mmol) at 0 °C. The mixture was stirred at rt for 1 h and then added dropwise to a mixture of intermediate 2a (6.42 g, 26.7 mmol) and N,N-dimethylpyridin-2-amine (6.53 g, 53.4 mmol) in MeCN (50 mL) at 0 °C. The reaction mixture was stirred at 0 °C for 30 min. Upon completion, the mixture was quenched with water (6 mL) and then evaporated to remove MeCN. The residue was diluted with additional water (35 mL) and extracted with EtOAc (3 × 50 mL). The combined organic layers were washed with brine (100 mL), dried over NaSO, and evaporated. The crude product was purified by column chromatography (PE / EtOAc = 0 / 1) to give methyl (2S,3S)-2-((2-((tert-butoxycarbonyl)amino)-3-fluorophenyl)(methyl)carbamoyl)-5-oxopyrrolidine-3-carboxylate (8.7 g, 78% yield) as a white solid. [ka]

[0253] Step c. A mixture of methyl (2S,3S)-2-((2-((tert-butoxycarbonyl)amino)-3-fluorophenyl)(methyl)carbamoyl)-5-oxopyrrolidine-3-carboxylate (22.0 g, 53.7 mmol), 2-bromo-6-methyl-4-(trifluoromethyl)pyridine (CAS: 451459-17-9; 15.4 g, 64.4 mmol), Pd(dba) (4.92 g, 5.37 mmol), Xantphos (6.22 g, 10.7 mmol), and KCO (18.5 g, 134 mmol) in 1,4-dioxane (220 mL) was degassed and purged with N three times. The reaction mixture was stirred at 100 °C under N atmosphere for 3 h. After completion, the mixture was filtered and evaporated, water (150 mL) was added, and the mixture was extracted with EtOAc (3 × 170 mL). The combined organic layers were washed with brine (300 mL), dried over NaSO, and evaporated. The crude product was purified by column chromatography (PE / EtOAc = 1 / 1) to give methyl (2S,3S)-2-((2-((tert-butoxycarbonyl)amino)-3-fluorophenyl)(methyl)carbamoyl)-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-5-oxopyrrolidine-3-carboxylate (27.7 g, 89% yield) as a yellow solid. [ka]

[0254] Step d. To a solution of (2S,3S)-2-((2-((tert-butoxycarbonyl)amino)-3-fluorophenyl)(methyl)carbamoyl)-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-5-oxopyrrolidine-3-carboxylate (53.4 g, 93.9 mmol) in THF (530 mL) and MeOH (53 mL) was added NaBH (7.11 g, 187 mmol) portionwise at 0 °C. The reaction mixture was stirred at 20 °C for 1 h. After completion, the mixture was slowly quenched with saturated aqueous NH Cl 50 (mL). The mixture was stirred for an additional 30 min, evaporated, water (200 mL) was added, and the mixture was extracted with EtOAc (3 × 250 mL). The combined organic layers were washed with brine (500 mL), dried over Na SO , and evaporated. The crude product was purified by column chromatography (PE / EtOAc=0 / 1) to give tert-butyl (2-fluoro-6-((2S,3S)-3-(hydroxymethyl)-N-methyl-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-5-oxopyrrolidine-2-carboxamido)phenyl)carbamate (47 g, 93% yield) as a yellow solid. [ka]

[0255] Step e. To a solution of tert-butyl (2-fluoro-6-((2S,3S)-3-(hydroxymethyl)-N-methyl-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-5-oxopyrrolidine-2-carboxamido)phenyl)carbamate (47.0 g, 86.9 mmol) in DCM (500 mL) was added TEA (35.2 g, 347 mmol) at 0° C. Then, MsCl (14.9 g, 130 mmol) was added dropwise at 0° C. The reaction mixture was stirred at 0° C. for 1 h. After completion, the reaction mixture was quenched with water (400 mL) and extracted with EtOAc (2×400 mL). The combined organic layers were washed with brine (800 mL), dried over NaSO, and evaporated to give ((2S,3S)-2-((2-((tert-butoxycarbonyl)amino)-3-fluorophenyl)(methyl)carbamoyl)-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-5-oxopyrrolidin-3-yl)methyl methanesulfonate (52.0 g, 98% yield) as a yellow solid. m / z ES+[M+H] + 619.1.

[0256] Step f. To a solution of ((2S,3S)-2-((2-((tert-butoxycarbonyl)amino)-3-fluorophenyl)(methyl)carbamoyl)-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-5-oxopyrrolidin-3-yl)methyl methanesulfonate (26.0 g, 42.0 mmol) in NMP (400 mL) was added KPO (26.7 g, 126 mmol). The mixture was stirred at 60 °C for 12 h. After completion, the mixture was diluted with water (1.2 L) and extracted with EtOAc (3 × 800 mL). The combined organic layers were washed with water (2 × 1 L), brine (2 × 1 L), dried over NaSO, and evaporated. The crude product was purified by column chromatography (PE / EtOAc=3 / 1) to give tert-butyl (3aR,11aS)-6-fluoro-10-methyl-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-2,11-dioxo-1,2,3,3a,4,10,11,11a-octahydro-5H-benzo[b]pyrrolo[2,3-f][1,4]diazocine-5-carboxylate (31.0 g, 67% yield) as a yellow solid. m / z ES+[M+H] + 523.0.

[0257] Step g. To a solution of tert-butyl (3aR,11aS)-6-fluoro-10-methyl-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-2,11-dioxo-1,2,3,3a,4,10,11,11a-octahydro-5H-benzo[b]pyrrolo[2,3-f][1,4]diazocine-5-carboxylate (31.0 g, 59.3 mmol) in DCM (320 mL) was added TFA (123 g, 1.08 mol). The mixture was stirred at 20 °C for 2 h. After completion, the mixture was basified to pH 8 with saturated aqueous NaHCO3. The organic layer was separated, and the aqueous was further extracted with EtOAc (3 × 600 mL). The combined organic layers were washed with brine (2 x 500 mL), dried over Na2SO4 and evaporated to give the title compound (22.3 g, 90% yield) as a yellow solid. [ka]

[0258] Intermediate 5b: (3aR,11aS)-6-chloro-10-methyl-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-1,3a,4,5,10,11a-hexahydro-2H-benzo[b]pyrrolo[2,3-f][1,4]diazocine-2,11(3H)-dione [ka] The title compound was prepared in a similar manner to intermediate 5a, using intermediate 2b in step b. [ka]

[0259] Intermediate 5c: (3aR,11aS)-8-fluoro-10-methyl-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-1,3a,4,5,10,11a-hexahydro-2H-benzo[b]pyrrolo[2,3-f][1,4]diazocine-2,11(3H)-dione [ka] The title compound was prepared in a similar manner to intermediate 5a, using intermediate 2c in step b. [ka]

[0260] Intermediate 5d: (3aR,11aS)-6,8-difluoro-10-methyl-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-1,3a,4,5,10,11a-hexahydro-2H-benzo[b]pyrrolo[2,3-f][1,4]diazocine-2,11(3H)-dione [ka] The title compound was prepared in a similar manner to intermediate 5a, using intermediate 2d in step b. m / z ES+[M+H]+ 441.1.

[0261] Intermediate 5e: (3aR,11aS)-6-chloro-8-fluoro-10-methyl-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-1,3a,4,5,10,11a-hexahydro-2H-benzo[b]pyrrolo[2,3-f][1,4]diazocin-2,11(3H)-dione [ka] The title compound was prepared in a similar manner to intermediate 5a, using intermediate 3 in step b. [ka]

[0262] Intermediate 5f: (3aR,11aS)-6-chloro-8,9-difluoro-10-methyl-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-1,3a,4,5,10,11a-hexahydro-2H-benzo[b]pyrrolo[2,3-f][1,4]diazocine-2,11(3H)-dione [ka] The title compound was prepared in a similar manner to intermediate 5a, using intermediate 4 in step b. m / z ES+[M+H] + 475.0.

[0263] Intermediate 6a: (3aR,11aS)-8-fluoro-6,10-dimethyl-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-1,3a,4,5,10,11a-hexahydro-2H-benzo[b]pyrrolo[2,3-f][1,4]diazocine-2,11(3H)-dione [ka] Step a. To a solution of intermediate 5e (200 mg, 0.44 mmol), methylboronic acid (262 mg, 4.38 mmol), and Na2CO3 (139 mg, 1.31 mmol) in 1,4-dioxane (1.5 mL) and water (0.2 mL) was added XPhos-Pd-G2 (34.4 mg, 0.044 mmol). The mixture was degassed and purged with N2 three times. The reaction mixture was stirred under a N2 atmosphere at 110 °C for 1 h. After completion, the reaction mixture was diluted with water (5 mL) and extracted with EtOAc (3 × 25 mL). The combined organic layers were washed with brine (5 mL), dried over Na2SO4, and evaporated. The residue was purified by preparative TLC (PE / EtOAc = 3 / 1) to give the title compound (150 mg, 72% yield) as a yellow solid. [ka]

[0264] Intermediate 6b: (3aR,11aS)-6-cyclopropyl-8-fluoro-10-methyl-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-1,3a,4,5,10,11a-hexahydro-2H-benzo[b]pyrrolo[2,3-f][1,4]diazocine-2,11(3H)-dione [ka] The title compound was prepared in a similar manner to intermediate 6a, using cyclopropylboronic acid in step a. [ka]

[0265] Intermediate 6c: (3aR,11aS)-6,10-dimethyl-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-1,3a,4,5,10,11a-hexahydro-2H-benzo[b]pyrrolo[2,3-f][1,4]diazocine-2,11(3H)-dione [ka] The title compound was prepared in a similar manner to intermediate 6a using intermediate 5b and methylboronic acid in step a. [ka]

[0266] Intermediate 7a: 2-((3aR,11aS)-6-fluoro-10-methyl-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-2,11-dioxo-1,2,3,3a,4,10,11,11a-octahydro-5H-benzo[b]pyrrolo[2,3-f][1,4]diazocin-5-yl)acetaldehyde [ka] Step a. A mixture of intermediate 5a (7.6 g, 17.9 mmol), Na2CO3 (5.72 g, 53.9 mmol), and TBAB (580 mg, 1.80 mmol) in DMF (70 mL) was degassed and purged with N2 three times, after which 3-bromoprop-1-ene (8.71 g, 71.9 mmol) was added dropwise at 20 °C. The mixture was stirred at 100 °C under a N2 atmosphere for 2 h. After completion, the reaction mixture was diluted with water (200 mL) and extracted with EtOAc (3 × 200 mL). The combined organic layers were washed with water (3 × 200 mL), brine (2 × 200 mL), dried over Na2SO4, and evaporated. The crude product was purified by column chromatography (PE / EtOAc=5 / 1) to give (3aR,11aS)-5-allyl-6-fluoro-10-methyl-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-1,3a,4,5,10,11a-hexahydro-2H-benzo[b]pyrrolo[2,3-f][1,4]diazocine-2,11(3H)-dione (7 g, 82% yield) as a yellow solid. [ka]

[0267] Step b. To a solution of (3aR,11aS)-5-allyl-6-fluoro-10-methyl-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-1,3a,4,5,10,11a-hexahydro-2H-benzo[b]pyrrolo[2,3-f][1,4]diazocine-2,11(3H)-dione (7.0 g, 15.1 mmol) in THF (140 mL) and water (70 mL) was added NaIO (9.71 g, 45.4 mmol) and OsO (385 mg, 1.51 mmol) at 0 °C. The mixture was stirred at 0 °C for 1 h. After completion, saturated aqueous NaSO (100 mL) was added and stirred at rt for an additional 30 min, after which the aqueous mixture was extracted with EtOAc (3 × 200 mL). The combined organic layers were washed with saturated aqueous Na2S2O3 (2 x 150 mL), saturated NaHCO3 (2 x 150 mL), brine (300 mL), dried over Na2SO4, and evaporated to give the title compound (7 g, crude) as a yellow solid. m / z ES+[M+H] + 465.2.

[0268] Intermediate 7b: 2-((3aR,11aS)-6-chloro-10-methyl-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-2,11-dioxo-1,2,3,3a,4,10,11,11a-octahydro-5H-benzo[b]pyrrolo[2,3-f][1,4]diazocin-5-yl)acetaldehyde [ka] The title compound was prepared in a similar manner to intermediate 7a, using intermediate 5b in step a. [ka]

[0269] Intermediate 7c: 2-((3aR,11aS)-8-fluoro-10-methyl-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-2,11-dioxo-1,2,3,3a,4,10,11,11a-octahydro-5H-benzo[b]pyrrolo[2,3-f][1,4]diazocin-5-yl)acetaldehyde [ka] The title compound was prepared in a similar manner to intermediate 7a, using intermediate 5c in step a. m / z ES+[M+H] + 465.2.

[0270] Intermediate 7d: 2-((3aR,11aS)-6,8-difluoro-10-methyl-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-2,11-dioxo-1,2,3,3a,4,10,11,11a-octahydro-5H-benzo[b]pyrrolo[2,3-f][1,4]diazocin-5-yl)acetaldehyde [ka] The title compound was prepared in a similar manner to intermediate 7a, using intermediate 5d in step a. m / z ES+[M+H] + 483.4.

[0271] Intermediate 7e: 2-((3aR,11aS)-6-chloro-8-fluoro-10-methyl-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-2,11-dioxo-1,2,3,3a,4,10,11,11a-octahydro-5H-benzo[b]pyrrolo[2,3-f][1,4]diazocin-5-yl)acetaldehyde [ka] The title compound was prepared in a similar manner to intermediate 7a, using intermediate 5e in step a. m / z ES+[M+H] + 499.2.

[0272] Intermediate 7f: 2-((3aR,11aS)-6-chloro-8,9-difluoro-10-methyl-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-2,11-dioxo-1,2,3,3a,4,10,11,11a-octahydro-5H-benzo[b]pyrrolo[2,3-f][1,4]diazocin-5-yl)acetaldehyde [ka] The title compound was prepared in a similar manner to intermediate 7a, using intermediate 5f in step a. m / z ES+[M+H] + 516.9.

[0273] Intermediate 7g: 2-((3aR,11aS)-8-fluoro-6,10-dimethyl-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-2,11-dioxo-1,2,3,3a,4,10,11,11a-octahydro-5H-benzo[b]pyrrolo[2,3-f][1,4]diazocin-5-yl)acetaldehyde [ka] The title compound was prepared in a similar manner to intermediate 7a, using intermediate 6a in step a. [ka]

[0274] Intermediate 7h: 2-((3aR,11aS)-6-cyclopropyl-8-fluoro-10-methyl-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-2,11-dioxo-1,2,3,3a,4,10,11,11a-octahydro-5H-benzo[b]pyrrolo[2,3-f][1,4]diazocin-5-yl)acetaldehyde [ka] The title compound was prepared in a similar manner to intermediate 7a, using intermediate 6b in step a. m / z ES+[M+H] + 505.4.

[0275] Intermediate 7i: 2-((3aR,11aS)-6,10-dimethyl-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-2,11-dioxo-1,2,3,3a,4,10,11,11a-octahydro-5H-benzo[b]pyrrolo[2,3-f][1,4]diazocin-5-yl)acetaldehyde [ka] The title compound was prepared in a similar manner to intermediate 7a, using intermediate 6c in step a. [ka]

[0276] Intermediate 8: (3aR,11aS)-6-Fluoro-5-(2-iodoethyl)-10-methyl-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-1,3a,4,5,10,11a-hexahydro-2H-benzo[b]pyrrolo[2,3-f][1,4]diazocine-2,11(3H)-dione [ka] Step a. To a solution of intermediate 7a (1.00 g, 2.15 mmol) in MeOH (10 mL) was added NaBHCN (244 mg, 6.46 mmol), and the mixture was stirred at 0 °C for 30 min. After completion, the reaction mixture was quenched with saturated aqueous NH Cl (20 mL) at 0 °C. The mixture was diluted with water (30 mL) and extracted with EtOAc (3 × 50 mL). The combined organic layers were washed with brine (3 × 20 mL), dried over NaSO, and evaporated to give (3aR,11aS)-6-fluoro-5-(2-hydroxyethyl)-10-methyl-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-1,3a,4,5,10,11a-hexahydro-2H-benzo[b]pyrrolo[2,3-f][1,4]diazocine-2,11(3H)-dione (1 g, 99% yield) as a yellow solid. [ka]

[0277] Step b. To a solution of (3aR,11aS)-6-fluoro-5-(2-hydroxyethyl)-10-methyl-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-1,3a,4,5,10,11a-hexahydro-2H-benzo[b]pyrrolo[2,3-f][1,4]diazocine-2,11(3H)-dione (1 g, 2.14 mmol) in THF (10 mL) was added I2 (816 mg, 3.22 mmol), PPh3 (844 mg, 3.22 mmol), and imidazole (292 mg, 4.29 mmol). The reaction mixture was stirred at 0 °C for 12 h. After completion, the reaction mixture was quenched with saturated aqueous NH4Cl (20 mL), diluted with water (30 mL), and extracted with EtOAc (3 × 50 mL). The combined organic layers were washed with brine (3×30 mL), dried over NaSO, and evaporated. The crude product was purified by column chromatography (PE / EtOAc=4 / 1) to give the title compound (1 g, 80% yield) as a yellow solid. m / z ES+[M+H] + 577.1.

[0278] Intermediate 9a: 2-((3aR,11aS)-6-fluoro-10-methyl-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-2,11-dioxo-1,2,3,3a,4,10,11,11a-octahydro-5H-benzo[b]pyrrolo[2,3-f][1,4]diazocin-5-yl)acetic acid [ka] Step a. To a solution of intermediate 5a (300 mg, 0.71 mmol) and tert-butyl 2-bromoacetate (277 mg, 1.42 mmol) in NMP (4 mL) was added K2CO3 (294 mg, 2.13 mmol) and TBAI (26.2 mg, 0.071 mmol). The mixture was stirred at 120 °C for 24 h. After completion, the reaction mixture was diluted with EtOAc (50 mL) and washed with brine (3 × 10 mL). The organic layer was dried over Na2SO4 and evaporated. The crude product was purified by column chromatography (PE / EtOAc=5 / 1) to give tert-butyl 2-((3aR,11aS)-6-fluoro-10-methyl-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-2,11-dioxo-1,2,3,3a,4,10,11,11a-octahydro-5H-benzo[b]pyrrolo[2,3-f][1,4]diazocin-5-yl)acetate (210 mg, 54% yield) as a yellow gum. [ka]

[0279] Step b. To a solution of tert-butyl 2-((3aR,11aS)-6-fluoro-10-methyl-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-2,11-dioxo-1,2,3,3a,4,10,11,11a-octahydro-5H-benzo[b]pyrrolo[2,3-f][1,4]diazocin-5-yl)acetate (100 mg, 0.19 mmol) in DCM (2 mL) was added TFA (3.08 g, 27.0 mmol). The mixture was stirred at 20 °C for 30 minutes. After completion, the reaction mixture was evaporated to give the title compound (100 mg, crude) as a yellow oil. m / z ES+[M+H] + 481.3.

[0280] Intermediate 9b: 2-((3aR,11aS)-6-chloro-10-methyl-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-2,11-dioxo-1,2,3,3a,4,10,11,11a-octahydro-5H-benzo[b]pyrrolo[2,3-f][1,4]diazocin-5-yl)acetic acid [ka] The title compound was prepared in a similar manner to intermediate 9a, using intermediate 5b in step a. m / z ES+[M+H] + 497.1.

[0281] Intermediate 10a: benzyl 3-((R)-4-(2-((3aR,11aS)-6-fluoro-10-methyl-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-2,11-dioxo-1,2,3,3a,4,10,11,11a-octahydro-5H-benzo[b]pyrrolo[2,3-f][1,4]diazocin-5-yl)ethyl)-2-(fluoromethyl)piperazin-1-yl)azetidine-1-carboxylate and Intermediate 10b: benzyl 3-((S)-6-fluoro-4-(2-((3aR,11aS)-6-fluoro-10-methyl-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-2,11-dioxo-1,2,3,3a,4,10,11,11a-octahydro-5H-benzo[b]pyrrolo[2,3-f][1,4]diazocin-5-yl)ethyl)-1,4-diazepan-1-yl)azetidine-1-carboxylate [ka] Step a. To a solution of Intermediate 7a (100 mg, 0.22 mmol) and Intermediate A3 (99 mg, 0.32 mmol) in MeOH (2 mL) was added 4 Å molecular sieves (100 mg) and acetic acid (65 mg, 1.08 mmol). The mixture was stirred at 25 °C for 30 minutes, after which NaBHCN (27 mg, 0.43 mmol) was added. The mixture was stirred at 25 °C for 30 minutes. Upon completion, the mixture was diluted with DCM (5 mL) and basified to pH 8 with saturated aqueous NaHCO. The organic phase was separated, and the aqueous phase was further extracted with DCM (2 × 5 mL). The combined organic layers were dried over NaSO and evaporated. The residue was purified by column chromatography (PE / EtOAc = 1 / 4) and further purified by chiral SFC (column: Daicel ChiralPak AS (250 × 30 mm, 10 μm); mobile phase: A: 0.1% NH OH / MeOH; B%: 50% CO ) to give two products.

[0282] Intermediate 10a: Benzyl 3-((R)-4-(2-((3aR,11aS)-6-fluoro-10-methyl-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-2,11-dioxo-1,2,3,3a,4,10,11,11a-octahydro-5H-benzo[b]pyrrolo[2,3-f][1,4]diazocin-5-yl)ethyl)-2-(fluoromethyl)piperazin-1-yl)azetidine-1-carboxylate (22 mg, 22% yield) as a yellow solid. [ka]

[0283] Intermediate 10b: Benzyl 3-((S)-6-fluoro-4-(2-((3aR,11aS)-6-fluoro-10-methyl-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-2,11-dioxo-1,2,3,3a,4,10,11,11a-octahydro-5H-benzo[b]pyrrolo[2,3-f][1,4]diazocin-5-yl)ethyl)-1,4-diazepan-1-yl)azetidine-1-carboxylate (50 mg, 48% yield) as a yellow solid. [ka]

[0284] Intermediate 11a: tert-butyl 3-(5-(((3aR,11aS)-6-fluoro-10-methyl-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-2,11-dioxo-1,2,3,3a,4,10,11,11a-octahydro-5H-benzo[b]pyrrolo[2,3-f][1,4]diazocin-5-yl)methyl)-1-methyl-1H-1,2,4-triazol-3-yl)azetidine-1-carboxylate and Intermediate 11b: tert-butyl 3-(3-(((3aR,11aS)-6-fluoro-10-methyl-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-2,11-dioxo-1,2,3,3a,4,10,11,11a-octahydro-5H-benzo[b]pyrrolo[2,3-f][1,4]diazocin-5-yl)methyl)-1-methyl-1H-1,2,4-triazol-5-yl)azetidine-1-carboxylate [ka] Step a. To a solution of intermediate 5a (400 mg, 0.95 mmol) and 2-bromoacetonitrile (1.14 g, 9.47 mmol) in DMF (5 mL) was added Na2CO3 (402 mg, 3.79 mmol) and TBAB (31 mg, 0.095 mmol). The reaction mixture was stirred at 100 °C for 12 h. After completion, the reaction mixture was diluted with water (20 mL) and extracted with EtOAc (3 × 30 mL). The combined organic layers were washed with brine (20 mL), dried over NaSO, evaporated, and purified by column chromatography (PE / EtOAc = 2 / 1) to give 2-((3aR,11aS)-6-fluoro-10-methyl-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-2,11-dioxo-1,2,3,3a,4,10,11,11a-octahydro-5H-benzo[b]pyrrolo[2,3-f][1,4]diazocin-5-yl)acetonitrile (410 mg, 94% yield) as a brown solid. [ka]

[0285] Step b: To a solution of 2-((3aR,11aS)-6-fluoro-10-methyl-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-2,11-dioxo-1,2,3,3a,4,10,11,11a-octahydro-5H-benzo[b]pyrrolo[2,3-f][1,4]diazocin-5-yl)acetonitrile (200 mg, 0.43 mmol) in MeOH (4 mL) was added sodium methoxide (30 mg, 0.56 mmol) and tert-butyl 3-(hydrazinecarbonyl)azetidine-1-carboxylate (CAS: 1001907-44-3; 280 mg, 1.3 mmol), and the mixture was stirred at 80° C. for 12 hours. After completion, the reaction mixture was quenched with saturated aqueous NH4Cl (20 mL), diluted with water (30 mL), and extracted with EtOAc (3 × 50 mL). The combined organic layers were washed with brine (3 × 20 mL), dried over Na2SO4, evaporated, and purified by column chromatography (EtOAc) to afford tert-butyl 3-(3-(((3aR,11aS)-6-fluoro-10-methyl-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-2,11-dioxo-1,2,3,3a,4,10,11,11a-octahydro-5H-benzo[b]pyrrolo[2,3-f][1,4]diazocin-5-yl)methyl)-1H-1,2,4-triazol-5-yl)azetidine-1-carboxylate (110 mg, 39% yield) as a yellow solid. [ka]

[0286] Step c. To a solution of tert-butyl 3-(3-(((3aR,11aS)-6-fluoro-10-methyl-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-2,11-dioxo-1,2,3,3a,4,10,11,11a-octahydro-5H-benzo[b]pyrrolo[2,3-f][1,4]diazocin-5-yl)methyl)-1H-1,2,4-triazol-5-yl)azetidine-1-carboxylate (100 mg, 0.15 mmol) in DMF (3 mL) was added KCO (63 mg, 0.46 mmol) and MeI (43 mg, 0.30 mmol). The reaction mixture was stirred at 25 °C for 2 h. After completion, the reaction mixture was diluted with water (20 mL) and extracted with EtOAc (3 × 30 mL). The combined organic layers were washed with brine (20 mL), dried over Na2SO4, evaporated, and purified by preparative TLC (EtOAc / MeOH=10 / 1) to give two products. The regiochemistry was confirmed by 2D NMR.

[0287] Intermediate 11a: tert-butyl 3-(5-(((3aR,11aS)-6-fluoro-10-methyl-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-2,11-dioxo-1,2,3,3a,4,10,11,11a-octahydro-5H-benzo[b]pyrrolo[2,3-f][1,4]diazocin-5-yl)methyl)-1-methyl-1H-1,2,4-triazol-3-yl)azetidine-1-carboxylate (50 mg, 49% yield) as a yellow solid. [ka]

[0288] Intermediate 11b: tert-butyl 3-(3-(((3aR,11aS)-6-fluoro-10-methyl-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-2,11-dioxo-1,2,3,3a,4,10,11,11a-octahydro-5H-benzo[b]pyrrolo[2,3-f][1,4]diazocin-5-yl)methyl)-1-methyl-1H-1,2,4-triazol-5-yl)azetidine-1-carboxylate (20 mg, 20% yield) as a yellow solid. [ka]

[0289] Intermediate 12a: tert-butyl 3-(((S / R)-3-((3aR,11aS)-6-chloro-10-methyl-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-2,11-dioxo-1,2,3,3a,4,10,11,11a-octahydro-5H-benzo[b]pyrrolo[2,3-f][1,4]diazocin-5-yl)-2-hydroxypropyl)(methyl)amino)azetidine-1-carboxylate and Intermediate 12b: tert-butyl 3-(((R / S)-3-((3aR,11aS)-6-chloro-10-methyl-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-2,11-dioxo-1,2,3,3a,4,10,11,11a-octahydro-5H-benzo[b]pyrrolo[2,3-f][1,4]diazocin-5-yl)-2-hydroxypropyl)(methyl)amino)azetidine-1-carboxylate [ka] Step a. This step was carried out in a similar manner to step a of intermediate 7a using intermediate 5b.

[0290] Step b. To a mixture of (3aR,11aS)-5-allyl-6-chloro-10-methyl-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-1,3a,4,5,10,11a-hexahydro-2H-benzo[b]pyrrolo[2,3-f][1,4]diazocine-2,11(3H)-dione (100 mg, 0.21 mmol) in DCM (5 mL) was added m-CPBA (144 mg, 0.63 mmol). The reaction mixture was stirred at 30 °C for 20 h. After completion, the reaction mixture was diluted with water (50 mL) and extracted with EtOAc (3 × 30 mL). The organic layers were combined, washed with brine (3 × 50 mL), dried over NaSO, and evaporated. Purification by preparative TLC (PE / EtOAc=1 / 2) afforded (3aR,11aS)-6-chloro-10-methyl-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-5-(oxiran-2-ylmethyl)-1,3a,4,5,10,11a-hexahydro-2H-benzo[b]pyrrolo[2,3-f][1,4]diazocine-2,11(3H)-dione (90 mg, 87% yield) as a yellow solid. [ka]

[0291] Step c. To a mixture of (3aR,11aS)-6-chloro-10-methyl-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-5-(oxiran-2-ylmethyl)-1,3a,4,5,10,11a-hexahydro-2H-benzo[b]pyrrolo[2,3-f][1,4]diazocin-2,11(3H)-dione (208 mg, 0.42 mmol) in MeOH (5 mL) was added tert-butyl 3-(methylamino)azetidine-1-carboxylate (CAS 454703-20-9; 391 mg, 2.10 mmol). The reaction mixture was stirred at 70 °C for 18 h. After completion, the reaction mixture was evaporated and the residue was purified by preparative HPLC to give tert-butyl 3-(((rac)-3-((3aR,11aS)-6-chloro-10-methyl-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-2,11-dioxo-1,2,3,3a,4,10,11,11a-octahydro-5H-benzo[b]pyrrolo[2,3-f][1,4]diazocin-5-yl)-2-hydroxypropyl)(methyl)amino)azetidine-1-carboxylate (150 mg, 52% yield) as a yellow solid. [ka]

[0292] The racemic material (150 mg) was purified by chiral SFC (column: Daicel ChiralPak IC (250 x 30 mm, 10 μm); mobile phase: A: 0.1% NH4OH / MeOH; B: 55% CO2) to give two products.

[0293] Intermediate 12a: tert-butyl 3-(((S / R)-3-((3aR,11aS)-6-chloro-10-methyl-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-2,11-dioxo-1,2,3,3a,4,10,11,11a-octahydro-5H-benzo[b]pyrrolo[2,3-f][1,4]diazocin-5-yl)-2-hydroxypropyl)(methyl)amino)azetidine-1-carboxylate (60 mg, 40% yield) as a colorless oil. m / z ES+[M+H] + 681.3.

[0294] Intermediate 12b: tert-butyl 3-(((R / S)-3-((3aR,11aS)-6-chloro-10-methyl-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-2,11-dioxo-1,2,3,3a,4,10,11,11a-octahydro-5H-benzo[b]pyrrolo[2,3-f][1,4]diazocin-5-yl)-2-hydroxypropyl)(methyl)amino)azetidine-1-carboxylate (75 mg, 50% yield) as a colorless oil. m / z ES+[M+H] + 681.3.

[0295] Intermediate 13: tert-butyl 3-((3-((3aR,11aS)-6-fluoro-10-methyl-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-2,11-dioxo-1,2,3,3a,4,10,11,11a-octahydro-5H-benzo[b]pyrrolo[2,3-f][1,4]diazocin-5-yl)propyl)amino)azetidine-1-carboxylate [ka] Step a. This step was carried out as described in step a of intermediate 7a.

[0296] Step b. To a solution of (3aR,11aS)-5-allyl-6-fluoro-10-methyl-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-1,3a,4,5,10,11a-hexahydro-2H-benzo[b]pyrrolo[2,3-f][1,4]diazocine-2,11(3H)-dione (100 mg, 0.22 mmol) in tetrahydrofuran (3 mL) was added a solution of borane dimethyl sulfide complex (10 M in THF, 65 μL) in DCM (0.59 mL). The reaction mixture was stirred at 25 °C for 2 hours. The reaction mixture was quenched with methanol (2 mL) and evaporated. The residue was dissolved in THF (4 mL), and 1 M sodium hydroxide (0.65 mL) and 30% hydrogen peroxide (221 mg, 1.95 mmol) were added. The resulting mixture was stirred at 25 °C for 1 h. After completion, the reaction mixture was diluted with water (30 mL) and extracted with EtOAc (30 mL). The organic layer was washed with water (2 × 30 mL), 1 M sodium thiosulfate (30 mL), brine (30 mL), dried over NaSO, and evaporated. The residue was purified by preparative HPLC to give (3aR,11aS)-6-fluoro-5-(3-hydroxypropyl)-10-methyl-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-1,3a,4,5,10,11a-hexahydro-2H-benzo[b]pyrrolo[2,3-f][1,4]diazocine-2,11(3H)-dione (14 mg, 69% yield) as a white solid. [ka]

[0297] Step c. To a solution of (3aR,11aS)-6-fluoro-5-(3-hydroxypropyl)-10-methyl-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-1,3a,4,5,10,11a-hexahydro-2H-benzo[b]pyrrolo[2,3-f][1,4]diazocine-2,11(3H)-dione (300 mg, 0.62 mmol) in DCM (5 mL) was added DMP (397 mg, 0.94 mmol). The reaction mixture was stirred at 25 °C for 1 h. Upon completion, the reaction mixture was quenched with saturated aqueous NaSO (20 mL), diluted with water (30 mL), and extracted with DCM (3 × 50 mL). The combined organic layers were washed with saturated aqueous NaHCO (20 mL), dried over NaSO, and evaporated to give 3-((3aR,11aS)-6-fluoro-10-methyl-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-2,11-dioxo-1,2,3,3a,4,10,11,11a-octahydro-5H-benzo[b]pyrrolo[2,3-f][1,4]diazocin-5-yl)propanal (290 mg, crude) as a yellow solid. m / z ES+[M+H] + 479.2.

[0298] Step d: To a solution of 3-((3aR,11aS)-6-fluoro-10-methyl-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-2,11-dioxo-1,2,3,3a,4,10,11,11a-octahydro-5H-benzo[b]pyrrolo[2,3-f][1,4]diazocin-5-yl)propanal (0.29 g, 0.61 mmol) and tert-butyl 3-aminoazetidine-1-carboxylate (CAS: 193269-78-2; 209 mg, 1.21 mmol) in MeOH (5 mL) was added acetic acid (182 mg, 3.03 mmol), 4 Å molecular sieves (300 mg), and NaBH(OAc) (257 mg, 1.21 mmol). The reaction mixture was stirred for 12 hours at 25° C. After completion, the reaction mixture was evaporated and purified by column chromatography (EtOAc) to afford the title compound (370 mg, 96% yield) as a yellow solid. [ka]

[0299] Intermediate 14: (3aR,11aS)-6-chloro-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-1,3a,4,5,10,11a-hexahydro-2H-benzo[b]pyrrolo[2,3-f][1,4]diazocine-2,11(3H)-dione [ka] Step a. Mix Intermediate 1 (100 g, 411 mmol), 2-bromo-6-methyl-4-(trifluoromethyl)pyridine (CAS: 451459-17-9; 128 g, 534 mmol), KCO (114 g, 822 mmol), CuI (15.7 g, 82.2 mmol), and N in toluene (1.4 L). 1 ,N 2 A mixture of 2-(tert-butyl) 3-methyl(2S,3S)-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-5-oxopyrrolidine-2,3-dicarboxylate (108 g, 63% yield) was obtained as a yellow solid. [ka]

[0300] Step b. Note: The following process was carried out in six parallel batches. To a solution of 2-(tert-butyl) 3-methyl(2S,3S)-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-5-oxopyrrolidine-2,3-dicarboxylate (50 g, 124 mmol) in THF (450 mL) and MeOH (50 mL) was added NaBH (7.05 g, 186 mmol) portionwise at 0 °C. The mixture was stirred at 0–5 °C for 3 h. After completion, the reaction mixture was quenched with saturated aqueous NH Cl (3 L) and extracted with EtOAc (2 × 3 L). The organic layers from the parallel batches were combined, washed with brine (3 L), dried over NaSO, and evaporated to give tert-butyl (2S,3S)-3-(hydroxymethyl)-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-5-oxopyrrolidine-2-carboxylate (300 g, crude) as a yellow gum. [ka]

[0301] Step c. To a solution of tert-butyl (2S,3S)-3-(hydroxymethyl)-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-5-oxopyrrolidine-2-carboxylate (100 g, 267 mmol) and TEA (54.1 g, 534 mmol) in DCM (1 L) was added MsCl (33.7 g, 294 mmol) dropwise at 0° C. The reaction mixture was stirred at 20° C. for 1 h. Upon completion, the reaction mixture was diluted with water (1 L). The layers were separated, and the organic layer was washed with brine (3 × 1 L), dried over NaSO, filtered through a pad of silica gel (100-200 mesh), and evaporated to give tert-butyl (2S,3S)-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-3-(((methylsulfonyl)oxy)methyl)-5-oxopyrrolidine-2-carboxylate (120 g, 99% yield) as a yellow gum. [ka]

[0302] Step d. A mixture of tert-butyl (2S,3S)-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-3-(((methylsulfonyl)oxy)methyl)-5-oxopyrrolidine-2-carboxylate (50 g, 111 mmol), isoindoline-1,3-dione (16.4 g, 112 mmol), and K2CO3 (25.1 g, 181 mmol) in NMP (400 mL) was stirred at 100 °C for 12 h. After completion, the reaction mixture was diluted with water (1 L) and filtered. The filter cake was dissolved in EtOAc (1 L), washed with brine (3 × 1 L), dried over Na2SO4, and evaporated. The crude product was triturated at 25° C. for 12 hours (PE / MTBE=1 / 1, 3.0 L) to give tert-butyl (2S,3R)-3-((1,3-dioxoisoindolin-2-yl)methyl)-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-5-oxopyrrolidine-2-carboxylate (25 g, 44% yield) as a white solid. [ka]

[0303] Step e. Note: The following process was carried out in four parallel batches. To a solution of tert-butyl (2S,3R)-3-((1,3-dioxoisoindolin-2-yl)methyl)-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-5-oxopyrrolidine-2-carboxylate (25.0 g, 49.7 mmol) in MeOH (250 mL) was added hydrazine monohydrate (85% purity; 4.68 g, 79.5 mmol). The reaction mixture was stirred at 70° C. under a N atmosphere for 12 h. Upon completion, the reaction mixture was cooled to rt, filtered, and the filtrate was evaporated. The residues from the parallel batches were combined, diluted with water (1 L), extracted with EtOAc (2 × 1 L), washed with brine (1 L), dried over NaSO, and evaporated to give tert-butyl (2S,3R)-3-(aminomethyl)-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-5-oxopyrrolidine-2-carboxylate (76 g, crude) as a brown gum. [ka]

[0304] Step f. Note: The following process was carried out in four parallel batches. A mixture of tert-butyl (2S,3R)-3-(aminomethyl)-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-5-oxopyrrolidine-2-carboxylate (40 g, 107 mmol), 1-chloro-2-fluoro-3-nitrobenzene (CAS: 2106-49-2; 17.8 g, 102 mmol), and NaHCO (18.0 g, 214 mmol) in EtOH (380 mL) and water (20 mL) was stirred for 12 h at 105° C. After completion, the reaction mixture was evaporated, diluted with EtOAc (5 L), and washed with water (2 L). The organic layers from parallel batches were combined, dried over Na2SO4, evaporated, and purified by column chromatography (PE / EA=10 / 1) to give tert-butyl (2S,3R)-3-(((2-chloro-6-nitrophenyl)amino)methyl)-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-5-oxopyrrolidine-2-carboxylate (175 g, 77% yield) as a yellow oil. [ka]

[0305] Step g. To a solution of tert-butyl (2S,3R)-3-(((2-chloro-6-nitrophenyl)amino)methyl)-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-5-oxopyrrolidine-2-carboxylate (110 g, 208 mmol) in THF (1.1 L) was added 3% Pt-V / C (11 g, 1.26 mmol). The reaction mixture was stirred at 25 °C under an atmosphere of H (30 psi) for 16 hours. Upon completion, the reaction mixture was filtered and evaporated to give tert-butyl (2S,3R)-3-(((2-amino-6-chlorophenyl)amino)methyl)-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-5-oxopyrrolidine-2-carboxylate (102 g, 98% yield) as a brown oil. [ka]

[0306] Step h. Note: The following process was carried out in three parallel batches. To a solution of tert-butyl (2S,3R)-3-(((2-amino-6-chlorophenyl)amino)methyl)-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-5-oxopyrrolidine-2-carboxylate (34.0 g, 68.2 mmol) in DCM (170 mL) was added HCl in 1,4-dioxane (4 M, 170 mL). The reaction mixture was stirred at 25° C. for 12 hours. Upon completion, the reaction mixture was diluted with water (1 L). The pH of the reaction mixture was adjusted to pH 5 with solid NaOH and then evaporated to remove DCM. The residues from the parallel batches were combined, extracted with EtOAc (3 × 1 L), washed with brine (1 L), dried over NaSO, and evaporated to give (2S,3R)-3-[(2-amino-6-chloro-anilino)methyl]-1-[6-methyl-4-(trifluoromethyl)-2-pyridyl]-5-oxo-pyrrolidine-2-carboxylic acid (90 g, 99% yield) as a yellow oil. [ka] Step i. Note: The following process was carried out in two parallel batches. To a solution of (2S,3R)-3-(((2-amino-6-chlorophenyl)amino)methyl)-1-(6-methyl-4-(trifluoromethyl)pyridin-2-yl)-5-oxopyrrolidine-2-carboxylic acid (30.0 g, 67.8 mmol) and DIPEA (17.5 g, 136 mmol) in DCM (1800 mL) and EtOAc (600 mL) was added T3P (50% in EtOAc; 43.1 g, 67.8 mmol). The reaction mixture was stirred at 20 °C for 1 h. Upon completion, the reaction mixture was quenched with water (500 mL) and extracted with EtOAc (3 × 1 L). The organic layers from parallel batches were combined, washed with brine (1 L), dried over Na2SO4, and evaporated. Purification by column chromatography (PE / EtOAc / NH4OH=1 / 1 / 0.002) afforded the title compound (40 g, 67% yield) as an off-white solid. [ka]

[0307] Intermediate A1: tert-butyl 3-(piperazin-1-yl)azetidine-1-carboxylate [ka] Step a. To a solution of tert-butyl 3-oxoazetidine-1-carboxylate (CAS: 398489-26-4; 29.2 g, 170 mmol) and benzylpiperazine-1-carboxylate (CAS: 31166-44-6; 25 g, 114 mmol) in MeOH (500 mL) was added 4 Å molecular sieves (25 g) and acetic acid (6.8 g, 114 mmol). The mixture was stirred at rt for 12 h, after which NaBH3CN (21.4 g, 341 mmol) was added. The mixture was stirred at rt for 1 h. Upon completion, the mixture was filtered and evaporated. The crude product was purified by reverse-phase flash chromatography (water (0.1% TFA) / MeCN). The product-containing fractions were combined, basified to pH 8 with saturated aqueous Na2CO3, and evaporated to remove MeCN and water. The resulting residue was extracted with EtOAc (3 × 500 mL), and the combined layers were washed with brine (800 mL), dried over NaSO, and evaporated to give benzyl 4-(1-(tert-butoxycarbonyl)azetidin-3-yl)piperazine-1-carboxylate (30 g, 67% yield) as a yellow solid. [ka]

[0308] Step b. A mixture of benzyl 4-(1-(tert-butoxycarbonyl)azetidin-3-yl)piperazine-1-carboxylate (60 g, 160 mmol) and 10% Pd / C (9 g) in MeOH (600 mL) was stirred under H atmosphere (50 psi) at 40° C. for 16 h. After completion, the mixture was filtered and evaporated to give the title compound (37 g, crude) as a white solid. [ka]

[0309] Intermediate A2: tert-butyl 3-(1,4-diazepan-1-yl)azetidine-1-carboxylate [ka] Step a. To a solution of tert-butyl 1,4-diazepane-1-carboxylate (CAS: 112275-50-0; 10.0 g, 49.9 mmol) in THF (100 mL) and water (30 mL) was added CbzCl (8.52 g, 49.9 mmol) and Na2CO3 (15.9 g, 150 mmol). The mixture was stirred at 25 °C for 2 h. After completion, the reaction mixture was quenched with saturated aqueous NH4Cl (100 mL), diluted with water (100 mL), and extracted with EtOAc (3 × 200 mL). The combined organic layers were washed with brine (3 × 100 mL), dried over Na2SO4, and evaporated. The residue was purified by column chromatography (PE / EtOAc=4 / 1) to give 1-benzyl 4-(tert-butyl) 1,4-diazepane-1,4-dicarboxylate (15 g, 89% yield) as a yellow oil. [ka]

[0310] Step b. To a solution of 1-benzyl 4-(tert-butyl) 1,4-diazepane-1,4-dicarboxylate (5 g, 15.0 mmol) in DCM (50 mL) was added TFA (10 mL) and the mixture was stirred for 30 minutes at 25° C. After completion, the reaction mixture was evaporated to give benzyl 1,4-diazepane-1-carboxylate as the TFA salt (5.1 g, crude) as a colorless oil. m / z ES+[M+H] + 235.2.

[0311] Step c. To a solution of benzyl 1,4-diazepane-1-carboxylate (5.1 g, 14.6 mmol) and tert-butyl 3-oxoazetidine-1-carboxylate (3.01 g, 17.6 mmol) in MeOH (50 mL) was added acetic acid (4.40 g, 73.2 mmol), 4 Å molecular sieves (5 g), and NaBHCN (1.84 g, 29.3 mmol). The mixture was stirred at 25 °C for 2 hours. Upon completion, the reaction mixture was filtered and evaporated. The residue was diluted with saturated aqueous NaHCO (50 mL) and water (100 mL) and extracted with EtOAc (3 × 150 mL). The combined organic layer was washed with brine (3 × 100 mL), dried over NaSO, filtered, and evaporated. The residue was purified by column chromatography (PE / EtOAc=3 / 1) to give benzyl 4-(1-(tert-butoxycarbonyl)azetidin-3-yl)-1,4-diazepane-1-carboxylate (3.5 g, 61% yield) as a colorless oil. [ka]

[0312] Step d. To a solution of benzyl 4-(1-(tert-butoxycarbonyl)azetidin-3-yl)-1,4-diazepane-1-carboxylate (3.5 g, 8.99 mmol) in MeOH (50 mL) was added 10% Pd / C (954 mg), and the mixture was stirred under H atmosphere (15 psi) at 25 °C for 1 h. After completion, the reaction mixture was filtered and evaporated to give the title compound (2.1 g, 91% yield) as a colorless oil. [ka]

[0313] Intermediate A3: A mixture of benzyl (S)-3-(6-fluoro-1,4-diazepan-1-yl)azetidine-1-carboxylate and benzyl (R)-3-(2-(fluoromethyl)piperazin-1-yl)azetidine-1-carboxylate [ka] Step a. To a solution of tert-butyl (R)-3-(hydroxymethyl)piperazine-1-carboxylate (CAS: 278788-66-2; 5.00 g, 23.1 mmol) and benzaldehyde (2.94 g, 27.7 mmol) in DCE (50 mL) was added acetic acid (2.08 g, 34.6 mmol) and 4 Å molecular sieves (5 g). The mixture was stirred at 25 °C for 1 h, after which NaBH(OAc) (5.88 g, 27.7 mmol) was added. The mixture was stirred at 25 °C for 12 h. Upon completion, the mixture was filtered, diluted with water (20 mL), and extracted with EtOAc (3 × 20 mL). The combined layers were dried over NaSO and evaporated. The residue was purified by column chromatography (PE / EtOAc=3 / 1) to give tert-butyl (R)-4-benzyl-3-(hydroxymethyl)piperazine-1-carboxylate (3.5 g, 47% yield) as a yellow solid. m / z ES+[M+H] + 307.2.

[0314] Step b. To a solution of tert-butyl (R)-4-benzyl-3-(hydroxymethyl)piperazine-1-carboxylate (500 mg, 1.63 mmol) in DCM (10 mL) was added DAST (1.32 g, 8.16 mmol) dropwise at 0 °C. The mixture was stirred at 25 °C for 5 h. After completion, the mixture was diluted with saturated aqueous NaHCO (20 mL) and extracted with EtOAc (2 × 30 mL). The combined organic layers were dried over Na SO and evaporated. The residue was purified by column chromatography (PE / EtOAc = 20 / 1) to give an inseparable mixture of tert-butyl (R)-4-benzyl-6-fluoro-1,4-diazepane-1-carboxylate and tert-butyl (R)-4-benzyl-3-(fluoromethyl)piperazine-1-carboxylate (450 mg, 86% yield) as a brown oil. m / z ES+[M+H] + 309.3.

[0315] Step c. A mixture of tert-butyl (R)-4-benzyl-6-fluoro-1,4-diazepane-1-carboxylate and tert-butyl (R)-4-benzyl-3-(fluoromethyl)piperazine-1-carboxylate (400 mg, 1.30 mmol), 10% Pd / C (100 mg), and 20% Pd(OH) / C (100 mg) in MeOH (10 mL) was stirred under a H atmosphere (15 psi) at 40 °C for 24 h. Upon completion, the reaction mixture was filtered and evaporated to give an inseparable mixture of tert-butyl (R)-6-fluoro-1,4-diazepane-1-carboxylate and tert-butyl (R)-3-(fluoromethyl)piperazine-1-carboxylate (280 mg, 99% yield) as a colorless oil. m / z ES+[M+H] + 219.1.

[0316] Step d. To a solution of tert-butyl (R)-6-fluoro-1,4-diazepane-1-carboxylate, tert-butyl (R)-3-(fluoromethyl)piperazine-1-carboxylate (280 mg, 1.28 mmol), and benzyl 3-oxoazetidine-1-carboxylate (395 mg, 1.92 mmol) in MeOH (5 mL) was added 4 Å molecular sieves (280 mg) and acetic acid (385 mg, 6.41 mmol). The mixture was stirred at 25 °C for 30 minutes, after which NaBH CN (121 mg, 1.92 mmol) was added. The mixture was stirred at 25 °C for 12 hours. Upon completion, the reaction mixture was diluted with DCM (5 mL) and basified to pH 8 with saturated aqueous NaHCO . The organic layer was separated, and the aqueous was further extracted with DCM (2 × 5 mL). The combined organic layers were dried over Na SO and evaporated. The residue was purified by column chromatography (PE / EtOAc=5 / 1) and then re-purified by preparative TLC (PE / EtOAc=1 / 1) to give an inseparable mixture of tert-butyl (R)-4-(1-((benzyloxy)carbonyl)azetidin-3-yl)-6-fluoro-1,4-diazepane-1-carboxylate and tert-butyl (R)-4-(1-((benzyloxy)carbonyl)azetidin-3-yl)-3-(fluoromethyl)piperazine-1-carboxylate (250 mg, 37% yield) as a colorless oil. m / z ES+[M+H] + 408.2.

[0317] Step e. To a solution of tert-butyl (R)-4-(1-((benzyloxy)carbonyl)azetidin-3-yl)-6-fluoro-1,4-diazepane-1-carboxylate and tert-butyl (R)-4-(1-((benzyloxy)carbonyl)azetidin-3-yl)-3-(fluoromethyl)piperazine-1-carboxylate (220 mg, 0.54 mmol) in DCM (3 mL) was added TFA (1 mL). The mixture was stirred at rt for 30 min. After completion, the mixture was diluted with DCM (5 mL) and basified to pH 8 with saturated aqueous NaHCO. The organic layer was separated, and the aqueous was further extracted with DCM (2 × 5 mL). The combined organic layers were dried over NaSO and evaporated to give an inseparable mixture of the title compounds (100 mg, crude) as a colorless oil. m / z ES+[M+H] + 307.9.

[0318] Intermediate A4: 5-benzyl 2-(tert-butyl) 2,5,8-triazaspiro[3.5]nonane-2,5-dicarboxylate [ka] Step a. To a solution of tert-butyl 3-oxoazetidine-1-carboxylate (100 g, 584 mmol) in MeNO (678 g, 11.1 mol) was added TEA (11.8 g, 117 mmol). The mixture was stirred at 25 °C for 1 h. Upon completion, the mixture was evaporated to give tert-butyl 3-hydroxy-3-(nitromethyl)azetidine-1-carboxylate (135 g, crude) as a yellow solid. [ka]

[0319] Step b. To a solution of tert-butyl 3-hydroxy-3-(nitromethyl)azetidine-1-carboxylate (50 g, 215 mmol) in DCM (1 L) was added TEA (43.6 g, 431 mmol). Then, MsCl (24.7 g, 215 mmol) in DCM (500 mL) was added dropwise at −78° C. The mixture was stirred at −78° C. for 1.5 h. Methyl 2-aminoacetate hydrochloride (CAS: 34582-32-6; 54.0 g, 430 mmol) and TEA (43.6 g, 431 mmol) were dissolved in DCM (500 mL) and stirred for 10 min. This solution was added to the reaction mixture at −78° C. The mixture was stirred at 25° C. for 16 h. After completion, the mixture was diluted with water (400 mL) and extracted with DCM (2×500 mL). The combined organic layers were washed with brine (300 mL), dried over NaSO, and evaporated. The crude product was purified by silica gel chromatography column (PE / EtOAc=5 / 1) to give tert-butyl 3-((2-methoxy-2-oxoethyl)amino)-3-(nitromethyl)azetidine-1-carboxylate (41.5 g, 63% yield) as a white solid. [ka]

[0320] Step c. To a solution of tert-butyl 3-((2-methoxy-2-oxoethyl)amino)-3-(nitromethyl)azetidine-1-carboxylate (20 g, 66.0 mmol) in MeOH (500 mL) was added Raney-Ni (20 g, 233 mmol), and the reaction mixture was stirred under a H atmosphere (50 psi) at 25 °C for 12 h. Upon completion, the mixture was filtered and evaporated to give tert-butyl 7-oxo-2,5,8-triazaspiro[3.5]nonane-2-carboxylate (63 g, crude) as a colorless oil. m / z ES+[M+H] + 242.1.

[0321] Step d. To a solution of tert-butyl 7-oxo-2,5,8-triazaspiro[3.5]nonane-2-carboxylate (63 g, 261 mmol) and NaHCO (65.8 g, 783 mmol) in THF (600 mL) and water (200 mL) was added CbzCl (66.8 g, 392 mmol), and the mixture was stirred at 25 °C for 12 h. After completion, the mixture was diluted with water (200 mL) and extracted with EtOAc (2 × 200 mL). The combined organic layers were washed with brine (200 mL), dried over NaSO, and evaporated. The crude product was purified by column chromatography (PE / EtOAc=1 / 1) to give 5-benzyl 2-(tert-butyl) 7-oxo-2,5,8-triazaspiro[3.5]nonane-2,5-dicarboxylate (46 g, 42% yield) as a colorless oil. [ka]

[0322] Step e. To a solution of 5-benzyl 2-(tert-butyl) 7-oxo-2,5,8-triazaspiro[3.5]nonane-2,5-dicarboxylate (13 g, 34.6 mmol) in THF (100 mL) was added borane dimethyl sulfide complex (10 M in THF, 10.39 mL) at 0 °C, and the mixture was stirred at 25 °C for 1 h. After completion, the mixture was quenched with MeOH (10 mL) and evaporated. The crude product was purified by column chromatography (PE / EtOAc = 1 / 1) to give the title compound (2 g, 16% yield) as a yellow oil. [ka]

[0323] Intermediate A5: 5-benzyl 2-(tert-butyl)(R)-6-methyl-2,5,8-triazaspiro[3.5]nonane-2,5-dicarboxylate [ka] The title compound was prepared in a similar manner to intermediate A4, using methyl D-alaninate (CAS: 14316-06-4) in step b. m / z ES+[M+H] + 376.2.

[0324] Intermediate A6: 5-benzyl 2-(tert-butyl)(S)-6-methyl-2,5,8-triazaspiro[3.5]nonane-2,5-dicarboxylate [ka] The title compound was prepared in a similar manner to intermediate A4, using methyl L-alaninate (CAS: 2491-20-5) in step b. m / z ES+[M-tBu+H] + 320.2.

[0325] Intermediate A7: 5-benzyl 2-(tert-butyl) 9-methyl-2,5,8-triazaspiro[3.5]nonane-2,5-dicarboxylate [ka] The title compound was prepared in a similar manner to intermediate A4, using EtNO2 in step a. m / z ES+[M+H] + 376.2.

[0326] Intermediate A8: 5-benzyl 2-(tert-butyl)(6R)-6,9-dimethyl-2,5,8-triazaspiro[3.5]nonane-2,5-dicarboxylate [ka] The title compound was prepared in a similar manner to intermediate A4 using EtNO2 in step a and methyl D-alaninate in step b. m / z ES+[M+H] + 390.3.

[0327] Intermediate A9: tert-butyl (R)-6-methyl-2,5,8-triazaspiro[3.5]nonane-2-carboxylate [ka] Step a. To a solution of intermediate A5 (0.8 g, 2.13 mmol) in THF (9 mL) and water (3 mL) was added Na2CO3 (226 mg, 2.13 mmol) and CbzCl (545 mg, 3.20 mmol). The mixture was stirred at 25 °C for 12 h. After completion, the reaction mixture was quenched with saturated aqueous NH4Cl (20 mL), further diluted with water (30 mL), and extracted with EtOAc (3 × 50 mL). The combined organic layers were washed with brine (3 × 20 mL), dried over Na2SO4, and evaporated. The residue was purified by column chromatography (PE / EtOAc = 5 / 1) to afford 5,8-dibenzyl 2-(tert-butyl)(R)-6-methyl-2,5,8-triazaspiro[3.5]nonane-2,5,8-tricarboxylate (1 g, 92% yield) as a colorless solid. [ka]

[0328] Step b. To a solution of 5,8-dibenzyl 2-(tert-butyl)(R)-6-methyl-2,5,8-triazaspiro[3.5]nonane-2,5,8-tricarboxylate (1.0 g, 1.96 mmol) in THF (10 mL), 10% Pd / C (208 mg) was added, and the mixture was stirred at 25 °C under a H atmosphere (15 psi) for 12 hours. After completion, the reaction mixture was filtered and evaporated. The residue was purified by reverse-phase flash chromatography (water (0.1% FA) / MeCN) to give the title compound (450 mg, 95% yield) as a colorless oil. [ka]

[0329] Intermediate A10: tert-butyl (R)-hexahydro-1'H-spiro[azetidine-3,4'-pyrrolo[1,2-a]pyrazine]-1-carboxylate [ka] Step a. This step was carried out as described in step a of intermediate A4.

[0330] Step b. To a solution of tert-butyl 3-hydroxy-3-(nitromethyl)azetidine-1-carboxylate (5.0 g, 21.5 mmol) and TEA (4.4 g, 43.1 mmol) in DCM (100 mL) was added MsCl (2.5 g, 21.5 mmol) at −78° C. under a N atmosphere. The mixture was stirred at −78° C. for 2 hours. Then, a solution of methyl D-propionate hydrochloride (CAS: 184719-80-0; 5.6 g, 33.6 mmol) and TEA (4.4 g, 43.1 mmol) in DCM (100 mL) was added to the reaction mixture at −78° C. The reaction mixture was stirred at 25° C. under a N atmosphere for 12 hours. After completion, the reaction mixture was diluted with DCM (100 mL), washed with brine (3 × 100 mL), dried over NaSO, and evaporated. The crude product was purified by column chromatography (PE / EtOAc = 1 / 1) to give methyl (1-(tert-butoxycarbonyl)-3-(nitromethyl)azetidin-3-yl)-D-propionate (5.0 g, 68% yield) as a yellow oil. [ka]

[0331] Step c. To a solution of methyl (1-(tert-butoxycarbonyl)-3-(nitromethyl)azetidin-3-yl)-D-propionate (5.0 g, 14.6 mmol) in MeOH (100 mL) was added Raney-Ni (1.3 g, 14.6 mmol), and the mixture was heated to 25° C. under a H atmosphere (50 psi) for 12 hours. After completion, the reaction mixture was filtered and evaporated to give tert-butyl (R)-1′-oxohexahydro-1′H-spiro[azetidine-3,4′-pyrrolo[1,2-a]pyrazine]-1-carboxylate (3.5 g, 85% yield) as a yellow solid. m / z ES+[M+H] + 282.2.

[0332] Step d. To a mixture of tert-butyl (R)-1'-oxohexahydro-1'H-spiro[azetidine-3,4'-pyrrolo[1,2-a]pyrazine]-1-carboxylate (400 mg, 1.42 mmol) in THF (5 mL) was added borane dimethyl sulfide complex (10 M in THF, 0.43 mL). The mixture was stirred at 25°C for 1 hour under a N2 atmosphere. After completion, the reaction mixture was quenched with MeOH (10 mL) at 0°C and stirred at 25°C for 2 hours. The mixture was evaporated to give the title compound (400 mg, crude) as a white solid. [ka]

[0333] Intermediate A11: tert-butyl (S)-6-(methoxymethyl)-2,5,8-triazaspiro[3.5]nonane-2-carboxylate [ka] Step a. To a solution of N-(tert-butoxycarbonyl)-O-methyl-D-serine (CAS no. 86123-95-7; 500 mg, 2.28 mmol) in MeOH (5 mL) was added SOCl (597 mg, 5.02 mmol) dropwise at 0 °C. The reaction mixture was stirred at 20 °C for 2 h. After completion, the mixture was evaporated. The residue was triturated with EtOAc (30 mL), filtered, and the filter cake was dried to give methyl O-methyl-D-serinate hydrochloride (310 mg, 80% yield) as a white solid. [ka]

[0334] Steps b-d. These three steps were carried out in the same manner as steps b-d of Intermediate A10. m / z ES+[M+H] + 271.9.

[0335] Intermediate A12: tert-butyl hexahydro-1'H-spiro[azetidine-3,6'-pyrazino[2,1-c][1,4]oxazine]-1-carboxylate [ka] Step a. This step was carried out as described in step a of intermediate A4.

[0336] Step b. To a solution of tert-butyl 3-hydroxy-3-(nitromethyl)azetidine-1-carboxylate (2 g, 8.61 mmol) in DCM (20 mL) was added DAST (2.08 g, 12.9 mmol) dropwise at 0 °C. The reaction mixture was stirred at 0 °C for 30 minutes. After completion, the mixture was quenched with water (20 mL) and the layers were separated. The organic layer was washed with brine (50 mL), dried over Na SO , and evaporated. The crude product was purified by column chromatography (PE / EtOAc = 8 / 1) to give tert-butyl 3-(nitromethylene)azetidine-1-carboxylate (1.55 g, 84% yield) as a yellow solid. [ka]

[0337] Step c. To a solution of tert-butyl 3-(nitromethylene)azetidine-1-carboxylate (1.35 g, 6.30 mmol) in DCM (20 mL) was added methyl morpholine-3-carboxylate (CAS: 126264-49-1; 1.37 g, 9.45 mmol). The reaction mixture was stirred at 20 °C for 12 h. After completion, the mixture was evaporated, and the crude product was purified by column chromatography (PE / EtOAc = 5 / 1) to give methyl 4-(1-(tert-butoxycarbonyl)-3-(nitromethyl)azetidin-3-yl)morpholine-3-carboxylate (1.2 g, 53% yield) as a yellow oil. [ka]

[0338] Steps d-e: These two steps were carried out in a similar manner to steps cd of Intermediate A10. m / z ES+[M+H] + 284.0.

[0339] Intermediates A13a and A13b: tert-butyl (7'R / S,9a'S)-7'-methylhexahydro-1'H-spiro[azetidine-3,6'-pyrazino[2,1-c][1,4]oxazine]-1-carboxylate and tert-butyl (7'S / R,9a'S)-7'-methylhexahydro-1'H-spiro[azetidine-3,6'-pyrazino[2,1-c][1,4]oxazine]-1-carboxylate [ka] The title compound was prepared in a similar manner to intermediate A12 using nitroethane in step a and methyl (R)-morpholine-3-carboxylate (CAS: 1187933-47-6) in step c. Two diastereoisomers of unknown absolute configuration were separated during step d using preparative HPLC. The separated enantiomers were then used separately in step e.

[0340] Intermediate A13a m / z ES+[M+H] + 298.0.

[0341] Intermediate A13b m / z ES+[M+H] + 298.0.

[0342] Intermediates A14a and A14b: tert-butyl (3S,9aS / R)-3-methyloctahydro-2H-pyrazino[1,2-a]pyrazine-2-carboxylate and tert-butyl (3S,9aR / S)-3-methyloctahydro-2H-pyrazino[1,2-a]pyrazine-2-carboxylate [ka] Step a. A mixture of 1,4-bis(tert-butoxycarbonyl)piperazine-2-carboxylic acid (CAS: 181955-79-3; 5 g, 15.1 mmol), methyl L-alaninate hydrochloride (CAS: 2491-20-5; 2.53 g, 18.2 mmol), HATU (5.75 g, 15.1 mmol), and DIPEA (9.78 g, 75.7 mmol) in DCM (50 mL) was stirred at 25° C. for 1 h. After completion, the reaction mixture was evaporated, and the crude product was purified by column chromatography (PE / EtOAc = 1 / 1) to give di-tert-butyl 2-(((S)-1-methoxy-1-oxopropan-2-yl)carbamoyl)piperazine-1,4-dicarboxylate (6.0 g, 95% yield) as a colorless oil. [ka]

[0343] Step b. A mixture of di-tert-butyl 2-(((S)-1-methoxy-1-oxopropan-2-yl)carbamoyl)piperazine-1,4-dicarboxylate (2.0 g, 4.8 mmol) and TFA (15.4 g, 135 mmol) in DCM (10 mL) was stirred at 0° C. for 2 h. After completion, the reaction mixture was evaporated to give methyl (piperazine-2-carbonyl)-L-alaninate as the TFA salt (1.6 g, crude) as a yellow oil. m / z ES+[M+H] + 216.1.

[0344] Step c. A mixture of methyl (piperazine-2-carbonyl)-L-alaninate (1.6 g, 4.86 mmol) and TEA (2.46 g, 24.3 mmol) in THF (20 mL) was stirred at 60° C. for 4 h. After completion, the reaction mixture was evaporated, and the crude product was purified by column chromatography (DCM / MeOH=10 / 1) to give (7S)-7-methylhexahydro-2H-pyrazino[1,2-a]pyrazine-6,9-dione (1.0 g, crude) as a yellow oil. [ka]

[0345] Step d. A mixture of (7S)-7-methylhexahydro-2H-pyrazino[1,2-a]pyrazine-6,9-dione (1.0 g, 5.46 mmol), CbzCl (1.12 g, 6.55 mmol), and NaHCO (2.29 g, 27.3 mmol) in THF (10 mL) and water (10 mL) was stirred at 25 °C for 12 h. After completion, the reaction mixture was evaporated, water (100 mL) was added, and the mixture was extracted with EtOAc (3 × 50 mL). The combined organic layers were washed with brine (50 mL), dried over NaSO, and evaporated. The crude product was purified by column chromatography (PE / EtOAc=1 / 1) to give benzyl (7S)-7-methyl-6,9-dioxooctahydro-2H-pyrazino[1,2-a]pyrazine-2-carboxylate (550 mg, 32% yield) as a colorless oil. [ka]

[0346] Step e. A mixture of benzyl (7S)-7-methyl-6,9-dioxooctahydro-2H-pyrazino[1,2-a]pyrazine-2-carboxylate (500 mg, 1.58 mmol) and borane dimethyl sulfide complex (10 M in THF, 0.47 mL) in THF (5 mL) was stirred at 20 °C for 1 h. After completion, the reaction mixture was quenched with MeOH (10 mL) and stirred at 25 °C for 2 h. The reaction mixture was evaporated to give benzyl (7S)-7-methyloctahydro-2H-pyrazino[1,2-a]pyrazine-2-carboxylate (500 mg, crude) as a colorless oil. m / z ES+[M+H] + 290.5.

[0347] Step f. A mixture of benzyl (7S)-7-methyloctahydro-2H-pyrazino[1,2-a]pyrazine-2-carboxylate (500 mg, 1.73 mmol), di-tert-butyl dicarbonate (377 mg, 1.73 mmol), and DIPEA (669 mg, 5.18 mmol) in THF (10 mL) was stirred for 1 h at 25° C. After completion, the reaction mixture was evaporated and purified by column chromatography (PE / EtOAc=1 / 1) to give two diastereoisomers of unknown absolute configuration.

[0348] 8-Benzyl 2-(tert-butyl)(3S,9aS / R)-3-methylhexahydro-2H-pyrazino[1,2-a]pyrazine-2,8(1H)-dicarboxylate (110 mg, 16% yield) as a yellow oil. [ka]

[0349] 8-Benzyl 2-(tert-butyl)(3S,9aR / S)-3-methylhexahydro-2H-pyrazino[1,2-a]pyrazine-2,8(1H)-dicarboxylate (110 mg, 16% yield) as a yellow oil. [ka]

[0350] Step g. To a solution of 8-benzyl 2-(tert-butyl)(3S,9aR / S)-3-methylhexahydro-2H-pyrazino[1,2-a]pyrazine-2,8(1H)-dicarboxylate (100 mg, 0.26 mmol) in 2-propanol (10 mL), 10% Pd / C (10 mg) was added, and the mixture was stirred at rt under a H atmosphere (15 psi) for 4 h. Upon completion, the reaction mixture was filtered and evaporated to give tert-butyl (3S,9aR / S)-3-methyloctahydro-2H-pyrazino[1,2-a]pyrazine-2-carboxylate (50 mg, 76% yield) as a colorless oil.

[0351] Intermediate A14a: m / z ES+[M+H] + 256.5.

[0352] Intermediate A14b was prepared in a similar manner to intermediate A14a using 8-benzyl 2-(tert-butyl)(3S,9aS / R)-3-methylhexahydro-2H-pyrazino[1,2-a]pyrazine-2,8(1H)-dicarboxylate in step g.

[0353] Intermediate A14b: m / z ES+[M+H] + 256.5.

[0354] Intermediate A15: tert-butyl 3-(((rel-trans)-4-hydroxypyrrolidin-3-yl)oxy)azetidine-1-carboxylate [ka] Step a. To a solution of benzyl 6-oxa-3-azabicyclo[3.1.0]hexane-3-carboxylate (CAS: 31865-25-5; 10.0 g, 45.6 mmol) in DMSO (40 mL) and water (40 mL) was added CsCO (22.3 g, 68.4 mmol) and tert-butyl 3-hydroxyazetidine-1-carboxylate (CAS: 141699-55-0; 9.5 g, 54.7 mmol). The reaction mixture was then stirred at 110 °C for 45 minutes under microwave irradiation. After completion, the reaction mixture was poured into cold water (50 mL) and extracted with EtOAc (3 × 100 mL). The combined organic layers were washed with cold water, brine, dried over NaSO, and evaporated. Purification by column chromatography gave benzyl (rel-trans)-3-((1-(tert-butoxycarbonyl)azetidin-3-yl)oxy)-4-hydroxypyrrolidine-1-carboxylate as an off-white solid (3.7 g, 21% yield). m / z ES+[M-CO2tBu] + 293.6.

[0355] Step b. To a solution of benzyl (rel-trans)-3-((1-(tert-butoxycarbonyl)azetidin-3-yl)oxy)-4-hydroxypyrrolidine-1-carboxylate (3.7 g, 9.4 mmol) in MeOH (100 mL) was added 10% Pd / C (3.6 g) and the mixture was stirred at rt under an atmosphere of H for 2 h. After completion, the reaction mixture was filtered and evaporated to give the title compound as an off-white solid (1.5 g, 62% yield). m / z ES+[M+H] + 259.6.

[0356] Intermediate A16: Benzyl 3-((rel-trans)-hexahydropyrrolo[3,4-b][1,4]oxazin-4(4aH)-yl)azetidine-1-carboxylate [ka] Step a. To a solution of tert-butyl (rel-trans)-hexahydropyrrolo[3,4-b][1,4]oxazine-6(2H)-carboxylate (CAS: 138026-93-4; 950 mg, 4.16 mmol) and benzyl 3-oxoazetidine-1-carboxylate (CAS: 105258-93-3; 1.28 g, 6.24 mmol) in DCE (15 mL) was added 4 Å molecular sieves (1 g). The mixture was stirred at 20 °C for 30 minutes, after which NaBH(OAc) (2.65 g, 12.8 mmol) was added. The mixture was stirred at 20 °C for an additional 12 hours. Upon completion, the mixture was filtered and evaporated. The residue was purified by column chromatography (PE / EtOAc=1 / 1) to give tert-butyl (rel-trans)-4-(1-((benzyloxy)carbonyl)azetidin-3-yl)hexahydropyrrolo[3,4-b][1,4]oxazine-6(2H)-carboxylate (1.8 g, crude) as a colorless oil. [ka]

[0357] Step b. To a solution of tert-butyl (rel-trans)-4-(1-((benzyloxy)carbonyl)azetidin-3-yl)hexahydropyrrolo[3,4-b][1,4]oxazine-6(2H)-carboxylate (1.0 g, 2.40 mmol) in DCM (10 mL) was added TFA (2 mL). The mixture was stirred at 20 °C for 30 min. After completion, the mixture was diluted with DCM (5 mL) and basified to pH 8 with saturated aqueous NaHCO. The layers were separated, and the aqueous phase was further extracted with DCM (4 × 15 mL). The combined organic layers were washed with brine (20 mL), dried over NaSO, and evaporated to give the title compound (760 mg, crude) as a colorless oil. m / z ES+[M+H] + 318.2.

[0358] Intermediate A17a: 2-benzyl 8-(tert-butyl)(rel-3R,9aR)-3-methyl-4-oxohexahydro-2H-pyrazino[1,2-a]pyrazine-2,8(1H)-dicarboxylate and Intermediate A17b: 2-benzyl 8-(tert-butyl)(rel-3R,9aS)-3-methyl-4-oxohexahydro-2H-pyrazino[1,2-a]pyrazine-2,8(1H)-dicarboxylate [ka] Step a. To a solution of tert-butyl 3-cyanopiperazine-1-carboxylate (CAS: 859518-35-7; 1.3 g, 6.15 mmol) in THF (10 mL) and water (10 mL) was added Na2CO3 (1.3 g, 12.3 mmol) and CbzCl (1.15 g, 6.77 mmol). The mixture was stirred at 25 °C for 12 h. After completion, the reaction mixture was diluted with HO (20 mL) and extracted with EtOAc (3 × 30 mL). The combined organic layers were washed with brine (50 mL), dried over Na2SO4, evaporated, and purified by preparative TLC (PE / EtOAc = 6 / 1) to give 1-benzyl 4-(tert-butyl) 2-cyanopiperazine-1,4-dicarboxylate (100 mg, 43% yield) as an off-white solid. m / z ES+[M+Na] + 368.1.

[0359] Step b. A mixture of 1-benzyl 4-(tert-butyl) 2-cyanopiperazine-1,4-dicarboxylate (2.1 g, 6.08 mmol), Raney-Ni (1 g, 11.7 mmol), and 30% NHOH (71 mg, 0.61 mmol) in MeOH (25 mL) was degassed and purged with H three times. The reaction mixture was stirred under a H atmosphere (50 psi) at 25 °C for 5 h. Upon completion, the reaction mixture was filtered and evaporated to give 1-benzyl 4-(tert-butyl) 2-(aminomethyl)piperazine-1,4-dicarboxylate (2.1 g, crude) as a colorless oil. [ka]

[0360] Step c. To a solution of 1-benzyl 4-(tert-butyl) 2-(aminomethyl)piperazine-1,4-dicarboxylate (2.1 g, 6.01 mmol) in THF (25 mL) was added TEA (1.22 g, 12.0 mmol) and methyl 2-bromopropionate (CAS: 5445-17-0; 1.30 g, 7.81 mmol). The reaction mixture was stirred at 80 °C for 12 h. After completion, the mixture was diluted with water (40 mL) and extracted with EtOAc (3 × 40 mL). The combined organic layers were washed with brine (100 mL), dried over NaSO, evaporated, and purified by column chromatography (PE / EtOAc=1 / 1) to give 1-benzyl 4-(tert-butyl) 2-(((1-methoxy-1-oxopropan-2-yl)amino)methyl)piperazine-1,4-dicarboxylate (1.5 g, 57% yield) as a colorless oil. [ka]

[0361] Step d. A mixture of 1-benzyl 4-(tert-butyl) 2-(((1-methoxy-1-oxopropan-2-yl)amino)methyl)piperazine-1,4-dicarboxylate (2.9 g, 6.66 mmol), 10% Pd / C (300 mg) in MeOH (40 mL) was degassed and purged with H three times. The reaction mixture was stirred under a H atmosphere (15 psi) at 45 °C for 12 h. Upon completion, the reaction mixture was filtered and evaporated to give tert-butyl 7-methyl-6-oxooctahydro-2H-pyrazino[1,2-a]pyrazine-2-carboxylate (1.75 g, crude) as a colorless oil. [ka]

[0362] Step e. To a solution of tert-butyl 7-methyl-6-oxooctahydro-2H-pyrazino[1,2-a]pyrazine-2-carboxylate (1.2 g, 4.46 mmol) in THF (12 mL) and water (12 mL) was added Na2CO3 (944 mg, 8.91 mmol) and CbzCl (1.14 g, 6.68 mmol). The reaction mixture was stirred at 25 °C for 12 h. After completion, the reaction mixture was diluted with water (20 mL) and extracted with EtOAc (3 × 30 mL). The combined organic layers were washed with brine (60 mL), dried over Na2SO4, evaporated, and purified by column chromatography (PE / EtOAc = 3 / 2) to give two products of unknown absolute configuration.

[0363] Intermediate A17a: 2-benzyl 8-(tert-butyl)(rel-3R / S,9aR / S)-3-methyl-4-oxohexahydro-2H-pyrazino[1,2-a]pyrazine-2,8(1H)-dicarboxylate (550 mg, 29% yield) as a white solid. [ka]

[0364] Intermediate A17b: 2-benzyl 8-(tert-butyl)(rel-3R / S,9aS / R)-3-methyl-4-oxohexahydro-2H-pyrazino[1,2-a]pyrazine-2,8(1H)-dicarboxylate (430 mg, 23% yield) as a yellow oil. [ka]

[0365] Intermediate A18a: 2-benzyl 8-(tert-butyl)(3R / S,9aR / S)-3-methyl-4-oxohexahydro-2H-pyrazino[1,2-a]pyrazine-2,8(1H)-dicarboxylate and Intermediate A18b: 2-benzyl 8-(tert-butyl)(3S / R,9aS / R)-3-methyl-4-oxohexahydro-2H-pyrazino[1,2-a]pyrazine-2,8(1H)-dicarboxylate [ka] The title compound was prepared by chiral SFC separation of an intermediate.

[0366] Intermediate A18a: [ka]

[0367] Intermediate A18b: [ka]

[0368] Intermediate A18c: 2-benzyl 8-(tert-butyl)(3R / S,9aS / R)-3-methyl-4-oxohexahydro-2H-pyrazino[1,2-a]pyrazine-2,8(1H)-dicarboxylate and Intermediate A18d: 2-benzyl 8-(tert-butyl)(3S / R,9aR / S)-3-methyl-4-oxohexahydro-2H-pyrazino[1,2-a]pyrazine-2,8(1H)-dicarboxylate [ka] The title compound was prepared by chiral SFC separation of intermediate A17b.

[0369] Intermediate A18c: m / z ES+[M+H] + 404.0.

[0370] Intermediate A18d: m / z ES+[M+H] + 404.0.

[0371] Intermediate A19a: Benzyl (3R / S,9aR / S)-3-methyl-4-oxooctahydro-2H-pyrazino[1,2-a]pyrazine-2-carboxylate [ka] Step a. To a solution of intermediate A18a (110 mg, 0.27 mmol) in DCM (1.5 mL) was added TFA (508 mg, 4.46 mmol). The mixture was stirred at 25 °C for 1 hour. After completion, the reaction mixture was basified to pH 8 with saturated aqueous NaHCO and extracted with EtOAc (3 × 15 mL). The combined organic layers were washed with brine (30 mL), dried over NaSO, and evaporated to give the title compound (68 mg, crude) as a yellow solid. m / z ES+[M+H] + 304.0

[0372] Intermediate A19b: Benzyl (3S / R,9aS / R)-3-methyl-4-oxooctahydro-2H-pyrazino[1,2-a]pyrazine-2-carboxylate [ka] The title compound was prepared in a similar manner to Intermediate A19a using Intermediate A18b. m / z ES+[M+H] + 304.1.

[0373] Intermediate A19c: Benzyl (3R / S,9aS / R)-3-methyl-4-oxooctahydro-2H-pyrazino[1,2-a]pyrazine-2-carboxylate [ka] The title compound was prepared in a similar manner to Intermediate A19a using Intermediate A18c. m / z ES+[M+H] + 304.1.

[0374] Intermediate A19d: Benzyl (3S / R,9aR / S)-3-methyl-4-oxooctahydro-2H-pyrazino[1,2-a]pyrazine-2-carboxylate [ka] The title compound was prepared in a similar manner to Intermediate A19a using Intermediate A18d. m / z ES+[M+H] + 304.2.

[0375] Intermediate A20a: tert-butyl (7R / S,9aS / R)-7-methyl-6-oxooctahydro-2H-pyrazino[1,2-a]pyrazine-2-carboxylate [ka] Step a. A mixture of intermediate A18a (110 mg, 0.27 mmol) and 10% Pd / C (10 mg) in MeOH (2 mL) was degassed and purged with H three times. The mixture was stirred under an H atmosphere (15 psi) at 30° C. for 1 h. The mixture was filtered and evaporated to give the title compound (65 mg, crude) as a yellow solid. m / z ES+[M+H] + 270.0.

[0376] Intermediate A20b: tert-butyl (7S / R,9aR / S)-7-methyl-6-oxooctahydro-2H-pyrazino[1,2-a]pyrazine-2-carboxylate [ka] The title compound was prepared in a similar manner to Intermediate A20a using Intermediate A18b. m / z ES+[M+H] + 270.1.

[0377] Intermediate A20c: tert-butyl (7R / S,9aR / S)-7-methyl-6-oxooctahydro-2H-pyrazino[1,2-a]pyrazine-2-carboxylate [ka] The title compound was prepared in a similar manner to Intermediate A20a using Intermediate A18c. m / z ES+[M+H] + 270.1.

[0378] Intermediate A20d: tert-butyl (7S / R,9aS / R)-7-methyl-6-oxooctahydro-2H-pyrazino[1,2-a]pyrazine-2-carboxylate [ka] The title compound was prepared in a similar manner to Intermediate A20a using Intermediate A18d. m / z ES+[M+H] + 270.1.

[0379] Intermediate A21: tert-Butyl 6-oxooctahydro-2H-pyrazino[1,2-a]pyrazine-2-carboxylate [ka] Steps ad: These four steps were carried out in a similar manner to steps ad of Intermediate A17a and Intermediate A17b, using methyl 2-bromoacetate in step c. [ka]

[0380] Intermediate A22: Benzyl 4-oxooctahydro-2H-pyrazino[1,2-a]pyrazine-2-carboxylate [ka] Step a: This step was carried out in a similar manner to step e of Intermediate A17a and Intermediate A17b using Intermediate A21.

[0381] Step b. This step was carried out in a similar manner to intermediate 19a. [ka]

[0382] Intermediate A23a: Methyl (rel-2R,6R)-4-benzyl-6-methylpiperazine-2-carboxylate and Intermediate A23b: Methyl (rel-2S,6R)-4-benzyl-6-methylpiperazine-2-carboxylate [ka] Step a. To a mixture of 6-methylpyrazine-2-carboxylic acid (10.0 g, 72.4 mmol) and CsCO (47.1 g, 144 mmol) in DMF (100 mL) was added MeI (15.4 g, 108 mmol). The reaction mixture was stirred at 25 °C for 1 h. After completion, the reaction mixture was quenched with water (100 mL) and extracted with EtOAc (3 × 150 mL). The combined organic layers were washed with brine (100 mL), dried over NaSO, and evaporated to give methyl 6-methylpyrazine-2-carboxylate (6.5 g, 59% yield) as a yellow solid. [ka]

[0383] Step b. A mixture of methyl 6-methylpyrazine-2-carboxylate (6.50 g, 42.7 mmol), PtO (650 mg, 2.86 mmol), and acetic acid (5.13 g, 85.4 mmol) in MeOH (120 mL) was stirred under a H atmosphere (50 psi) at 50 °C for 48 h. Upon completion, the reaction mixture was filtered and evaporated to give methyl 6-methylpiperazine-2-carboxylate (6.0 g, 88% yield) as a yellow oil. m / z ES+[M+H] + 158.9.

[0384] Step c. A mixture of methyl 6-methylpiperazine-2-carboxylate (5.0 g, 15.8 mmol) and benzaldehyde (1.68 g, 15.8 mmol) in MeOH (100 mL) was stirred at 0 °C for 30 min. Then, NaBH CN (1.19 g, 18.9 mmol) was added and stirred at 0 °C for an additional 1 h. After completion, the reaction mixture was evaporated, dissolved in water (50 mL), and extracted with EtOAc (2 × 50 mL). The combined organic layers were washed with brine (50 mL), dried over Na SO , and evaporated. The residue was purified by reverse-phase flash chromatography (water (0.1% NH OH) / MeCN) to give two products.

[0385] Intermediate A23a: Methyl (rel-2R,6R)-4-benzyl-6-methylpiperazine-2-carboxylate (2.10 g, 53% yield) as a yellow oil. [ka]

[0386] Intermediate A23b: Methyl (rel-2S,6R)-4-benzyl-6-methylpiperazine-2-carboxylate (1.20 g, 31% yield) as a yellow oil. [ka]

[0387] Intermediate A24a: (rel-4R,9aS)-2-benzyl-4-methyloctahydro-2H-pyrazino[1,2-a]pyrazine [ka] Step a. A mixture of (tert-butoxycarbonyl)glycine (1.69 g, 9.66 mmol), HATU (3.67 g, 9.66 mmol), and DIPEA (3.12 g, 24.1 mmol) in DMF (15 mL) was stirred at 25° C. for 30 min. Then, intermediate A23a (2.00 g, 8.05 mmol) in DMF (15 mL) was added, and the reaction mixture was stirred for an additional 2 h at 25° C. After completion, the reaction mixture was diluted with water (50 mL) and extracted with EtOAc (2×50 mL). The combined organic layers were washed with brine (20 mL), dried over NaSO, evaporated, and purified by column chromatography (PE / EtOAc = 3 / 1) to give methyl (rel-2R,6R)-4-benzyl-1-((tert-butoxycarbonyl)glycyl)-6-methylpiperazine-2-carboxylate (2.3 g, 70% yield) as a yellow oil. [ka]

[0388] Step b. To a solution of methyl (rel-2R,6R)-4-benzyl-1-((tert-butoxycarbonyl)glycyl)-6-methylpiperazine-2-carboxylate (2.0 g, 4.93 mmol) in MeOH (20 mL) was added 4 M HCl in MeOH (10 mL), and the reaction mixture was stirred at 25° C. for 16 h. Upon completion, the mixture was evaporated to afford methyl (rel-2R,6R)-4-benzyl-1-glycyl-6-methylpiperazine-2-carboxylate hydrochloride (1.50 g, 88% yield) as a white solid. m / z ES+[M+H] + 306.0.

[0389] Step c. A mixture of methyl (rel-2R,6R)-4-benzyl-1-glycyl-6-methylpiperazine-2-carboxylate hydrochloride (1.50 g, 4.91 mmol) and TEA (2.49 g, 24.5 mmol) in MeOH (30 mL) was stirred at 70° C. for 2 h. After completion, the reaction mixture was evaporated and triturated with THF (5 mL) to afford (rel-4R,9aR)-2-benzyl-4-methylhexahydro-2H-pyrazino[1,2-a]pyrazine-6,9-dione (1.20 g, 89% yield) as a yellow solid. [ka]

[0390] Step d. To a solution of (rel-4R,9aR)-2-benzyl-4-methylhexahydro-2H-pyrazino[1,2-a]pyrazine-6,9-dione (400 mg, 1.46 mmol) in THF (1 mL) was added LiAlH (555 mg, 14.6 mmol), and the reaction mixture was stirred at 0 °C for 1 h. After completion, the reaction mixture was slowly quenched with water (1 mL), 15% aqueous NaOH solution (3 mL), and additional water (1 mL) at 0 °C, followed by the addition of NaSO. The mixture was filtered, and the filtrate was evaporated to give the title compound (330 mg, 91% yield) as a yellow oil. [ka]

[0391] Intermediate A24b: (rel-4R,9aR)-2-benzyl-4-methyloctahydro-2H-pyrazino[1,2-a]pyrazine [ka] The title compound was prepared in a similar manner to intermediate A24a, using intermediate A23b in step a. [ka]

[0392] Intermediate A25: 1-(1-benzhydryl-3-methylazetidin-3-yl)piperazine [ka] Step a. To a mixture of 1-benzhydryl-3-methyl-azetidin-3-ol (CAS: 40320-63-6; 500 mg, 1.97 mmol) and TEA (399 mg, 3.95 mmol) in DCM (10 mL) was added MsCl (339 mg, 2.96 mmol) at 0 °C. The reaction mixture was stirred at 20 °C under a N atmosphere for 1 h. After completion, the mixture was diluted with water (50 mL) and extracted with EtOAc (3 × 20 mL). The combined organic layers were washed with brine (3 × 50 mL), dried over NaSO, and evaporated to give 1-benzhydryl-3-methylazetidin-3-yl methanesulfonate (650 mg, 99% yield) as a yellow solid. [ka]

[0393] Step b. A mixture of 1-benzhydryl-3-methylazetidin-3-yl methanesulfonate (1.0 g, 3.02 mmol) and piperazine (2.60 g, 30.1 mmol) in 2-propanol (10 mL) was stirred for 16 hours at 70° C. After completion, the reaction mixture was evaporated and purified by reverse-phase flash chromatography (water (0.1% NHOH) / MeCN) to afford the title compound (950 mg, 97% yield) as a yellow solid. [ka]

[0394] Intermediate A26: tert-Butyl 6-oxo-2,5,8-triazaspiro[3.5]nonane-2-carboxylate [ka] Step a. To a solution of tert-butyl 3-oxoazetidine-1-carboxylate (5.0 g, 29.2 mmol) in THF (50 mL) was added Ti(OEt) (20 g, 87.6 mmol) and 2-methylpropane-2-sulfinamide (4.25 g, 35.1 mmol). The reaction mixture was stirred at 25 °C for 12 h. After completion, the mixture was diluted with EtOAc (300 mL), quenched with water (150 mL), and filtered. The filtrate was extracted with EtOAc (3 × 150 mL), and the combined organic layers were washed with brine (150 mL), dried over NaSO, evaporated, and purified by column chromatography (PE / EtOAc = 5 / 1) to give tert-butyl 3-((tert-butylsulfinyl)imino)azetidine-1-carboxylate (7.5 g, 93.6% yield) as a yellow solid. [ka]

[0395] Step b. To a solution of tert-butyl 3-((tert-butylsulfinyl)imino)azetidine-1-carboxylate (7.1 g, 25.9 mmol) in DCM (100 mL) was added Ti(OEt) (11.8 g, 51.8 mmol) and trimethylsilanecarbonitrile (6.42 g, 64.7 mmol). The reaction mixture was stirred at 25 °C for 12 h. After completion, the mixture was quenched with water (200 mL) and extracted with DCM (300 mL and 3 × 200 mL). The combined organic layers were washed with brine (3 × 100 mL), dried over NaSO, evaporated, and purified by column chromatography (PE / EtOAc = 1 / 1) to give tert-butyl 3-((tert-butylsulfinyl)amino)-3-cyanoazetidine-1-carboxylate (6.6 g, 84% yield) as a yellow solid. [ka]

[0396] Step c. To a solution of tert-butyl 3-((tert-butylsulfinyl)amino)-3-cyanoazetidine-1-carboxylate (2.0 g, 6.64 mmol) in THF (25 mL) and water (5 mL) was added iodine (337 mg, 1.33 mmol), and the mixture was stirred at 50° C. for 12 hours. After completion, the reaction mixture was quenched with saturated aqueous NaHCO (20 mL), diluted with water (30 mL), and extracted with EtOAc (3×50 mL). The combined organic layers were washed with brine (20 mL), dried over NaSO, evaporated, and purified by column chromatography (PE / EtOAc=1 / 1) to give tert-butyl 3-amino-3-cyanoazetidine-1-carboxylate (950 mg, 73% yield) as a yellow solid. [ka]

[0397] Step d. A mixture of tert-butyl 3-amino-3-cyanoazetidine-1-carboxylate (300 mg, 1.52 mmol), CbzCl (389 mg, 2.28 mmol), and NaCO (484 mg, 4.56 mmol) in THF (6 mL) and water (2 mL) was stirred at 25 °C for 2 h. After completion, the reaction was quenched with saturated aqueous NHCl (20 mL), diluted with water (20 mL), and extracted with EtOAc (3 × 30 mL). The combined organic layers were washed with brine (20 mL), dried over NaSO, evaporated, and purified by column chromatography (PE / EtOAc = 5 / 1) to give tert-butyl 3-(((benzyloxy)carbonyl)amino)-3-cyanoazetidine-1-carboxylate (450 mg, 89% yield) as a yellow solid. [ka]

[0398] Step e. To a solution of tert-butyl 3-(((benzyloxy)carbonyl)amino)-3-cyanoazetidine-1-carboxylate (300 mg, 0.91 mmol) in MeOH (30 mL) was added Raney-Ni (78 mg, 0.91 mmol). The suspension was degassed and purged with H three times, and the reaction mixture was stirred under an H atmosphere (15 psi) at 25 °C for 12 h. Upon completion, the reaction mixture was filtered and evaporated to give tert-butyl 3-(aminomethyl)-3-(((benzyloxy)carbonyl)amino)azetidine-1-carboxylate (300 mg, crude) as a yellow solid, which was used directly in the next step. m / z ES+[M+H] + 336.2.

[0399] Step f. To a solution of tert-butyl 3-(aminomethyl)-3-(((benzyloxy)carbonyl)amino)azetidine-1-carboxylate (300 mg, 0.90 mmol) in THF (5 mL) was added TEA (272 mg, 2.68 mmol) and methyl 2-bromoacetate (274 mg, 1.79 mmol). The reaction mixture was stirred at 25 °C for 12 h. After completion, the mixture was quenched with saturated aqueous NH4Cl (20 mL), diluted with water (20 mL), and extracted with EtOAc (3 x 30 mL). The combined organic layers were washed with brine (20 mL), dried over NaSO, evaporated and purified by column chromatography (PE / EtOAc=1 / 2) to give tert-butyl 3-(((benzyloxy)carbonyl)amino)-3-(((2-methoxy-2-oxoethyl)amino)methyl)azetidine-1-carboxylate (300 mg, 82% yield) as a yellow solid. [ka]

[0400] Step g. To a solution of tert-butyl 3-(((benzyloxy)carbonyl)amino)-3-(((2-methoxy-2-oxoethyl)amino)methyl)azetidine-1-carboxylate (1.3 g, 3.19 mmol) in MeOH (50 mL) was added 10% Pd / C (300 mg), and the mixture was stirred under H atmosphere (15 psi) at 40° C. for 12 h. After completion, the reaction mixture was filtered and evaporated to give the title compound (670 mg, crude) as a white solid. [ka]

[0401] Intermediate A27: tert-butyl 5-methyl-6-oxo-2,5,8-triazaspiro[3.5]nonane-2-carboxylate [ka] Step a. This step was carried out in a similar manner to step d of intermediate A26 using intermediate A26.

[0402] Step b. To a solution of 8-benzyl 2-(tert-butyl) 6-oxo-2,5,8-triazaspiro[3.5]nonane-2,8-dicarboxylate (0.25 g, 0.67 mmol) in DMF (5 mL) was added CsCO (651 mg, 2.0 mmol) and MeI (284 mg, 2.00 mmol). The reaction mixture was stirred at 25 °C for 12 h. Upon completion, the reaction mixture was quenched with saturated aqueous NHCl (20 mL), diluted with water (30 mL), and extracted with EtOAc (3 × 30 mL). The combined organic layers were washed with brine (20 mL), dried over NaSO, evaporated, and purified by column chromatography (PE / EtOAc=1 / 2) to give 8-benzyl 2-(tert-butyl) 5-methyl-6-oxo-2,5,8-triazaspiro[3.5]nonane-2,8-dicarboxylate (220 mg, 84% yield) as a colorless oil. [ka]

[0403] Step c. This step was carried out in a similar manner to step g of Intermediate A26. m / z ES+[M+H] + 256.1.

[0404] Intermediate A28: tert-Butyl 7',8'-dihydro-6'H-spiro[azetidine-3,5'-imidazo[1,2-a]pyrazine]-1-carboxylate [ka] Steps ab: These two steps were carried out as described in steps ab of Intermediate A12. [ka]

[0405] Step c. To a solution of methyl 1H-imidazole-2-carboxylate (2.59 g, 20.5 mmol) in toluene (40 mL) was added NaH (971 mg, 24.3 mmol, 60% dispersion in mineral oil). The mixture was stirred at 0 °C for 30 minutes, after which tert-butyl 3-(nitromethylene)azetidine-1-carboxylate (4 g, 18.7 mmol) in toluene (40 mL) was slowly added. The mixture was stirred at 0 °C for an additional 30 minutes. Upon completion, the reaction mixture was quenched with saturated aqueous NH4Cl (100 mL) at 25 °C, diluted with water (100 mL), and extracted with EtOAc (3 × 150 mL). The combined organic layers were washed with brine (50 mL), dried over NaSO, evaporated, and purified by column chromatography (PE / EtOAc=1 / 2) to give methyl 1-(1-(tert-butoxycarbonyl)-3-(nitromethyl)azetidin-3-yl)-1H-imidazole-2-carboxylate (0.72 g, 2.12 mmol, 11% yield) as a yellow solid. [ka]

[0406] Step d. This step was carried out in a similar manner to step c of Intermediate A10.

[0407] Step e. To a solution of tert-butyl 8'-oxo-7',8'-dihydro-6'H-spiro[azetidine-3,5'-imidazo[1,2-a]pyrazine]-1-carboxylate (200 mg, 0.72 mmol) in THF (3 mL) was added a solution of borane dimethyl sulfide complex (10 M in THF, 0.36 mL). The reaction mixture was stirred at 25 °C for 12 h. Upon completion, the reaction mixture was quenched with MeOH (2 mL) at 0 °C, evaporated, and purified by reverse-phase flash chromatography (water (0.1% FA) / MeCN) to afford the title compound (90 mg, 47% yield) as a yellow solid. m / z ES+[M+H] + 265.1.

[0408] Intermediate A29: tert-Butyl 1',2'-dihydrospiro[azetidine-3,3'-imidazo[1,2-a]imidazole]-1-carboxylate [ka] Steps ab: These two steps were carried out as described in steps ab of Intermediate A12.

[0409] Step c. This step was carried out in a similar manner to step c of Intermediate A28 using 2-bromo-1H-imidazole (CAS: 16681-56-4).

[0410] Step d. To a solution of tert-butyl 3-(2-bromo-1H-imidazol-1-yl)-3-(nitromethyl)azetidine-1-carboxylate (700 mg, 1.94 mmol) in MeOH (20 mL) was added cobalt(II) chloride (1.51 g, 11.6 mmol) and NaBH (440 mg, 11.6 mmol). The reaction mixture was stirred at 0 °C for 1 h. After completion, the mixture was quenched with saturated aqueous NH Cl (1 mL), filtered, and the filtrate was evaporated. The residue was purified by reverse-phase flash chromatography (water (0.1% FA) / MeCN) to give the title compound (300 mg, 61.9% yield) as a white solid. m / z ES+[M+H] + 250.9.

[0411] Intermediate A30: tert-butyl 3-(2-oxopiperazin-1-yl)azetidine-1-carboxylate [ka] Step a. To a suspension of NaH (128 mg, 3.20 mmol, 60% dispersion in mineral oil) in DMF (5 mL) was added benzyl 3-oxopiperazine-1-carboxylate (CAS: 78818-15-2; 0.5 g, 2.13 mmol) at 0 °C. The mixture was stirred at 0 °C for 30 minutes under a N atmosphere, after which tert-butyl 3-iodoazetidine-1-carboxylate (CAS: 254454-54-1; 724 mg, 2.56 mmol) was added. The reaction mixture was stirred at 20 °C for an additional hour. Upon completion, the reaction mixture was partitioned between water (40 mL) and EtOAc (40 mL). The aqueous layer was further extracted with EtOAc (2 × 40 mL), and the combined organic layers were dried over NaSO and evaporated. The residue was purified by reverse-phase flash chromatography (water (0.1% FA) / MeCN) to afford benzyl 4-(1-(tert-butoxycarbonyl)azetidin-3-yl)-3-oxopiperazine-1-carboxylate (60 mg, 7% yield) as a yellow oil. m / z ES+[M+H] + 390.1

[0412] Step b. To a solution of benzyl 4-(1-(tert-butoxycarbonyl)azetidin-3-yl)-3-oxopiperazine-1-carboxylate (60 mg, 0.15 mmol) in 2-propanol (2 mL) was added 10% Pd / C (5 mg). The reaction mixture was stirred at 40° C. under an atmosphere of H (15 psi) for 12 hours. Upon completion, the reaction mixture was filtered, and the filtrate was evaporated to give the title compound (44 mg, crude) as a yellow oil, which was used without further purification.

[0413] Intermediate A31: tert-butyl (rel-3R,4R)-4-hydroxy-3-(methylamino)piperidine-1-carboxylate [ka] Step a. A solution of tert-butyl 7-oxa-3-azabicyclo[4.1.0]heptane-3-carboxylate (CAS: 161157-50-2; 1.0 g, 5.02 mmol) in methanamine (2 M in THF, 50.2 mL) was stirred at 100 °C for 12 hours. After completion, the reaction mixture was filtered and evaporated to give a yellow oil (1.15 g, crude). The oil was dissolved in THF (12 mL) and water (6 mL), and CbzCl (1.22 g, 7.16 mmol) and Na2CO3 (1.52 g, 14.3 mmol) were added. The reaction mixture was stirred at 25 °C for 1 hour. After completion, the mixture was diluted with water (30 mL) and extracted with EtOAc (3 × 50 mL). The combined organic layers were washed with brine (3 × 20 mL), dried over Na2SO4, and evaporated. The residue was purified by column chromatography (PE / EtOAc = 1 / 1) to give tert-butyl (rel-3R,4R)-3-(((benzyloxy)carbonyl)(methyl)amino)-4-hydroxypiperidine-1-carboxylate (200 mg, 11% yield) as a colorless oil. The regiochemistry was confirmed by 2D NMR. [ka]

[0414] Step b. To a solution of tert-butyl (rel-3R,4R)-3-(((benzyloxy)carbonyl)(methyl)amino)-4-hydroxypiperidine-1-carboxylate (200 mg, 0.55 mmol) in THF (5 mL) was added 10% Pd / C (30 mg). The mixture was stirred at 25 °C under a H atmosphere (15 psi) for 30 min. After completion, the reaction mixture was filtered and the filtrate was evaporated to give the title compound (110 mg, crude) as a colorless oil, which was used without further purification.

[0415] Intermediate A32: tert-Butyl 2,5,8-triazaspiro[3.5]nonane-2-carboxylate [ka] Step a. Ethyl 2,3-dibromopropanoate (CAS: 3674-13-3; 21.6 g, 83.2 mmol) was dissolved in N 1 ,N 2 To a solution of 1,4-dibenzylethane-1,2-diamine (CAS: 140-28-3; 20 g, 83.2 mmol) and triethylamine (26 mL, 164 mmol) in toluene (300 mL) was added dropwise at 40 °C. The reaction mixture was stirred at 80 °C for 4 h. After completion, the reaction mixture was cooled to rt and the solvent was evaporated under vacuum. The reaction mixture was diluted with EtOAc (300 mL) and washed with water (2 × 100 mL). The organic layer was further washed with brine, dried over Na SO and evaporated. Purification by column chromatography (n-hexane / EtOAc = 4 / 1) afforded ethyl 1,4-dibenzylpiperazine-2-carboxylate (20 g, 73% yield) as a pale yellow oil. m / z ES+[M+H] + 339.7.

[0416] Step b. To a solution of ethyl 1,4-dibenzylpiperazine-2-carboxylate (10 g, 29.6 mmol) in THF (200 mL) cooled to −78° C., paraformaldehyde (0.89 g) was added, followed by a solution of LiHMDS (1 M in THF, 88.8 mL, 88.8 mmol) under a N atmosphere. The reaction mixture was stirred at −78° C. for 15 min and then at rt for 2 h. Upon completion, the reaction mixture was quenched with water (200 mL), and the aqueous mixture was extracted with EtOAc (2 × 500 mL). The organic layers were combined, dried over NaSO, and evaporated. Purification by column chromatography (n-hexane / EtOAc = 3 / 2) afforded 5,8-dibenzyl-2,5,8-triazaspiro[3.5]nonan-1-one (5.6 g, 60% yield) as a white solid. m / z ES+[M+H] + 322.2.

[0417] Step c. To a solution of 5,8-dibenzyl-2,5,8-triazaspiro[3.5]nonan-1-one (5.6 g, 17.4 mmol) in THF (60 mL) cooled to 0 °C was added a solution of LiAlH (2.5 M in THF, 20.9 mL, 52.3 mmol). The reaction mixture was stirred at 60 °C for 15 h. Upon completion, the reaction mixture was cooled to 0 °C and quenched by the slow addition of saturated aqueous NH Cl. The reaction mixture was extracted with EtOAc (2 × 100 mL). The organic layers were combined, dried over Na SO , and evaporated to give 5,8-dibenzyl-2,5,8-triazaspiro[3.5]nonane (5.2 g, 97% crude) as a yellow solid. m / z ES+[M+H] + 308.2.

[0418] Step d. To a solution of 5,8-dibenzyl-2,5,8-triazaspiro[3.5]nonane (5.2 g, 16.9 mmol) in methanol (52 mL) was added triethylamine (4.7 mL, 33.8 mmol), DMAP (0.12 g, 1.0 mmol), and di-tert-butyl decarbonate (4.6 g, 21.1 mmol). The reaction mixture was stirred at rt for 3 h. Upon completion, the reaction mixture was quenched with water (50 mL) and extracted with EtOAc (2 × 100 mL). The organic layers were combined, dried over NaSO, and evaporated. Purification by column chromatography (n-hexane / EtOAc = 4 / 1) afforded tert-butyl 5,8-dibenzyl-2,5,8-triazaspiro[3.5]nonane-2-carboxylate (5.1 g, 74% yield) as a yellow solid. m / z ES+[M+H] + 408.3.

[0419] Step e. To a solution of tert-butyl 5,8-dibenzyl-2,5,8-triazaspiro[3.5]nonane-2-carboxylate (5.0 g, 12.3 mmol) in 1,2-dimethoxyethane (50 mL) cooled to 0 °C, 1-chloroethyl chloroformate (0.69 g, 18.4 mmol) was added. The reaction mixture was stirred at 80 °C for 2 h. Upon completion, the reaction mixture was poured into cold water (50 mL) and extracted with DCM (2 × 100 mL). The organic layers were combined, washed with cold water and brine, dried over Na SO , and evaporated. The crude material was triturated with diethyl ether to give tert-butyl 5-benzyl-2,5,8-triazaspiro[3.5]nonane-2-carboxylate (1.5 g, 39% yield) as a white solid. m / z ES+[M+H] + 318.7.

[0420] Step f. To a solution of tert-butyl 5-benzyl-2,5,8-triazaspiro[3.5]nonane-2-carboxylate (2.5 g, 7.88 mmol) in MeOH (25 mL) was added 10% Pd / C (250 mg) under a N atmosphere. The suspension was degassed and purged with H three times. The mixture was stirred at 25 °C under a H atmosphere (15 psi) for 4 h. Upon completion, the reaction mixture was filtered, and the filtrate was evaporated to give the title compound (1.2 g, crude) as a yellow solid. [ka]

[0421] Intermediate A33: tert-butyl 8-cyano-2,6-diazaspiro[3.4]octane-2-carboxylate [ka] Step a. N-benzyl-1-methoxy-N-((trimethylsilyl)methyl)methanamine (CAS: 93102-05-7; 4.40 g, 18.5 mmol) and LiF (1.20 g, 46.3 mmol) were added to a solution of tert-butyl 3-(cyanomethylene)azetidine-1-carboxylate (CAS: 1153949-11-1; 3 g, 15.4 mmol) in MeCN (30 mL). The mixture was stirred at 60 °C for 72 h. After completion, the mixture was filtered, and the filtrate was evaporated. The residue was purified by column chromatography (PE / EtOAc = 3 / 1) to give tert-butyl 6-benzyl-8-cyano-2,6-diazaspiro[3.4]octane-2-carboxylate (3.7 g, 73% yield) as a colorless oil. m / z ES+[M+H] + 328.1.

[0422] Step b. A mixture of tert-butyl 6-benzyl-8-cyano-2,6-diazaspiro[3.4]octane-2-carboxylate (3.2 g, 9.77 mmol), 10% Pd / C (1.0 g), and ammonium formate (3.08 g, 48.8 mmol) in EtOH (30 mL) was stirred at 80° C. for 12 h. After completion, the mixture was filtered and evaporated to give the title compound (2 g, crude) as a pale yellow oil. m / z ES+[M+H] + 238.2.

[0423] Intermediate A34: tert-butyl 8-cyano-8-methyl-2,6-diazaspiro[3.4]octane-2-carboxylate [ka] Step a. To a solution of diethyl (1-cyanoethyl)phosphonate (1.0 g, 5.23 mmol) in THF (50 mL) was added NaH (313 mg, 7.85 mmol, 60% dispersion in mineral oil) at 0 °C. The mixture was stirred for 30 minutes, after which tert-butyl 3-oxoazetidine-1-carboxylate (1.79 g, 10.46 mmol) was added, and the reaction mixture was slowly warmed to 15 °C and stirred for 12 hours. Upon completion, the reaction was quenched with water (50 mL) and extracted with EtOAc (2 × 50 mL). The combined organic layers were evaporated, and the residue was purified by column chromatography (PE / EtOAc = 5 / 1) to afford tert-butyl 3-(1-cyanoethylidene)azetidine-1-carboxylate (600 mg, 55% yield) as a colorless oil. [ka]

[0424] Steps bc: These two steps were carried out in the same manner as steps ab of intermediate A33. [ka]

[0425] Intermediate B1: tert-butyl 3-(4-formyl-1H-imidazol-1-yl)azetidine-1-carboxylate [ka] Step a. A mixture of tert-butyl 3-iodoazetidine-1-carboxylate (CAS: 254454-54-1; 10.0 g, 35.3 mmol), methyl 1H-imidazole-4-carboxylate (CAS: 17325-26-7; 8.91 g, 70.6 mmol), and CsCO (34.5 g, 106 mmol) in DMF (100 mL) was stirred at 100 °C for 1 h. After completion, the reaction mixture was diluted with water (300 mL) and extracted with EtOAc (300 mL). The organic layer was washed with brine (300 mL), dried over NaSO, and evaporated. The residue was purified by reverse-phase flash chromatography (water (0.1% NHOH) / MeCN) to afford methyl 1-(1-(tert-butoxycarbonyl)azetidin-3-yl)-1H-imidazole-4-carboxylate (5.5 g, 55% yield) as a white solid. The regiochemistry was confirmed by 2D NMR. [ka]

[0426] Step b. To a solution of methyl 1-(1-(tert-butoxycarbonyl)azetidin-3-yl)-1H-imidazole-4-carboxylate (2.00 g, 7.11 mmol) in THF (20 mL) was added LiBH (465 mg, 21.3 mmol) at 0 °C. The reaction mixture was stirred at 0 °C for 1 h, and then MeOH (2 mL) was added. The reaction mixture was stirred at 25 °C for an additional 12 h. After completion, the reaction mixture was poured into saturated aqueous NH Cl (50 mL) and extracted with EtOAc (50 mL). The organic layer was washed with brine (50 mL), dried over Na SO and evaporated. The residue was purified by column chromatography (DCM / MeOH=10 / 1) to give tert-butyl 3-(4-(hydroxymethyl)-1H-imidazol-1-yl)azetidine-1-carboxylate (0.65 g, 36% yield) as a white solid. [ka]

[0427] Step c. To a solution of tert-butyl 3-(4-(hydroxymethyl)-1H-imidazol-1-yl)azetidine-1-carboxylate (50 mg, 0.20 mmol) in DCM (1 mL) was added MnO (52 mg, 0.59 mmol). The reaction mixture was stirred at 25 °C for 2 h. After completion, the reaction mixture was filtered and evaporated to give the title compound (40 mg, 81% yield) as a brown oil. [ka]

[0428] Intermediate B2: tert-butyl 3-(3-formyl-1H-pyrazol-1-yl)azetidine-1-carboxylate [ka] The title compound was prepared in a similar manner to Intermediate B1 using methyl 1H-pyrazole-3-carboxylate (CAS: 15366-34-4) in step a. m / z ES+[M+Na] + 274.1.

[0429] Intermediate B3: tert-butyl 3-(3-formyl-1H-1,2,4-triazol-1-yl)azetidine-1-carboxylate [ka] Step a. This step was carried out in a similar manner to step a of Intermediate B1 using methyl 1H-1,2,4-triazole-3-carboxylate (CAS: 4928-88-5).

[0430] Step b. To a solution of methyl 1-(1-(tert-butoxycarbonyl)azetidin-3-yl)-1H-1,2,4-triazole-3-carboxylate (250 mg, 0.89 mmol) in DCM (10 mL) was added DIBAL-H (1 M in DCM, 2.66 mL). The reaction mixture was stirred at -70°C for 1 h. After completion, the mixture was quenched with MeOH (0.5 mL) and stirred at 20°C for 20 min. The mixture was filtered and evaporated to give the title compound (170 mg, 76% yield) as a white solid. [ka]

[0431] Intermediate B4: tert-butyl 3-(3-oxopropoxy)azetidine-1-carboxylate [ka] Step a. To a solution of tert-butyl 3-hydroxyazetidine-1-carboxylate (CAS: 141699-55-0; 10 g, 57.7 mmol) in THF (100 mL) was added NaH (346 mg, 8.66 mmol, 60% dispersion in mineral oil). The mixture was stirred at 20 °C for 30 min. Then, methyl acrylate (CAS: 96-33-3; 24.9 g, 289 mmol) was added, and the reaction mixture was stirred at 20 °C for 12 h. After completion, the mixture was quenched with saturated aqueous NH Cl (100 mL) and extracted with EtOAc (2 × 100 mL). The combined organic layers were washed with brine (200 mL), dried over Na SO , and evaporated. The crude product was purified by column chromatography (PE / EtOAc=5 / 1) to give tert-butyl 3-(3-methoxy-3-oxopropoxy)azetidine-1-carboxylate (6 g, 40% yield) as a colorless oil. [ka]

[0432] Step b. To a solution of tert-butyl 3-(3-methoxy-3-oxopropoxy)azetidine-1-carboxylate (2 g, 7.71 mmol) in DCM (50 mL) was added DIBAL-H (1 M in THF, 23.1 mL) dropwise at −70° C. The reaction mixture was then stirred at −70° C. for 30 minutes. Upon completion, the mixture was quenched with MeOH (5 mL) at −70° C. and allowed to warm to 20° C. over 30 minutes. The mixture was filtered and evaporated to afford the title compound (1.4 g, 79% yield) as a colorless oil, which was used directly in the next step without further purification. [ka]

[0433] Intermediate B5: tert-butyl 3-(4-formyl-1H-pyrazol-1-yl)azetidine-1-carboxylate [ka] Step a. This step was carried out in a similar manner to step a of Intermediate B1 using methyl 1H-pyrazole-4-carboxylate (CAS: 51105-90-9).

[0434] Step b. This step was carried out in a similar manner to step b of Intermediate B3.

[0435] Step c. This step was carried out in a similar manner to step c of Intermediate B1. [ka]

[0436] Intermediate B6: tert-butyl 3-(4-formyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-2-yl)azetidine-1-carboxylate [ka] Step a. To a solution of tert-butyl 3-formylazetidine-1-carboxylate (4.8 g, 25.9 mmol) and glyoxal (40 wt% in water; 18.0 g, 129 mmol) in MeOH (50 mL) was added 30% ammonium hydroxide (18.1 g, 155 mmol). The reaction mixture was stirred at 20 °C for 12 h. Upon completion, the mixture was evaporated, and the residue was purified by reverse-phase flash chromatography (water (0.1% NH4OH) / MeCN) to give tert-butyl 3-(1H-imidazol-2-yl)azetidine-1-carboxylate (5.79 g, crude) as a brown oil. m / z ES+[M+H] + 224.2.

[0437] Step b. To a solution of tert-butyl 3-(1H-imidazol-2-yl)azetidine-1-carboxylate (5.79 g, 25.9 mmol) in THF (3 mL) was added NaH (1.24 g, 31.1 mmol, 60% dispersion in mineral oil). The mixture was stirred at 0 °C for 30 min, after which SEMCl (5.62 g, 33.7 mmol) was added and the reaction mixture was stirred for an additional 1 h. Upon completion, the mixture was quenched with saturated aqueous NH4Cl (5 mL), diluted with water (100 mL), and extracted with EtOAc (3 × 100 mL). The combined organic layers were evaporated and the residue was purified by reverse-phase flash chromatography (water (0.1% NHOH) / MeCN) to give tert-butyl 3-(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-2-yl)azetidine-1-carboxylate (6.0 g, 65% yield) as a brown oil. m / z ES+[M+H] + 354.0.

[0438] Step c. A mixture of tert-butyl 3-(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-2-yl)azetidine-1-carboxylate (3.1 g, 8.77 mmol), NBS (1.56 g, 8.77 mmol) in DCM (30 mL) and DMF (30 mL) was stirred at 25 °C under a N atmosphere for 12 h. After completion, the mixture was filtered and the filtrate was evaporated. The residue was purified by reverse-phase flash chromatography (water (0.1% NHOH) / MeCN) to give tert-butyl 3-(4-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-2-yl)azetidine-1-carboxylate (3.2 g, 84% yield) as a yellow oil. [ka]

[0439] Step d. A mixture of tert-butyl 3-(4-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-2-yl)azetidine-1-carboxylate (3.2 g, 7.40 mmol), Pd(dppf)Cl (270 mg, 0.37 mmol), and TEA (793 mg, 7.84 mmol) in MeOH (30 mL) was stirred at 60 °C under a CO atmosphere (50 psi) for 12 hours. After completion, the mixture was filtered, and the filtrate was evaporated. The residue was purified by reverse-phase flash chromatography (water (0.1% NH OH) / MeCN) to afford the title compound (3.0 g, 69% yield) as a yellow oil. m / z ES+[M+H] + 412.2.

[0440] Step e. This step was carried out in a similar manner to step b of Intermediate B3.

[0441] Step f. This step was carried out in a similar manner to step c of Intermediate B1. m / z ES+[M+H] + 382.2.

[0442] Intermediate B7: tert-butyl 4-(4-formyloxazol-2-yl)piperazine-1-carboxylate [ka] Step a. To a solution of ethyl 2-chlorooxazole-4-carboxylate (CAS: 460081-18-9; 1.0 g, 5.70 mmol) in DMF (10 mL) was added K2CO3 (1.57 g, 11.3 mmol) and tert-butyl piperazine-1-carboxylate (1.27 g, 6.83 mmol). The mixture was stirred at 25 °C for 5 h. After completion, the reaction mixture was diluted with water (20 mL) and extracted with EtOAc (3 × 10 mL). The combined organic layers were evaporated, and the residue was purified by column chromatography (PE / EtOAc = 3 / 1) to give ethyl 2-(4-(tert-butoxycarbonyl)piperazin-1-yl)oxazole-4-carboxylate (1.3 g, 68% yield) as a pale yellow solid. [ka]

[0443] Step b. This step was carried out in a similar manner to step b of Intermediate B3. m / z ES+[M+H] + 282.1.

[0444] Intermediate B8: tert-butyl 4-(4-formyl-1H-imidazol-2-yl)piperazine-1-carboxylate [ka] Step a. To a mixture of N,N-dimethyl-1H-imidazole-1-sulfonamide (CAS: 78162-58-0; 9 g, 51.3 mmol) in THF (90 mL) was added n-BuLi (2.5 M in THF, 24.6 mL) dropwise at −70° C. The mixture was stirred at −70° C. for 30 minutes, and then CBr (18.7 g, 56.5 mmol) was added at −70° C. The reaction mixture was stirred at 20° C. for 16 hours. After completion, the reaction mixture was quenched with saturated aqueous NH4Cl (300 mL) and extracted with EtOAc (3×200 mL). The combined organic layers were washed with brine (3×500 mL) and evaporated. The residue was purified by column chromatography (PE / EtOAc=2 / 1) to give 2-bromo-N,N-dimethyl-1H-imidazole-1-sulfonamide (10.0 g, 77% yield) as a red solid. [ka]

[0445] Step b. A mixture of 2-bromo-N,N-dimethyl-1H-imidazole-1-sulfonamide (2 g, 7.87 mmol) and tert-butyl piperazine-1-carboxylate (CAS: 143238-38-4; 14.6 g, 78.7 mmol) was stirred at 90° C. for 20 hours. After completion, the reaction mixture was evaporated, and the residue was purified by reverse-phase flash chromatography (water (0.1% FA) / MeCN) to afford tert-butyl 4-(1-(N,N-dimethylsulfamoyl)-1H-imidazol-2-yl)piperazine-1-carboxylate (1 g, 35% yield) as a yellow solid. [ka]

[0446] Step c. To a mixture of tert-butyl 4-(1-(N,N-dimethylsulfamoyl)-1H-imidazol-2-yl)piperazine-1-carboxylate (647 mg, 1.80 mmol) in THF (6 mL) was added n-BuLi (2.5 M in THF, 1.44 mL) dropwise at −70° C. The mixture was stirred at −70° C. for 30 minutes, and then DMF (789 mg, 10.8 mmol) was added at −70° C. The reaction mixture was stirred at 20° C. for 2 hours. After completion, the reaction mixture was quenched with saturated aqueous Na2CO3 (30 mL) and extracted with EtOAc (3 × 10 mL). The combined organic layers were evaporated, and the residue was purified by reverse-phase flash chromatography (water (0.1% FA) / MeCN) followed by preparative TLC (EtOAc) to afford tert-butyl 4-(1-(N,N-dimethylsulfamoyl)-5-formyl-1H-imidazol-2-yl)piperazine-1-carboxylate (154 mg, 22% yield) as a yellow solid. [ka]

[0447] Step d. A mixture of tert-butyl 4-(1-(N,N-dimethylsulfamoyl)-5-formyl-1H-imidazol-2-yl)piperazine-1-carboxylate (160 mg, 0.41 mmol) in concentrated HCl (2 mL) was stirred at 60° C. for 2 h. After completion, the reaction mixture was basified with saturated aqueous NaCO to pH 7 and extracted with EtOAc (3×10 mL). The combined organic layers were evaporated to give 2-(piperazin-1-yl)-1H-imidazole-4-carbaldehyde (70 mg, 94% yield) as a yellow solid. m / z ES+[M+H] + 181.2.

[0448] Step e. To a mixture of 2-(piperazin-1-yl)-1H-imidazole-4-carbaldehyde (70 mg, 0.39 mmol) and NaCO (82 mg, 0.78 mmol) in THF (3 mL) was added BocO (169 mg, 0.78 mmol). The reaction mixture was stirred at 20 °C for 30 min. After completion, the reaction mixture was filtered, and the filtrate was evaporated. The residue was purified by reverse-phase flash chromatography (water (0.1% FA) / MeCN) to give the title compound (80 mg, 73% yield) as a white solid. [ka]

[0449] Intermediate B9: tert-butyl 4-(3-formyl-1H-1,2,4-triazol-1-yl)piperidine-1-carboxylate [ka] The title compound was prepared in a similar manner to intermediate B3 using methyl 1H-1,2,4-triazole-3-carboxylate (CAS: 4928-88-5) and tert-butyl 4-iodopiperidine-1-carboxylate (CAS: 301673-14-3) in step a. [ka]

[0450] Intermediate B10: tert-butyl 3-(3-formylphenyl)azetidine-1-carboxylate [ka] Step a. Methyl 3-bromobenzoate (500 mg, 2.33 mmol), tert-butyl 3-bromoazetidine-1-carboxylate (CAS: 1064194-10-0; 714 mg, 3.02 mmol), (Ir[dF(CF3)ppy]2(dtbpy))PF6 (CAS: 870987-63-6; 26 mg, 0.023 mmol), [4,4'-bis(1,1-dimethylethyl)-2,2'-bipyridine]nickel(II) dichloride (CAS: 1034901-50-2; 4.6 mg, 0.012 mmol), tris(trimethylsilyl)silane (CAS: 1873-77-4; A mixture of Na2CO3 (578 mg, 2.33 mmol) and Na2CO3 (493 mg, 4.65 mmol) was degassed and purged with N2 three times, then the mixture was stirred under N2 atmosphere at 25 °C for 14 h. After completion, the reaction mixture was filtered and evaporated. The residue was diluted with water (20 mL) and extracted with EtOAc (3 × 30 mL). The combined organic layers were dried over Na2SO4, evaporated, and purified by column chromatography (PE / EtOAc = 9 / 1) to give tert-butyl 3-(3-(methoxycarbonyl)phenyl)azetidine-1-carboxylate (590 mg, 75% yield) as a pale yellow oil. [ka]

[0451] Step b. A mixture of tert-butyl 3-(3-(methoxycarbonyl)phenyl)azetidine-1-carboxylate (100 mg, 0.34 mmol) in DCM (5 mL) was degassed and purged with N three times. DIBAL-H (1 M in toluene, 1.03 mL) was added, and the reaction mixture was stirred at −60° C. under a N atmosphere for 1 h. After completion, the reaction mixture was quenched with MeOH (0.5 mL) at −60° C., filtered, and evaporated to give tert-butyl 3-(3-(hydroxymethyl)phenyl)azetidine-1-carboxylate (90 mg, crude) as a pale yellow oil. [ka]

[0452] Step c. To a solution of tert-butyl 3-(3-(hydroxymethyl)phenyl)azetidine-1-carboxylate (90 mg, 0.34 mmol) in DCM (1 mL) was added MnO (594 mg, 6.84 mmol). The mixture was stirred at 25 °C for 16 h. After completion, the reaction mixture was filtered and evaporated to give the title compound (70 mg, crude) as a pale yellow oil. [ka]

[0453] Intermediate B11: tert-butyl 3-(6-formylpyridin-2-yl)azetidine-1-carboxylate [ka] Step a. This step was carried out in a similar manner to step a of Intermediate B10 using methyl 6-bromopicolinate (CAS: 26218-75-7).

[0454] Step b. To a solution of methyl 6-(1-(tert-butoxycarbonyl)azetidin-3-yl)picolinate (100 mg, 0.34 mmol) in DCM (5 mL) was added DIBAL-H (1 M in THF, 1.03 mL) at −70° C. The reaction mixture was stirred at −70° C. for 1 h. After completion, the mixture was quenched with MeOH (0.2 mL), stirred at 20° C. for 30 min, filtered, and the filtrate was evaporated to give the title compound (80 mg, 89% yield) as a white solid. [ka]

[0455] Intermediate B12: tert-butyl 3-(4-formylpyrimidin-2-yl)azetidine-1-carboxylate [ka] The title compound was prepared in a similar manner to intermediate B10 using methyl 2-bromopyrimidine-4-carboxylate (CAS: 1209459-78-8) in step a. [ka]

[0456] Intermediate B13: tert-butyl 3-(4-formylphenyl)azetidine-1-carboxylate [ka] Step a. This step was carried out in a similar manner to step a of Intermediate B10 using tert-butyl 3-bromoazetidine-1-carboxylate and methyl 4-bromobenzoate.

[0457] Steps bc: These two steps were carried out in the same manner as steps bc of Intermediate B1. [ka]

[0458] Intermediate B14: tert-butyl 3-(4-formylcyclohexyl)azetidine-1-carboxylate [ka] Step a. This step was carried out in a similar manner to step a of Intermediate B10 using tert-butyl 3-bromoazetidine-1-carboxylate and methyl 4-bromobenzoate.

[0459] Step b. This step was carried out in a similar manner to step b of Intermediate A23a and Intermediate A23b.

[0460] Step c. This step was carried out in a similar manner to step b of Intermediate B3. [ka]

[0461] Intermediate B15: tert-butyl 3-(2-fluoro-5-formylphenyl)azetidine-1-carboxylate [ka] The title compound was prepared in a similar manner to Intermediate B13 using tert-butyl 3-bromoazetidine-1-carboxylate and methyl 3-bromo-4-fluorobenzoate (CAS: 82702-31-6). [ka]

[0462] Intermediate B16: tert-butyl 2-(4-formylphenyl)pyrrolidine-1-carboxylate [ka] The title compound was prepared in a similar manner to intermediate B10 using methyl 4-bromobenzoate and (tert-butoxycarbonyl)proline (CAS: 59433-50-0) in step a. [ka]

[0463] Intermediate B17: tert-butyl 6-formyl-3,4-dihydroisoquinoline-2(1H)-carboxylate [ka] Step a. A mixture of tert-butyl 6-bromo-3,4-dihydroisoquinoline-2(1H)-carboxylate (CAS: 893566-74-0; 1.0 g, 3.20 mmol), N-formylsaccharin (CAS: 50978-45-5; 1.35 g, 6.41 mmol), Pd(OAc) (58 mg, 0.26 mmol), 1,4-bis(diphenylphosphino)butane (CAS: 7688-25-7; 163 mg, 0.38 mmol), triethylsilane (819 mg, 7.05 mmol), and NaCO (848 mg, 8.01 mmol) in DMF (20 mL) was stirred at 80 °C under a N atmosphere for 16 h. After completion, the reaction mixture was filtered, evaporated and purified by column chromatography (PE / EtOAc=5 / 1) to give the title compound (100 mg, 11% yield) as a colorless oil. [ka]

[0464] Intermediate B18: tert-butyl 5-formylisoindoline-2-carboxylate [ka] The title compound was prepared in a similar manner to Intermediate B17 using tert-butyl 5-bromoisoindoline-2-carboxylate (CAS: 201940-08-1). [ka]

[0465] Intermediate B19: tert-butyl 2-formyl-5,6-dihydroimidazo[1,2-a]pyrazine-7(8H)-carboxylate [ka] Step a. To a solution of 7-(tert-butyl) 2-ethyl 5,6-dihydroimidazo[1,2-a]pyrazine-2,7(8H)-dicarboxylate (CAS: 1053656-22-6; 300 mg, 1.07 mmol) in DCM (8 mL) was added DIBAL-H (1 M in toluene, 3.20 mL). The reaction mixture was stirred at -70 °C for 1 h. After completion, the mixture was quenched with MeOH (0.7 mL), stirred at 20 °C for 30 min, filtered, and the filtrate was evaporated to give the title compound (210 mg, 78% yield) as a white solid. [ka]

[0466] Intermediate B20: tert-butyl 2-formyl-5,6-dihydro-[1,2,4]triazolo[1,5-a]pyrazine-7(8H)-carboxylate [ka] Step a. To a solution of NaH (1.59 g, 39.6 mmol, 60% dispersion in mineral oil) in DMF (100 mL) was added methyl (tert-butoxycarbonyl)glycinate (CAS: 31954-27-5; 5 g, 26.4 mmol) at 0° C. The reaction mixture was stirred at 0° C. for 30 minutes, after which 3-bromoprop-1-ene (3.20 g, 26.4 mmol) was added. The reaction mixture was stirred at 0° C. for an additional 3 hours. Upon completion, the reaction mixture was quenched with saturated aqueous NH4Cl (20 mL) at 0° C., then diluted with water (100 mL) and extracted with EtOAc (3×50 mL). The combined organic layers were washed with brine (50 mL), dried over NaSO, evaporated, and purified by column chromatography (PE / EtOAc = 5 / 1) to give methyl N-allyl-N-(tert-butoxycarbonyl)glycinate (3.0 g, 50% yield) as a colorless oil. [ka]

[0467] Step b. A mixture of methyl N-allyl-N-(tert-butoxycarbonyl)glycinate (500 mg, 2.18 mmol), OsO (55.4 mg, 0.22 mmol), NaIO (1.40 g, 6.54 mmol) in THF (5 mL) and water (5 mL) was stirred under a N atmosphere at 0 °C for 3 h. After completion, the mixture was quenched with saturated aqueous NaSO (5 mL) and stirred at 25 °C for an additional 30 min, then extracted with EtOAc (3 × 20 mL). The combined organic layers were washed with saturated aqueous NaSO (2 × 15 mL) and brine (20 mL), dried over NaSO, filtered, and evaporated to give methyl N-(tert-butoxycarbonyl)-N-(2-oxoethyl)glycinate (350 mg, 1.51 mmol, 69% yield) as a black oil. [ka]

[0468] Step c. A mixture of benzyl hydrazine carboxylate (862 mg, 5.19 mmol), methyl N-(tert-butoxycarbonyl)-N-(2-oxoethyl)glycinate (1.2 g, 5.19 mmol), NaBHCN (326 mg, 5.19 mmol), 4 Å molecular sieves (300 mg), and acetic acid (1.56 g, 25.9 mmol) in MeOH (30 mL) was stirred at 25 °C under a N atmosphere for 6 h. After completion, the reaction mixture was filtered, and the filtrate was evaporated. The residue was purified by column chromatography (PE / EtOAc = 1 / 1) to give benzyl 2-(2-((tert-butoxycarbonyl)(2-methoxy-2-oxoethyl)amino)ethyl)hydrazine-1-carboxylate (1.5 g, 76% yield) as a colorless oil. [ka]

[0469] Step d. To a solution of benzyl 2-(2-((tert-butoxycarbonyl)(2-methoxy-2-oxoethyl)amino)ethyl)hydrazine-1-carboxylate (1.5 g, 3.93 mmol) in MeOH (30 mL) was added 10% Pd / C (150 mg) under a N atmosphere. The suspension was degassed and purged with H three times. The mixture was stirred at 25 °C under a H atmosphere (15 psi) for 5 h. Upon completion, the reaction mixture was filtered and evaporated to give tert-butyl 4-amino-3-oxopiperazine-1-carboxylate (0.8 g, 95% yield) as a yellow solid. [ka]

[0470] Step e. A mixture of tert-butyl 4-amino-3-oxopiperazine-1-carboxylate (0.8 g, 3.72 mmol), ethyl 2-ethoxy-2-iminoacetate (CAS: 816-27-3; 540 mg, 3.72 mmol) in EtOH (10 mL) was degassed and purged with N three times. The mixture was stirred under a N atmosphere at 25 °C for 1 h. Upon completion, the mixture was evaporated and purified by reverse-phase flash chromatography (water (0.1% FA) / MeCN) to afford 7-(tert-butyl) 2-ethyl 5,6-dihydro-[1,2,4]triazolo[1,5-a]pyrazine-2,7(8H)-dicarboxylate (500 mg, 45% yield) as a colorless oil. [ka]

[0471] Step f. To a solution of 7-(tert-butyl) 2-ethyl 5,6-dihydro-[1,2,4]triazolo[1,5-a]pyrazine-2,7(8H)-dicarboxylate (100 mg, 0.34 mmol) in THF (5 mL) was added DIBAL-H (1 M in toluene, 1.01 mL). The mixture was stirred at −78° C. for 2 hours. Upon completion, the reaction mixture was quenched with MeOH (1 mL) at −78° C. and then stirred for an additional 2 hours. The mixture was filtered and evaporated to give the title compound (60 mg, 71% yield) as a white solid. [ka]

[0472] Intermediate B21: tert-butyl 3-formyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazine-7(8H)-carboxylate [ka] The title compound was prepared in a similar manner to Intermediate B19 using 7-(tert-butyl) 3-ethyl 5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazine-3,7(8H)-dicarboxylate (CAS: 1215852-11-1). [ka]

[0473] Intermediate B22: tert-butyl 3-(4-formylpiperidin-1-yl)-3-methylazetidine-1-carboxylate [ka] Steps ab: These two steps were carried out in a similar manner to steps ab of intermediate A25, using ethyl piperidine-4-carboxylate (CAS: 1126-09-6) in step b.

[0474] Step c. A mixture of ethyl 1-(1-benzhydryl-3-methylazetidin-3-yl)piperidine-4-carboxylate (580 mg, 1.48 mmol), 10% Pd / C (10 mg), 10% Pd(OH) / C (10 mg), and 4 M HCl in MeOH (0.37 mL, 1.48 mmol) in MeOH (5 mL) was stirred for 16 h at 25° C. After completion, the mixture was filtered, and the filtrate was evaporated to give ethyl 1-(3-methylazetidin-3-yl)piperidine-4-carboxylate (320 mg, 95% yield) as a colorless oil. A mixture of ethyl 1-(3-methylazetidin-3-yl)piperidine-4-carboxylate (220 mg, 0.97 mmol), BocO (318 mg, 1.46 mmol), and TEA (295 mg, 2.92 mmol) in THF (2 mL) was stirred for 16 h at 25° C. After completion, the reaction mixture was evaporated and the residue was purified by column chromatography (PE / EtOAc=2 / 1) to give ethyl 1-(1-(tert-butoxycarbonyl)-3-methylazetidin-3-yl)piperidine-4-carboxylate (300 mg, 94% yield) as a white solid. [ka]

[0475] Step d. This step was carried out in a similar manner to step b of Intermediate B3. [ka]

[0476] Intermediate B23: tert-butyl 3-(methyl(3-oxopropyl)amino)azetidine-1-carboxylate [ka] Step a. A mixture of tert-butyl 3-(methylamino)azetidine-1-carboxylate (100 mg, 0.54 mmol), TEA (271 mg, 2.68 mmol), and methyl acrylate (138 mg, 1.61 mmol) in MeOH (1 mL) was stirred at 25 °C for 16 h. After completion, the reaction mixture was diluted with water (10 mL) and extracted with EtOAc (3 × 10 mL). The combined organic layers were washed with brine (10 mL), dried over NaSO, and evaporated. The residue was purified by column chromatography (EtOAc) to afford tert-butyl 3-((3-methoxy-3-oxopropyl)(methyl)amino)azetidine-1-carboxylate (100 mg, 68% yield) as a yellow oil. [ka]

[0477] Step b. This step was carried out in a similar manner to step b of Intermediate B3. [ka]

[0478] Intermediate B24: tert-butyl (7S)-7-formyl-8-methyloctahydro-2H-pyrazino[1,2-a]pyrazine-2-carboxylate [ka] Step a. To a solution of 1-(tert-butyl) 3-methylpiperazine-1,3-dicarboxylate (5.0 g, 20.4 mmol) and ((benzyloxy)carbonyl)-D-serine (4.90 g, 20.4 mmol) in DCM (100 mL) was added HATU (7.78 g, 20.4 mmol) and DIPEA (5.29 g, 40.9 mmol). The mixture was stirred at rt for 1 h. After completion, the reaction mixture was diluted with water (100 mL) and extracted with EtOAc (3 x 100 mL). The combined organic layers were evaporated and the residue was purified by reverse-phase flash chromatography (water (0.1% FA) / MeCN) to give 1-(tert-butyl) 3-methyl 4-(((benzyloxy)carbonyl)-D-seryl)piperazine-1,3-dicarboxylate (4.3 g, 44% yield) as an off-white solid. [ka]

[0479] Step b. A solution of borane dimethyl sulfide complex (10 M in THF, 13.9 mL) was added dropwise to a solution of 1-(tert-butyl) 3-methyl 4-(((benzyloxy)carbonyl)-D-seryl)piperazine-1,3-dicarboxylate (6.5 g, 13.9 mmol) in THF (60 mL) at 0 °C. The mixture was stirred at 25 °C for 12 h. After completion, MeOH (30 mL) was added slowly, and the mixture was diluted with saturated aqueous NaHCO (100 mL) and extracted with DCM (3 × 100 mL). The combined organic layers were washed with brine (300 mL), dried over NaSO, and evaporated. The residue was purified by reverse-phase flash chromatography (water (0.1% NHOH) / MeCN) to give 1-(tert-butyl) 3-methyl 4-((S)-2-(((benzyloxy)carbonyl)amino)-3-hydroxypropyl)piperazine-1,3-dicarboxylate (4.7 g, 74% yield) as a yellow solid. [ka]

[0480] Step c. A mixture of 1-(tert-butyl) 3-methyl 4-((S)-2-(((benzyloxy)carbonyl)amino)-3-hydroxypropyl)piperazine-1,3-dicarboxylate (4.7 g, 10.4 mmol), 10% Pd / C (470 mg) in MeOH (80 mL) was stirred under an atmosphere of H (15 psi) at 20° C. for 2 h. Upon completion, the reaction mixture was filtered, and the filtrate was evaporated to give tert-butyl (7S)-7-(hydroxymethyl)-9-oxooctahydro-2H-pyrazino[1,2-a]pyrazine-2-carboxylate (2.97 g, crude) as an off-white solid. [ka]

[0481] Step d. A solution of borane dimethyl sulfide complex (10 M in THF, 6.7 mL) was added dropwise to a solution of tert-butyl (7S)-7-(hydroxymethyl)-9-oxooctahydro-2H-pyrazino[1,2-a]pyrazine-2-carboxylate (1.9 g, 6.66 mmol) in THF (30 mL) at 0 °C. The mixture was stirred at 50 °C for 12 h. After completion, MeOH (20 mL) was slowly added to the reaction mixture, which was diluted with saturated aqueous NaHCO (50 mL) and extracted with DCM (3 × 50 mL). The combined organic layers were washed with brine (120 mL), dried over NaSO, and evaporated to give tert-butyl (7S)-7-(hydroxymethyl)octahydro-2H-pyrazino[1,2-a]pyrazine-2-carboxylate (1.8 g, crude) as a yellow solid. [ka]

[0482] Step e. To a solution of tert-butyl (7S)-7-(hydroxymethyl)octahydro-2H-pyrazino[1,2-a]pyrazine-2-carboxylate (1.8 g, 6.63 mmol) and formaldehyde (37 wt.% in HO; 2.69 g, 33.1 mmol) in MeOH (25 mL) was added NaBHCN (833 mg, 13.2 mmol). The mixture was stirred at 20 °C for 12 h. Upon completion, the reaction mixture was evaporated, and the residue was purified by reverse-phase flash chromatography (water (0.1% NHOH) / MeCN) to afford tert-butyl (7S)-7-(hydroxymethyl)-8-methyloctahydro-2H-pyrazino[1,2-a]pyrazine-2-carboxylate (750 mg, 33% yield) as a white solid. m / z ES+[M+H] + 286.2.

[0483] Step f. A solution of DMSO (657 mg, 8.41 mmol) in DCM (0.5 mL) was added dropwise to a solution of oxalyl chloride (533 mg, 4.20 mmol) in DCM (6 mL) at −78° C. The mixture was stirred at −78° C. for 10 minutes, after which a solution of tert-butyl (7S)-7-(hydroxymethyl)-8-methyloctahydro-2H-pyrazino[1,2-a]pyrazine-2-carboxylate (400 mg, 1.40 mmol) in DCM (2 mL) was added dropwise at −78° C. The mixture was stirred at −78° C. for 20 minutes, after which TEA (1.42 g, 14.0 mmol) was added at −78° C. The mixture was stirred and warmed to 20° C. for 30 minutes. Upon completion, the reaction mixture was diluted with saturated aqueous NaHCO (10 mL) and the layers were separated. The aqueous mixture was further extracted with DCM (2 × 5 mL). The combined organic layers were washed with brine (10 mL), dried over Na2SO4 and evaporated to give the title compound (360 mg, crude) as a brown solid. m / z ES+[M+H] + 284.2.

[0484] Intermediate B25: tert-butyl 2-formyl-8-methyl-5,6-dihydroimidazo[1,2-a]pyrazine-7(8H)-carboxylate [ka] Step a. A mixture of 3-methylpyrazin-2-amine (CAS: 19838-08-5; 3.00 g, 27.5 mmol) and ethyl 3-bromo-2-oxopropanoate (6.43 g, 33.0 mmol) in 1,2-dimethoxyethane (30 mL) was stirred at 25° C. for 16 hours. After completion, the mixture was cooled to 0° C. and filtered. The filter cake was dissolved in EtOH (40 mL) and stirred at 80° C. for 2 hours. After completion, the reaction mixture was cooled to 0° C. and filtered to give ethyl 8-methylimidazo[1,2-a]pyrazine-2-carboxylate (3.2 g, crude) as a white solid. [ka]

[0485] Step b. To a solution of ethyl 8-methylimidazo[1,2-a]pyrazine-2-carboxylate (1.2 g, 5.85 mmol) in EtOH (40 mL) was added 10% Pd / C (320 mg). The mixture was stirred at 50 °C under an atmosphere of H (50 psi) for 16 h. Upon completion, the reaction mixture was filtered and evaporated to give ethyl 8-methyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine-2-carboxylate (1.2 g, crude) as a yellow solid. To a mixture of ethyl 8-methyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine-2-carboxylate (1.2 g, 5.73 mmol) and Na2CO3 (1.52 g, 14.3 mmol) in DCM (15 mL) was added Boc2O (1.88 g, 8.60 mmol). The reaction mixture was stirred at 20 °C for 2 h. After completion, the reaction mixture was quenched with water (30 mL) and extracted with EtOAc (3 × 20 mL). The combined organic layers were washed with brine (3 × 20 mL), dried over Na2SO4, and evaporated. The residue was purified by column chromatography (PE / EtOAc=1 / 1) to give 7-(tert-butyl) 2-ethyl 8-methyl-5,6-dihydroimidazo[1,2-a]pyrazine-2,7(8H)-dicarboxylate (1.1 g, 61% yield) as a white solid. [ka]

[0486] Step c. This step was carried out in a similar manner to step b of Intermediate B3. [ka]

[0487] Intermediate B26: tert-butyl 2-formyl-6-methyl-5,6-dihydroimidazo[1,2-a]pyrazine-7(8H)-carboxylate [ka] The title compound was prepared in a similar manner to intermediate B25 using 5-methylpyrazin-2-amine (CAS: 5521-58-4) in step a. [ka]

[0488] Intermediate B27: tert-butyl 4-(2-oxoethoxy)piperidine-1-carboxylate [ka] Step a. A solution of ethyl 2-diazoacetate (8.50 g, 74.5 mmol) in DCM (80 mL) at 10° C. was added dropwise over 2 h to a solution of tert-butyl 4-hydroxypiperidine-1-carboxylate (5.0 g, 24.8 mmol) and Rh(OAc) (275 mg, 1.24 mmol) in DCM (80 mL). The mixture was stirred at 20° C. for 46 h. After completion, the reaction mixture was evaporated, and the residue was purified by column chromatography (PE / EtOAc = 8 / 1) to give tert-butyl 4-(2-ethoxy-2-oxoethoxy)piperidine-1-carboxylate (3 g, 40% yield) as a pale yellow oil. [ka]

[0489] Step b. This step was carried out in a similar manner to step b of Intermediate B3. [ka]

[0490] Intermediate B28: tert-butyl (S)-3-((2-oxoethoxy)methyl)pyrrolidine-1-carboxylate [ka] The title compound was prepared in a similar manner to intermediate B27 using tert-butyl (S)-3-(hydroxymethyl)pyrrolidine-1-carboxylate (CAS: 199174-24-8) in step a. [ka]

[0491] Intermediate B29: tert-butyl (R)-3-((2-oxoethoxy)methyl)pyrrolidine-1-carboxylate [ka] The title compound was prepared in a similar manner to intermediate B27 using tert-butyl (R)-3-(hydroxymethyl)pyrrolidine-1-carboxylate (CAS: 138108-72-2) in step a. [ka]

[0492] Intermediate B30: tert-butyl 3-(4-oxobutyl)azetidine-1-carboxylate [ka] Step a. To a solution of oxalyl chloride (946 mg, 7.45 mmol) in DCM (5 mL) was added DMSO (1.16 g, 14.9 mmol) at −78° C. The mixture was stirred at −78° C. for 10 minutes. Then, a solution of tert-butyl 3-(2-hydroxyethyl)azetidine-1-carboxylate (CAS: 152537-03-6; 500 mg, 2.48 mmol) in DCM (4 mL) was added, and the mixture was stirred at −78° C. for an additional 30 minutes. Then, TEA (2.51 g, 24.8 mmol) was added, and the mixture was stirred at −78° C. for an additional 30 minutes. Upon completion, the reaction mixture was warmed to 20° C., diluted with water (50 mL), and extracted with DCM (20 mL). The combined organic layers were washed with brine (50 mL), dried over Na2SO4, and evaporated to give tert-butyl 3-(2-oxoethyl)azetidine-1-carboxylate (500 mg, crude) as a colorless liquid. [ka]

[0493] Step b. To a solution of tert-butyl 3-(2-oxoethyl)azetidine-1-carboxylate (500 mg, 2.51 mmol) in DCM (10 mL) was added ethyl 2-(triphenyl-λ 5 To the reaction mixture was added tert-butyl (E)-3-(4-ethoxy-4-oxobut-2-en-1-yl)azetidine-1-carboxylate (CAS: 1099-45-2; 962 mg, 2.76 mmol). The mixture was stirred at 20 °C for 16 h. After completion, the reaction mixture was filtered and evaporated. The residue was purified by column chromatography (E / EtOAc = 5 / 1) to give tert-butyl (E)-3-(4-ethoxy-4-oxobut-2-en-1-yl)azetidine-1-carboxylate (440 mg, 63% yield) as a colorless liquid. [ka]

[0494] Step c. To a solution of tert-butyl (E)-3-(4-ethoxy-4-oxobut-2-en-1-yl)azetidine-1-carboxylate (440 mg, 1.63 mmol) in EtOH (5 mL) was added 10% Pd / C (50 mg). The mixture was stirred at 25 °C under a H atmosphere (50 psi) for 16 h. Upon completion, the reaction mixture was filtered and evaporated to give tert-butyl 3-(4-ethoxy-4-oxobutyl)azetidine-1-carboxylate (400 mg, crude) as a colorless liquid. [ka]

[0495] Step d. This step was carried out in a similar manner to step b of Intermediate B3. [ka]

[0496] Intermediate B31: tert-butyl 3-((2-oxoethoxy)methyl)azetidine-1-carboxylate [ka] Step a. This step was carried out in a similar manner to step a of Intermediate B27 using tert-butyl 3-(hydroxymethyl)azetidine-1-carboxylate (CAS: 142253-56-3).

[0497] Step b. To a solution of tert-butyl 3-((2-ethoxy-2-oxoethoxy)methyl)azetidine-1-carboxylate (300 mg, 1.10 mmol) in THF (3 mL) was added LiBH (72 mg, 3.29 mmol) at 0 °C. The mixture was stirred at 0–20 °C for 16 h. Upon completion, the reaction mixture was quenched with saturated aqueous NH Cl (1 mL) at 0 °C, filtered, and evaporated to give tert-butyl 3-((2-hydroxyethoxy)methyl)azetidine-1-carboxylate (210 mg, crude) as a colorless oil. [ka]

[0498] Step c. To a solution of oxalyl chloride (346 mg, 2.72 mmol) in DCM (10 mL) was added DMSO (426 mg, 5.45 mmol) in DCM (5 mL) at −78° C. The mixture was stirred at −70° C. for 15 minutes. Then, a mixture of tert-butyl 3-((2-hydroxyethoxy)methyl)azetidine-1-carboxylate (210 mg, 0.91 mmol) in DCM (5 mL) was added, and the mixture was stirred at −70° C. for an additional 2 hours and 30 minutes. Then, TEA (827 mg, 8.17 mmol) was added, and the reaction mixture was stirred at −70° C. for an additional 30 minutes. After completion, the reaction mixture was diluted with water (5 mL) and extracted with DCM (3×5 mL). The combined organic layers were dried over NaSO and evaporated to give the title compound (180 mg, crude) as a pale yellow oil. [ka]

[0499] Intermediate B32: tert-butyl (3-formylbicyclo[1.1.1]pentan-1-yl)carbamate [ka] The title compound was prepared in a similar manner to step b of Intermediate B3 using methyl 3-((tert-butoxycarbonyl)amino)bicyclo[1.1.1]pentane-1-carboxylate (CAS: 676371-64-5). [ka]

[0500] Intermediate B33: tert-butyl 2-formyl-6,7-dihydropyrazolo[1,5-a]pyrazine-5(4H)-carboxylate [ka] Step a. A mixture of dimethyl 1H-pyrazole-3,5-dicarboxylate (5.0 g, 27.2 mmol), tert-butyl (2-bromoethyl)carbamate (7.30 g, 32.6 mmol), and K2CO3 (5.6 g, 40.7 mmol) in DMF (100 mL) was stirred at 0 °C under a N2 atmosphere for 2 h. Upon completion, the reaction mixture was quenched with water (100 mL) and filtered. The filter cake was washed with water (50 mL) to give dimethyl 1-(2-((tert-butoxycarbonyl)amino)ethyl)-1H-pyrazole-3,5-dicarboxylate (8.50 g, 96% yield) as a yellow solid. [ka]

[0501] Step b. A mixture of dimethyl 1-(2-((tert-butoxycarbonyl)amino)ethyl)-1H-pyrazole-3,5-dicarboxylate (1 g, 3.06 mmol) and TFA (6.97 g, 61.1 mmol) in DCM (10 mL) was stirred at 25° C. under a N atmosphere for 1 h. After completion, the mixture was evaporated to give dimethyl 1-(2-aminoethyl)-1H-pyrazole-3,5-dicarboxylate as the TFA salt (1.0 g, 96% yield) as a yellow oil. m / z ES+[M+H] + 228.0.

[0502] Step c. A mixture of dimethyl 1-(2-aminoethyl)-1H-pyrazole-3,5-dicarboxylate (TFA salt, 1.0 g, 2.93 mmol) and TEA (2.97 g, 29.3 mmol, 4.08 mL) in MeCN (100 mL) was stirred under a N atmosphere at 60° C. for 12 h. Upon completion, the reaction mixture was diluted with water (100 mL) and filtered to give methyl 4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine-2-carboxylate (500 mg, 87% yield) as a white solid. [ka]

[0503] Step d. A mixture of methyl 4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine-2-carboxylate (500 mg, 2.56 mmol) and borane dimethyl sulfide complex (10 M in THF, 1.28 mL) in THF (5 mL) was stirred at 25 °C for 12 h under a N atmosphere. After completion, the reaction mixture was quenched with MeOH (10 mL) at 0 °C and stirred for an additional 2 h. The mixture was evaporated to give methyl 4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine-2-carboxylate (0.5 g, crude) as a yellow oil. m / z ES+[M+H] + 182.1.

[0504] Step e. To a solution of methyl 4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine-2-carboxylate (8.0 g, 44.1 mmol) in DCM (80 mL) was added BocO (14.4 g, 66.2 mmol) and TEA (13.4 g, 132 mmol). The reaction mixture was stirred at 25 °C for 1 h. After completion, the mixture was diluted with water (100 mL) and extracted with EtOAc (3 × 40 mL). The combined organic layers were dried over NaSO and evaporated. The residue was purified by column chromatography (PE / EtOAc = 1 / 1) to give 5-(tert-butyl) 2-methyl 6,7-dihydropyrazolo[1,5-a]pyrazine-2,5(4H)-dicarboxylate (2.5 g, 19% yield) as a white solid. [ka]

[0505] Steps f-g: These two steps were carried out in a similar manner to steps b-c of Intermediate B5. m / z ES+[M+H] + 251.8.

[0506] Intermediate B34: tert-butyl ((3-formylbicyclo[1.1.1]pentan-1-yl)methyl)carbamate [ka] Step a. Oxalyl chloride (4.48 g, 35.3 mmol) and DMF (380 mg, 5.20 mmol) were added to a solution of 3-(methoxycarbonyl)bicyclo[1.1.1]pentane-1-carboxylic acid (CAS: 83249-10-9; 5.00 g, 29.4 mmol) in DCM (50 mL). The mixture was stirred at 25 °C for 2 h. After completion, the reaction mixture was evaporated to give the acid chloride (5.5 g, crude) as a white solid.

[0507] Ammonia gas was bubbled through DCM (40 mL) for 30 minutes, and then a solution of the acid chloride in DCM (10 mL) was added. The reaction mixture was stirred at 25° C. for 2 hours. Upon completion, the reaction mixture was diluted with water (50 mL) and extracted with EtOAc (3×20 mL). The combined organic layers were dried over Na2SO4, filtered, and evaporated. The residue was purified by column chromatography (PE / EtOAc=1 / 1) to give methyl 3-carbamoylbicyclo[1.1.1]pentane-1-carboxylate (3.7 g, 75% yield) as a white solid. [ka]

[0508] Step b. To a mixture of methyl 3-carbamoylbicyclo[1.1.1]pentane-1-carboxylate (1.5 g, 8.9 mmol) in THF (20 mL) was added a solution of borane dimethyl sulfide complex (10 M in THF, 2.66 mL). The reaction mixture was stirred at 25 °C for 4 h under a N atmosphere. Upon completion, the reaction mixture was quenched with MeOH (5 mL) at 0 °C, filtered, and evaporated to afford methyl 3-(aminomethyl)bicyclo[1.1.1]pentane-1-carboxylate (1.4 g, crude) as a white solid, which was used without further purification.

[0509] Step c. To a solution of methyl 3-(aminomethyl)bicyclo[1.1.1]pentane-1-carboxylate (1.4 g, 9.02 mmol) in THF (10 mL) and water (10 mL) was added TEA (2.74 g, 27.1 mmol) and BocO (2.95 g, 13.5 mmol). The mixture was stirred at 25 °C for 16 h. After completion, the reaction mixture was diluted with water (30 mL) and extracted with EtOAc (3 × 50 mL). The combined organic layers were dried over NaSO and evaporated. The residue was purified by column chromatography (PE / EtOAc = 3 / 1) to give methyl 3-(((tert-butoxycarbonyl)amino)methyl)bicyclo[1.1.1]pentane-1-carboxylate (400 mg, 17% yield) as a pale yellow oil. [ka]

[0510] Step d. This step was carried out in a similar manner to step b of Intermediate B1. [ka]

[0511] Step e. To a solution of oxalyl chloride (212 mg, 1.67 mmol) in DCM (3 mL) was added DMSO (261 mg, 3.34 mmol) in DCM (3 mL) at −78° C. The mixture was stirred at −60° C. for 15 min. Then, a mixture of methyl 3-(((tert-butoxycarbonyl)amino)methyl)bicyclo[1.1.1]pentane-1-carboxylate (190 mg, 0.84 mmol) in DCM (5 mL) was added. The mixture was stirred at −60° C. for an additional 2 h 30 min. Then, TEA (507 mg, 5.02 mmol) was added, and the reaction mixture was stirred at −60° C. for an additional 30 min. After completion, the reaction mixture was diluted with water (15 mL) and extracted with DCM (3 × 10 mL). The combined organic layers were dried over Na2SO4 and evaporated to give the title compound (180 mg, crude) as a colorless oil, which was used without further purification. [ka]

[0512] Intermediate B35: 2-(2-(1,3-dioxoisoindolin-2-yl)ethoxy)acetaldehyde [ka] Step a. To a solution of 2-(2-aminoethoxy)ethanol (CAS: 929-06-6; 10.0 g, 95.1 mmol) in toluene (100 mL) was added isobenzofuran-1,3-dione (14.1 g, 95.1 mmol). The reaction mixture was stirred at 110 °C for 4 h. Upon completion, the reaction mixture was evaporated. The residue was triturated with PE / EtOAc (5 / 1; 40 mL) and filtered to give 2-(2-(2-hydroxyethoxy)ethyl)isoindoline-1,3-dione (21 g, 92% yield) as a white solid. [ka]

[0513] Step b. To a solution of oxalyl chloride (3.24 g, 25.5 mmol) in DCM (30 mL) was added a solution of DMSO (3.99 g, 51.0 mmol) in DCM (5 mL) dropwise at −78° C. After stirring for 10 minutes, a solution of 2-(2-(2-hydroxyethoxy)ethyl)isoindoline-1,3-dione (2 g, 8.50 mmol) in DCM (20 mL) was added dropwise. The mixture was stirred at −78° C. for 30 minutes, after which TEA (7.74 g, 76.5 mmol) was added. The reaction mixture was stirred at −78° C. for an additional 30 minutes. Upon completion, the reaction mixture was warmed to 20° C. and water (50 mL) was added. The layers were separated, and the organic layer was washed with brine (50 mL), dried over NaSO, and evaporated to give the title compound (1.5 g, 76% yield) as a yellow oil. [ka]

[0514] Intermediate B36: 5-(1,3-dioxoisoindolin-2-yl)pentanal [ka] The title compound was prepared in a similar manner to intermediate B35 using 5-aminopentan-1-ol (CAS: 2508-29-4) in step a. [ka]

[0515] Intermediate B37: 3-Methoxy-4-nitrobenzaldehyde [ka] Step a. To a solution of 3-hydroxy-4-nitrobenzaldehyde (CAS: 704-13-2; 1.00 g, 6.0 mmol) in DMF (12 mL) was added K2CO3 (910 mg, 6.6 mmol) and MeI (1.70 g, 12.0 mmol). The mixture was stirred at 20 °C for 2 h. After completion, the reaction mixture was diluted with water (50 mL) and extracted with EtOAc (3 × 50 mL). The combined organic layers were washed with water (2 × 100 mL), brine (2 × 200 mL), dried over Na2SO4, and evaporated. The residue was purified by column chromatography (PE / EtOAc = 6 / 1) to give the title compound (1.1 g, 99% yield) as a yellow solid. [ka]

[0516] Intermediate B38: tert-butyl 4-fluoro-4-formylpiperidine-1-carboxylate [ka] Step a. To a solution of oxalyl chloride (1.63 g, 12.9 mmol) in DCM (5 mL) was added DMSO (2.01 g, 25.7 mmol) in DCM (5 mL) at -78 °C. The mixture was stirred at -70 °C for 15 minutes, after which a mixture of tert-butyl 4-fluoro-4-(hydroxymethyl)piperidine-1-carboxylate (CAS: 614730-97-1; 1.5 g, 6.43 mmol) in DCM (5 mL) was added, and the mixture was stirred at -70 °C for an additional 2 hours and 30 minutes. After this, TEA (3.90 g, 38.6 mmol) was added, and the reaction mixture was stirred at -70 °C for an additional 30 minutes. After completion, the reaction mixture was diluted with water (40 mL) and extracted with DCM (2 × 20 mL). The combined organic layers were washed with brine (3 × 20 mL), dried over Na SO , and evaporated. The residue was purified by column chromatography (PE / EtOAc=3 / 1) to give the title compound (1.1 g, 74% yield) as a pale yellow oil. [ka]

[0517] Intermediate B39: tert-butyl 3-((tert-butyldiphenylsilyl)oxy)-4-formylpiperidine-1-carboxylate [ka] Step a. To a solution of 1-(tert-butyl) 4-ethyl 3-oxopiperidine-1,4-dicarboxylate (CAS: 71233-25-5; 10 g, 36.9 mmol) in EtOH (60 mL) was added NaBH (697 mg, 18.4 mmol). The reaction mixture was stirred at 20 °C for 2 h. After completion, the reaction mixture was slowly poured into saturated aqueous NH Cl (50 mL) and extracted with EtOAc (3 × 50 mL). The combined organic layers were washed with brine (50 mL), dried over Na SO and evaporated. The crude product was purified by column chromatography (PE / EtOAc = 5 / 1) to give 1-(tert-butyl) 4-ethyl 3-hydroxypiperidine-1,4-dicarboxylate (7.5 g, 74% yield) as a colorless oil. [ka]

[0518] Step b. To a solution of 1-(tert-butyl) 4-ethyl 3-hydroxypiperidine-1,4-dicarboxylate (1.5 g, 5.49 mmol) and imidazole (1.12 g, 16.46 mmol) in DCM (15 mL) was added TBDPSCl (1.96 g, 7.13 mmol) at 0 °C. The reaction mixture was stirred at 10 °C for 12 h. Upon completion, the mixture was filtered and evaporated. The residue was purified by reverse-phase flash chromatography (water (0.1% FA) / MeCN) to afford 1-(tert-butyl) 4-ethyl 3-((tert-butyldiphenylsilyl)oxy)piperidine-1,4-dicarboxylate (1.9 g, 64% yield) as a yellow oil. m / z ES+[M+H] + 512.2.

[0519] Step c. This step was carried out in a similar manner to step b of Intermediate B3. [ka]

[0520] Intermediate B40: tert-butyl((5-formylpyridin-2-yl)methyl)carbamate [ka] Step a. To a solution of methyl 6-cyanonicotinate (CAS: 89809-65-4; 1 g, 6.17 mmol) and 10% Pd / C (0.2 g) in MeOH (20 mL) was added HCl (729 mg, 7.40 mmol). The reaction mixture was stirred under a H atmosphere (15 psi) at 20 °C for 15 h. Upon completion, the mixture was filtered, and the filtrate was evaporated to give methyl 6-(aminomethyl)nicotinate as the HCl salt (1.2 g, 96% yield) as a yellow oil. [ka]

[0521] Step b. To a solution of methyl 6-(aminomethyl)nicotinate hydrochloride (1.2 g, 5.92 mmol) and TEA (1.80 g, 17.8 mmol) in MeOH (20 mL) was added BocO (1.94 g, 8.88 mmol). The reaction mixture was stirred at 20 °C for 12 h. After completion, the mixture was evaporated, water (50 mL) was added, and the aqueous mixture was extracted with EtOAc (2 × 50 mL). The combined organic layers were evaporated. The residue was purified by column chromatography (PE / EtOAc = 6 / 1) to afford methyl 6-(((tert-butoxycarbonyl)amino)methyl)nicotinate (1.4 g, 89% yield) as a white solid. [ka]

[0522] Step c. This step was carried out in a similar manner to step b of Intermediate B3. [ka]

[0523] Intermediate B41: tert-butyl (R)-3-(2-oxoethyl)pyrrolidine-1-carboxylate [ka] Step a. To a solution of (R)-2-(1-(tert-butoxycarbonyl)pyrrolidin-3-yl)acetic acid (CAS: 204688-60-8; 1.00 g, 4.36 mmol) in THF (10 mL) was added a solution of borane tetrahydrofuran complex (1 M in THF, 5.23 mL) at 0 °C. The reaction mixture was stirred at 20 °C for 1 h. After completion, the reaction mixture was quenched with 10% aqueous NaOH (2 mL). The reaction mixture was diluted with water (30 mL) and extracted with EtOAc (30 mL). The organic layer was dried over Na SO and evaporated to give tert-butyl (R)-3-(2-hydroxyethyl)pyrrolidine-1-carboxylate (0.93 g, 99% yield) as a colorless oil. [ka]

[0524] Step b. To a solution of tert-butyl (R)-3-(2-hydroxyethyl)pyrrolidine-1-carboxylate (0.3 g, 1.39 mmol) in DCM (3 mL) was added Dess-Martin periodinane (1.18 g, 2.79 mmol). The reaction mixture was stirred at 20 °C for 1 h. After completion, the pH of the reaction mixture was adjusted to ~pH 9 with saturated aqueous NaHCO (20 mL). The layers were separated, and the organic layer was washed with brine (20 mL), dried over NaSO, evaporated, and purified by column chromatography (PE / EtOAc = 3 / 1) to give the title compound (150 mg, 50% yield) as a colorless oil. [ka]

[0525] Intermediate B42: tert-butyl (S)-3-(2-oxoethyl)pyrrolidine-1-carboxylate [ka] The title compound was prepared in a similar manner to intermediate B41 using tert-butyl (S)-3-(hydroxymethyl)pyrrolidine-1-carboxylate (CAS: 204688-61-9) in step a. [ka]

[0526] Intermediate B43: tert-butyl (S)-3-formylpyrrolidine-1-carboxylate [ka] Step a. This step was carried out in a similar manner as step b of Intermediate B41 using tert-butyl (S)-3-(hydroxymethyl)pyrrolidine-1-carboxylate (CAS: 199174-24-8). [ka]

[0527] Intermediate B44: tert-butyl (R)-3-formylpyrrolidine-1-carboxylate [ka] The title compound was prepared in a similar manner to Intermediate B43 using tert-butyl (R)-3-(hydroxymethyl)pyrrolidine-1-carboxylate (CAS: 138108-72-2). [ka]

[0528] Intermediate B45: tert-butyl 4-(3-oxopropyl)piperidine-1-carboxylate [ka] The title compound was prepared in a similar manner to Intermediate B43 using tert-butyl 4-(3-hydroxypropyl)piperidine-1-carboxylate (CAS: 156185-63-6). [ka]

[0529] Intermediate B46: Benzyl 4-(1-oxopropan-2-yl)piperazine-1-carboxylate [ka] Step a. To a solution of benzylpiperazine-1-carboxylate (3.00 g, 13.6 mmol) and 1-hydroxypropan-2-one (1.11 g, 15.0 mmol) in MeOH (40 mL) was added acetic acid (82 mg, 1.36 mmol) and 4 Å molecular sieves (1 g). The mixture was stirred at 15 °C for 30 minutes, after which NaBH CN (2.57 g, 40.9 mmol) was added. The reaction mixture was stirred at 15 °C for 90 minutes. Upon completion, the reaction mixture was filtered, and the filtrate was evaporated. Saturated aqueous NaHCO (10 mL) was added, and the aqueous mixture was extracted with EtOAc (3 × 20 mL). The combined organic layers were washed with brine (10 mL), dried over Na SO , and evaporated. The crude product was purified by column chromatography (PE / EtOAc=5 / 1) to give benzyl 4-(1-hydroxypropan-2-yl)piperazine-1-carboxylate (1.7 g, 43% yield) as a yellow oil. [ka]

[0530] Step b. DMSO (505 mg, 6.47 mmol) was added to a solution of oxalyl chloride (410 mg, 3.23 mmol) in DCM (5 mL) at −78° C. The mixture was stirred at −78° C. for 10 minutes. Then, a solution of benzyl 4-(1-hydroxypropan-2-yl)piperazine-1-carboxylate (300 mg, 1.08 mmol) in DCM (2 mL) was added. The mixture was stirred at −78° C. for an additional 30 minutes, after which TEA (1.09 g, 10.8 mmol) was added. The mixture was stirred at −78° C. for an additional 60 minutes. Upon completion, the reaction mixture was quenched with water (30 mL) and extracted with EtOAc (3×25 mL). The combined organic layers were washed with brine (25 mL), dried over NaSO, and evaporated to give the title compound (300 mg, crude) as a yellow oil. [ka]

[0531] Intermediate B47a: 1-(tert-butyl) 4-ethyl (rac-cis)-3-cyanopiperidine-1,4-dicarboxylate and Intermediate B47b: 1-(tert-butyl) 4-ethyl (rac-trans)-3-cyanopiperidine-1,4-dicarboxylate [ka] Step a. To a solution of 1-(tert-butyl) 4-ethyl 3-oxopiperidine-1,4-dicarboxylate (CAS: 71233-25-5; 10 g, 36.9 mmol) in EtOH (60 mL) was added NaBH (697 mg, 18.4 mmol). The reaction mixture was stirred at 20 °C for 2 hours. After completion, the reaction mixture was slowly added to saturated aqueous NH Cl (50 mL), and the aqueous mixture was extracted with EtOAc (3 × 50 mL). The combined organic layers were washed with brine (50 ml), dried over Na SO , evaporated, and purified by column chromatography (PE / EtOAc = 5 / 1) to give 1-(tert-butyl) 4-ethyl 3-hydroxypiperidine-1,4-dicarboxylate (7.5 g, 74% yield) as a colorless oil. [ka]

[0532] Step b. To a solution of 1-(tert-butyl) 4-ethyl 3-hydroxypiperidine-1,4-dicarboxylate (7.5 g, 27.4 mmol) and TEA (11.1 g, 110 mmol) in DCM (75 mL) was added MsCl (6.29 g, 54.9 mmol) at 0 °C. The reaction mixture was stirred at 20 °C for 12 h. After completion, the reaction mixture was diluted with water (50 mL) and extracted with DCM (100 mL). The organic layer was washed with brine (50 mL), dried over Na SO , and evaporated to give 1-(tert-butyl) 4-ethyl 3-((methylsulfonyl)oxy)piperidine-1,4-dicarboxylate (9.6 g, crude) as a yellow oil. m / z ES+[M+Na] + 374.0.

[0533] Step c. A mixture of 1-(tert-butyl) 4-ethyl 3-((methylsulfonyl)oxy)piperidine-1,4-dicarboxylate (9.6 g, 27.3 mmol), TBAF (1 M in THF, 41.0 mL), and trimethylsilyl cyanide (4.07 g, 41.0 mmol) in MeCN (90 mL) was stirred at 80 °C for 12 h. After completion, the reaction mixture was diluted with water (40 mL) and extracted with EtOAc (3 × 40 mL). The combined organic layers were washed with brine (40 mL), dried over Na SO , and evaporated. The residue was purified by column chromatography (PE / EtOAc = 5 / 1) to give two isomers.

[0534] The first eluting isomer was confirmed by 2D NMR to be Intermediate B47b: 1-(tert-butyl) 4-ethyl (rac-trans)-3-cyanopiperidine-1,4-dicarboxylate (1.4 g, 18% yield) as a yellow oil. [ka]

[0535] The second eluting isomer was confirmed by 2D NMR to be Intermediate B47a: 1-(tert-butyl) 4-ethyl (rac-cis)-3-cyanopiperidine-1,4-dicarboxylate (5 g, crude) as a yellow oil. [ka]

[0536] Intermediate B48a: tert-butyl (rac-cis)-3-cyano-4-formylpiperidine-1-carboxylate [ka] Step a. To a solution of intermediate B47a (0.8 g, 2.83 mmol) in THF (8 mL) and MeOH (1 mL) was added LiBH (185 mg, 8.5 mmol), and the mixture was stirred at 10 °C for 12 h. After completion, the mixture was quenched with saturated aqueous NH Cl (0.2 mL), diluted with EtOAc (30 mL), filtered, and evaporated. The residue was purified by column chromatography (PE / EtOAc = 1 / 3) to give tert-butyl (rac-cis)-3-cyano-4-(hydroxymethyl)piperidine-1-carboxylate (500 mg, 73% yield) as a colorless oil. [ka]

[0537] Step b. To a solution of tert-butyl (rac-cis)-3-cyano-4-(hydroxymethyl)piperidine-1-carboxylate (450 mg, 1.87 mmol) in DCM (10 mL) was added Dess-Martin periodinane (1.59 g, 3.75 mmol), and the mixture was stirred at 15° C. for 1 h. After completion, the mixture was filtered, evaporated, and purified by column chromatography (PE / EtOAc=1 / 1) to give the title compound (434 mg, crude) as a yellow oil, which was used directly in the subsequent step.

[0538] Intermediate B48b: tert-butyl (rac-trans)-3-cyano-4-formylpiperidine-1-carboxylate [ka] The title compound was prepared in a similar manner to Intermediate B48a using Intermediate B47b. [ka]

[0539] Intermediate B49: Benzyl 2-formyl-5,7-dihydro-6H-pyrrolo[3,4-b]pyrazine-6-carboxylate [ka] Step a. To a solution of 2,3-dimethylpyrazine e (10 g, 92.5 mmol) in CCl (320 mL) was added NBS (41.2 g, 231 mmol) and AIBN (106 mg, 0.65 mmol). The mixture was stirred at 80 °C for 1 h under a N atmosphere. After 1 h, additional AIBN (106 mg, 0.65 mmol) was added and stirred at 80 °C for an additional 5 h under a N atmosphere. Upon completion, the mixture was filtered, and the filter cake was washed with CCl (100 mL). The filtrate was evaporated and purified by column chromatography (PE / EtOAc = 20 / 1) to give 2,3-bis(bromomethyl)pyrazine (20 g, 31% yield) as a purple oil. [ka]

[0540] Step b. To a solution of 2,3-bis(bromomethyl)pyrazine (40 g, 116 mmol) in DMF (1500 mL) was added a solution of triphenylmethanamine (90.1 g, 347 mmol) in DMF (500 mL) at 0° C. The mixture was stirred at 20° C. for 1 h and then at 60° C. for 12 h. After completion, the mixture was evaporated, diluted with water (400 mL), and extracted with EtOAc (3×400 mL). The combined organic layers were washed with brine (2×500 mL), dried over Na2SO4, evaporated, and purified by column chromatography (PE / EtOAc=7 / 1), followed by trituration with MeOH (100 mL) at 20° C. to give 6-trityl-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine (16 g, 37% yield) as a yellow solid. [ka]

[0541] Step c. A solution of 6-trityl-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine (16.0 g, 44.0 mmol) in 4 M HCl MeOH (120 mL) was stirred at 20 °C for 2 h. After completion, the mixture was evaporated, diluted with water (200 mL), and extracted with EtOAc (3 × 150 mL). The aqueous phase was lyophilized to give 6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine hydrochloride (7 g) as a black solid. [ka]

[0542] Step d. To a solution of 6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine hydrochloride (8.67 g, 55.0 mmol) in THF (200 mL) and water (100 mL) was added NaCO (14.6 g, 138 mmol) and CbzCl (11.3 g, 66.0 mmol). The reaction mixture was stirred at 20 °C for 5 h. After completion, the mixture was diluted with water (100 mL) and extracted with EtOAc (3 × 200 mL). The combined organic layers were washed with brine (500 mL), dried over NaSO, evaporated, and purified by column chromatography (PE / EtOAc = 2 / 1) to give benzyl 5,7-dihydro-6H-pyrrolo[3,4-b]pyrazine-6-carboxylate (7.5 g, 64% yield) as a yellow solid. [ka]

[0543] Step e. To a solution of benzyl 5,7-dihydro-6H-pyrrolo[3,4-b]pyrazine-6-carboxylate (10 g, 39.2 mmol) in DCM (150 mL) was added m-CPBA (80%; 9.3 g, 43.1 mmol). The reaction mixture was stirred at 25 °C for 12 h. After completion, the mixture was diluted with saturated aqueous NaSO (150 mL) and extracted with DCM (200 mL). The combined organic layers were washed with saturated aqueous NaSO (150 mL), brine (300 mL), dried over NaSO, evaporated, and purified by column chromatography (PE / EtOAc = 0 / 1) to give 6-((benzyloxy)carbonyl)-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine 1-oxide (8.3 g, 76% yield) as a yellow solid. [ka]

[0544] Step f. To a solution of 6-((benzyloxy)carbonyl)-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine 1-oxide (14.3 g, 52.7 mmol) in DMF (200 mL) was added oxalyl chloride (16.7 g, 132 mmol) dropwise at 0 °C. The reaction mixture was stirred at 40 °C for 12 h. After completion, the mixture was basified to pH 8 with saturated aqueous NaHCO, diluted with water (500 mL), and extracted with EtOAc (3 × 500 mL). The combined organic layers were washed with brine (2 × 800 mL), dried over NaSO, evaporated, and purified by column chromatography (PE / EtOAc = 7 / 1) to give benzyl 2-chloro-5,7-dihydro-6H-pyrrolo[3,4-b]pyrazine-6-carboxylate (11.6 g, 76% yield) as a yellow solid. [ka]

[0545] Step g. A mixture of benzyl 2-chloro-5,7-dihydro-6H-pyrrolo[3,4-b]pyrazine-6-carboxylate (10 g, 34.5 mmol), potassium trifluoro(vinyl)borate (CAS: 13682-77-4; 9.25 g, 69.0 mmol), Pd(dppf)Cl (2.53 g, 3.45 mmol), and NaCO (9.15 g, 86.3 mmol) in 1,4-dioxane (200 mL) and water (30 mL) was degassed and purged with N three times. The reaction mixture was stirred at 80 °C under a N atmosphere for 12 h. After completion, the mixture was diluted with water (250 mL) and extracted with EtOAc (3 × 250 mL). The combined organic layers were washed with brine (600 mL), dried over NaSO, evaporated, and purified by column chromatography (PE / EtOAc=9 / 1) to give benzyl 2-vinyl-5,7-dihydro-6H-pyrrolo[3,4-b]pyrazine-6-carboxylate (9.04 g, 93% yield) as an off-white solid. [ka]

[0546] Step h. To a solution of benzyl 2-vinyl-5,7-dihydro-6H-pyrrolo[3,4-b]pyrazine-6-carboxylate (8.8 g, 31.3 mmol) in THF (150 mL) and water (150 mL) was added NaIO (20.1 g, 93.9 mmol) and OsO (795 mg, 3.13 mmol) at 0 °C. The reaction mixture was stirred at 0 °C for 1 h. After completion, the mixture was quenched with saturated aqueous NaSO (200 mL) and stirred at 25 °C for 10 min. The mixture was diluted with water (50 mL) and extracted with EtOAc (3 × 250 mL). The combined organic layers were washed with saturated aqueous Na2S2O3 (400 mL), brine (500 mL), dried over Na2SO4, evaporated and purified by column chromatography (PE / EtOAc = 3 / 1) to give the title compound (6.4 g, 72% yield) as a yellow solid. [ka]

[0547] Intermediate B50a: tert-butyl (R / S)-7-(((tert-butyldimethylsilyl)oxy)methyl)-3-vinyl-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxylate and Intermediate B50b: tert-butyl (S / R)-7-(((tert-butyldimethylsilyl)oxy)methyl)-3-vinyl-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxylate [ka] Step a. To a solution of (tert-butoxycarbonyl)serine (50 g, 244 mmol) and imidazole (33.2 g, 487 mmol) in DMF (500 mL) was added TBSCl (36.7 g, 244 mmol) at 0 °C. The reaction mixture was stirred at 20 °C for 12 h. After completion, the mixture was diluted with water (1.5 L) and extracted with EtOAc (3 × 1 L). The combined organic layers were washed with brine (3 × 1 L), dried over Na SO , and evaporated to give N-(tert-butoxycarbonyl)-O-(tert-butyldimethylsilyl)serine (64 g, 82% yield) as a colorless oil. [ka]

[0548] Step b. A solution of N-(tert-butoxycarbonyl)-O-(tert-butyldimethylsilyl)serine (66.9 g, 209 mmol) and CDI (40.8 g, 251 mmol) in THF (670 mL) was stirred at 20 °C for 1 h, after which potassium 3-methoxy-3-oxopropanoate (32.7 g, 209 mmol) and MgCl (19.9 g, 209 mmol) were added. The reaction mixture was stirred at 50 °C for an additional 16 h. After completion, the mixture was diluted with water (500 mL) and extracted with EtOAc (500 mL). The organic layer was washed with brine (500 mL), dried over NaSO, evaporated, and purified by column chromatography (PE / EtOAc=10 / 1) to give methyl 4-((tert-butoxycarbonyl)amino)-5-((tert-butyldimethylsilyl)oxy)-3-oxopentanoate (27.6 g, 35% yield) as a colorless oil. [ka]

[0549] Step c. To a solution of methyl 4-((tert-butoxycarbonyl)amino)-5-((tert-butyldimethylsilyl)oxy)-3-oxopentanoate (27.6 g, 73.5 mmol) in THF (280 mL) was added t-BuOK (9.07 g, 80.9 mmol) at 0° C. The mixture was stirred at 0° C. for 45 minutes, and then DABCO (9.07 g, 80.9 mmol) and (Z)—N-(2-chloro-3-(dimethylamino)allylidene)-N-methylmethanaminium hexafluorophosphate (23.7 g, 77.2 mmol) were added at 0° C. The mixture was stirred at 20° C. for 3 hours, and then ammonium acetate (6.23 g, 80.9 mmol) was added. The reaction mixture was stirred at 20° C. for an additional 16 hours. After completion, the mixture was diluted with water (500 mL) and extracted with EtOAc (3 × 300 mL). The combined organic layers were washed with brine (300 mL), dried over NaSO, evaporated, and purified by column chromatography (PE / EtOAc = 10 / 1) to give methyl 5-chloro-2-(2,2,3,3,10,10-hexamethyl-8-oxo-4,9-dioxa-7-aza-3-silaundecan-6-yl)nicotinate (23 g, 69% yield) as a white solid. [ka]

[0550] Step d. To a solution of methyl 5-chloro-2-(2,2,3,3,10,10-hexamethyl-8-oxo-4,9-dioxa-7-aza-3-silaundecan-6-yl)nicotinate (13 g, 29.2 mmol) in EtOH (130 mL) was added NaBH (2.21 g, 58.4 mmol) and CaCl (3.24 g, 29.2 mmol) at 0 °C. The reaction mixture was stirred at 0 °C for 2 h. After completion, the mixture was quenched with saturated aqueous NH Cl (300 mL) and extracted with EtOAc (3 × 300 mL). The combined organic layers were washed with brine (300 mL), dried over NaSO, evaporated, and purified by column chromatography (PE / EtOAc=5 / 1) to give tert-butyl (2-((tert-butyldimethylsilyl)oxy)-1-(5-chloro-3-(hydroxymethyl)pyridin-2-yl)ethyl)carbamate (6.6 g, 53% yield) as a colorless oil. [ka]

[0551] Step e. To a solution of tert-butyl (2-((tert-butyldimethylsilyl)oxy)-1-(5-chloro-3-(hydroxymethyl)pyridin-2-yl)ethyl)carbamate (5.6 g, 13.4 mmol) in DCM (60 mL) was added TEA (4.08 g, 40.3 mmol) and TsCl (5.12 g, 26.9 mmol) at 0° C. The reaction mixture was stirred at 0° C. for 1 h. After completion, the mixture was quenched with saturated aqueous NaHCO (100 mL) and extracted with EtOAc (100 mL). The organic layer was washed with brine (100 mL), dried over NaSO, evaporated and purified by column chromatography (PE / EtOAc=10 / 1) to give (5-chloro-2-(2,2,3,3,10,10-hexamethyl-8-oxo-4,9-dioxa-7-aza-3-silaundecan-6-yl)pyridin-3-yl)methyl 4-methylbenzenesulfonate (5.3 g, 69% yield) as a colorless oil. [ka]

[0552] Step f. To a solution of (5-chloro-2-(2,2,3,3,10,10-hexamethyl-8-oxo-4,9-dioxa-7-aza-3-silaundecan-6-yl)pyridin-3-yl)methyl 4-methylbenzenesulfonate (4.8 g, 8.40 mmol) in DMF (150 mL) was added NaH (1.01 g, 25.2 mmol, 60% dispersion in mineral oil) at 0° C. The reaction mixture was stirred at 0° C. for 1 h. Upon completion, the mixture was diluted with water (500 mL) and extracted with EtOAc (500 mL). The organic layer was washed with brine (500 mL), dried over NaSO, evaporated, and purified by reverse-phase flash chromatography (water (0.1% NHOH) / MeCN) to afford tert-butyl 7-(((tert-butyldimethylsilyl)oxy)methyl)-3-chloro-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxylate (2.2 g, 66% yield) as a colorless oil. [ka]

[0553] Step g. This step was carried out in a similar manner as step g of intermediate B49 and, after an additional chiral SFC step, afforded the title compound.

[0554] Intermediate B50a: [ka]

[0555] Intermediate B50b: [ka]

[0556] Intermediate B51a: tert-butyl (R / S)-7-(((tert-butyldimethylsilyl)oxy)methyl)-3-formyl-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxylate [ka] Step a. This step was carried out in a similar manner to step h of Intermediate B49 using Intermediate B50a. [ka]

[0557] Intermediate B51b: tert-butyl (S / R)-7-(((tert-butyldimethylsilyl)oxy)methyl)-3-formyl-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxylate [ka] The title compound was prepared in a similar manner to intermediate B51a using intermediate B50b. [ka]

[0558] Intermediate B52: tert-butyl 5-(((tert-butyldiphenylsilyl)oxy)methyl)-2-formyl-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxylate [ka] Step a. To a solution of methyl 5-bromopicolinate (15 g, 69.4 mmol) in DCM (250 mL) was added m-CPBA (80%; 30.0 g, 139 mmol). The reaction mixture was stirred at 25 °C for 12 h. After completion, the mixture was diluted with saturated aqueous NaSO (500 mL) and extracted with DCM (500 mL). The combined organic layers were washed with saturated aqueous NaSO (300 mL), brine (500 mL), dried over NaSO, evaporated, and purified by column chromatography (PE / EtOAc = 1 / 2) to give 5-bromo-2-(methoxycarbonyl)pyridine 1-oxide (11.7 g, 70% yield) as an off-white solid. [ka]

[0559] Step b. A mixture of 5-bromo-2-(methoxycarbonyl)pyridine 1-oxide (11.7 g, 50.4 mmol), TMSCN (50.0 g, 504 mmol), and dimethylcarbamoyl chloride (54.2 g, 504 mmol) was stirred at 50 °C for 16 h under a N atmosphere. After completion, the mixture was basified to pH 8 with 1 M NaOH and extracted with EtOAc (3 × 250 mL). The combined organic layers were washed with brine (600 mL), dried over NaSO, evaporated, and purified by column chromatography (PE / EtOAc = 7 / 1) to give methyl 5-bromo-6-cyanopicolinate (10.4 g, 85% yield) as an off-white solid. [ka]

[0560] Step c. To a solution of methyl 5-bromo-6-cyanopicolinate (10.4 g, 43.2 mmol) in THF (120 mL) was added a solution of borane tetrahydrofuran complex (1 M in THF, 215.73 mL) dropwise at 0° C. The reaction mixture was stirred at 20° C. for 3 h. Upon completion, the mixture was quenched with MeOH (50 mL) at 0° C. and evaporated to give methyl 6-(aminomethyl)-5-bromopicolinate (12.0 g, crude) as a yellow solid.

[0561] Step d. To a solution of methyl 6-(aminomethyl)-5-bromopicolinate (12.0 g, 42.6 mmol) in THF (150 mL) was added NaHCO (7.16 g, 85.3 mmol) and BocO (11.2 g, 51.2 mmol). The reaction mixture was stirred at 20 °C for 12 h. After completion, the mixture was diluted with water (150 mL) and extracted with EtOAc (3 × 150 mL). The combined organic layers were washed with brine (300 mL), dried over NaSO, evaporated, and purified by column chromatography (PE / EtOAc = 7 / 1) to give methyl 5-bromo-6-(((tert-butoxycarbonyl)amino)methyl)picolinate (4.5 g, 29% yield) as a yellow solid. [ka]

[0562] Step e. A mixture of methyl 5-bromo-6-(((tert-butoxycarbonyl)amino)methyl)picolinate (2.5 g, 7.24 mmol), potassium trifluoro(vinyl)borate (CAS: 13682-77-4; 1.94 g, 14.5 mmol), Pd(dppf)Cl (265 mg, 0.36 mmol), and NaCO (1.92 g, 18.1 mmol) in 1,4-dioxane (40 mL) and water (4 mL) was degassed and purged with N three times. The reaction mixture was stirred at 80 °C under a N atmosphere for 24 h. After completion, the mixture was diluted with water (50 mL) and extracted with EtOAc (3 × 50 mL). The combined organic layers were washed with brine (150 mL), dried over NaSO, evaporated, and purified by column chromatography (PE / EtOAc=8 / 1) to give methyl 6-(((tert-butoxycarbonyl)amino)methyl)-5-vinylpicolinate (1.68 g, 76% yield) as a yellow solid. [ka]

[0563] Step f. To a solution of methyl 6-(((tert-butoxycarbonyl)amino)methyl)-5-vinylpicolinate (1.7 g, 5.82 mmol) in MeCN (15 mL), tBuOH (15 mL), and water (15 mL) was added OsO (148 mg, 0.58 mmol) and NMO (818 mg, 6.98 mmol). The reaction mixture was stirred at 20 °C for 2 h. After completion, the mixture was quenched with saturated aqueous NaSO (25 mL) at 20 °C and extracted with EtOAc (3 × 25 mL). The combined organic layers were washed with saturated aqueous NaSO (35 mL), brine (60 mL), dried over NaSO, evaporated, and purified by column chromatography (PE / EtOAc = 1 / 2) to give methyl 6-(((tert-butoxycarbonyl)amino)methyl)-5-(1,2-dihydroxyethyl)picolinate (1.5 g, 78% yield) as a yellow solid. [ka]

[0564] Step g: This step was carried out in a similar manner to step a of Intermediate B50a and Intermediate B50b using TBDPSCl. [ka]

[0565] Step h. To a solution of methyl 6-(((tert-butoxycarbonyl)amino)methyl)-5-(2-((tert-butyldiphenylsilyl)oxy)-1-hyd...

Claims

1. A compound of formula (I) or a tautomeric or stereochemically isomeric form, a pharma- ceutically acceptable salt, or solvate thereof: 【Chemistry 1】 (In the formula: n represents an integer selected from 0, 1, 2, 3, or 4; R 1 is C 1-6 Alkyl, C 2-6 Alkenyl, C 1-6 Alkoxy, hydroxy, halogen, haloC 1-6 Alkyl, haloC 1-6 Alkoxy, C 3-8 Cycloalkyl, cyano, or -NR x R y represents; X is a bond or one or more C 1-6 Alkyl, NR x , C optionally substituted with O, hydroxy, halogen, or CO groups; 1 -C 6 represents an alkylene group; R 2 is -ring A Or - Ring B -Y-ring C Represents a group; Or -XR 2 -C 1 -C 12 Alkylene-NR x R y group, where the alkylene group is one or more C 1-6 Alkyl, C 2-6 Alkenyl, -NR x , optionally substituted with O, hydroxy, or CO groups; ring A is -(CH 2 ) m -CO-C 1-6 Alkyl, -(CH 2 ) m -NHCO-C 1-6 Alkyl, -(CH 2 ) m -CO-C 2-6 Alkenyl, -(CH 2 ) m -NHCO-C 2-6 Alkenyl, -(CH 2 ) m -CO-C 2-6 Alkynyl, or -(CH 2 ) m -NHCO-C 2-6 represents a carbocyclyl, heterocyclyl, or heteroaryl which requires a substituent selected from an alkynyl group, wherein the alkyl, alkenyl, or alkynyl group contains one or more (e.g., one, two, or three) halogen, hydroxy, CO, or -NR x R y and wherein the carbocyclyl, heterocyclyl, or heteroaryl group is optionally substituted with halogen, C 1-6 Alkyl, Hydroxy, C 1-6 Alkoxy, -CO-C 1-6 Alkyl, oxo, C 1-6 and optionally further substituted with one or more (e.g., one, two, or three) substituents selected from alkyl, alkylamino, or cyano, wherein the C 1-6 The alkyl group may be optionally substituted with one or more halogen, hydroxy, or cyano groups; m represents an integer selected from 0, 1, 2, 3, or 4; ring B are each hydroxy, oxo, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, HaloC 1-6 Alkyl, -CO-C 1-6 represents carbocyclyl, heterocyclyl, or heteroaryl, which may be optionally substituted by one or more (e.g., 1, 2, or 3) substituents selected from alkyl, cyano, or halogen; ring C is a halogen, C 1-6 Alkyl, -CO-C 1-6 Alkyl and / or -NR x R y Optionally substituted with -(CH 2 ) m -CO-C 2-6 represents heterocyclyl substituted by one or more (e.g., 1, 2, or 3) substituents selected from alkenyl; Y is a bond, -O-, -NHCO-, CO, or one or more C 1-6 Alkyl, C 2-6 Alkenyl, -NR x , C optionally substituted with O, hydroxy, or CO groups; 1 -C 6 represents an alkylene group; R 3 is hydrogen or C 1-6 represents alkyl; R 4 , R 5 , R 6 , and R 7 are independently hydrogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 1-6 Alkoxy, halogen, haloC 1-6 Alkyl, haloC 1-6 Alkoxy, C 3-8 Cycloalkyl, cyano, or -NR x R y represents; and R x and R y are independently hydrogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 represents alkoxy or R x and R y are joined together with the nitrogen atom to which they are attached to form one or more C 1-6 forming a nitrogen-containing heterocyclic ring which may be optionally substituted by alkyl groups).

2. 2. The compound of claim 1, wherein n represents 0, 1, 2, or 3.

3. R 1 But, C 1-6 Alkyl (e.g., methyl), halogen (e.g., fluorine or chlorine), or C 3-8 cycloalkyl (e.g., cyclopropyl), e.g., R 1 C 1-6 alkyl (e.g., methyl) or halogen (e.g., fluorine or chlorine), in particular R 1 C 1-6 3. A compound according to claim 1 or claim 2, which represents alkyl (e.g. methyl).

4. R 2 Ga-ring A The compound according to any one of claims 1 to 3, which represents

5. ring A but, -(CH) optionally substituted with halogen groups 2 ) m -CO-C 2-6 Alkyl (e.g., -CO-CH 2 -Cl); One or more halogen, hydroxy, CO, or -NR x R y Optionally substituted with -(CH 2 ) m -CO-C 2-6 Alkenyl (e.g., -COCH=CH 2 , -CO-C(=CH 2 )-Me, -CO-CH=CH-CH 2 -N(Me) 2 , -CO-C(=CH 2 )-CH 2 -N(Me) 2 , -CO-C(=CH-Me)-CH 2 -N(Me) 2 , -CO-C(=CH 2 )-CH 2 -N(Me) 2 , -CO-C(Cl)=CH-CH 2 -N(Me) 2 , -CO-C(=CH 2 )-CH 2 -OH, -CO-C(=CH 2 )-CH 2 -OC(=O)-Me, -CO-CH=CH-CHF 2 , -CO-C(=CH 2 )-CH 2 -NEt 2 ); -NR x R y Optionally substituted with -(CH 2 ) m -NHCO-C 2-6 Alkenyl (e.g., -NH-CO-CH=CH 2 , -NH-CO-C(=CH 2 )-CH 2 -N(Me) 2 , -NH-CO-C(=CH-Me)-CH 2 -N(Me) 2 , -NH-CO-CH=CH-CH 2 -N(Me) 2 , -CH 2 -NH-CO-CH=CH 2 -, -CH 2 -NH-CO-CH=CH-CH 2 -N(Me) 2 , -CH 2 -NH-CO-C(=CH 2 )-CH 2 -N(Me) 2 ); -(CH 2 ) m -CO-C 2-6 Alkynyl (e.g., -CO-ethynyl or -CO-ethynyl-Me); or -(CH 2 ) m -NHCO-C 2-6 Alkynyl groups (e.g., -NH-CO-ethynyl) carbocyclyl (e.g., phenyl, cyclobutyl, 2,3-dihydro-1H-inden-2-yl, or bicyclo[1.1.1]pentan-1-yl), heterocyclyl rings (e.g., azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, isoindolin-1-yl, isoindolin-5-yl, tetrahydroisoquinolin-6-yl, diazaspiro[3.4]octan-6-yl, octahydro-2H-pyrazino[1,2-a]pyrazin-2-yl, octahydro-5H-pyrrolo[3,4-c]pyridin-5-yl, 5-oxa-2,8-diazaspiro[3.5]nonan-8-yl, 2,6-diazaspiro[3.4]octane, 9-oxa-3,7-diazabicyclo[3.3.1]nonan-3-yl, tetrahydro -1H-imidazo[4,5-c]pyridin-1-yl, tetrahydro-1'H-spiro[azetidine-3,4'-pyrrolo[1,2-a]pyrazine]-2'(3'H)-yl, tetrahydro-1'H-spiro[azetidine-3,6'-pyrazino[2,1-c][1,4]oxazine]-8'(7'H)-yl, tetrahydro-3H-imidazo[4,5-c]pyridin-3 ... Lahydro-[1,2,4]triazolo[1,5-a]pyrazin-2-yl, tetrahydroimidazo[1,2-a]pyrazin-2-yl, tetrahydropyrazolo[1,5-a]pyrazin-2-yl, octahydro-2H-pyrazino[1,2-a]pyrazin-3-yl, tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3-yl, 2,5,8-triazaspiro[3.5]nonan-8-yl, spiro[azetidin-3,3'-imidazo[1,2-a]imidazol]-1'(2'H)-yl, dihydro-5H-pyrrolo[3,4-b]pyrazin-2-yl, dihydro-5H-pyrrolo[3,4-b]pyridin-3-yl, dihydro-5H-pyrrolo[3,4-b]pyridin-2-yl, dihydro-5H-pyrrolo[3,4-b]pyridin-7-yl, dihydro 5H-pyrrolo[3,4-b]pyridin-5-yl, tetrahydropyrrolo[3,4-d]imidazol-2-yl, dihydro-2H-benzo[b][1,4]oxazin-6-yl, dihydro-2H-benzo[b][1,4]oxazin-7-yl, dihydro-4H-pyrrolo[3,4-d]imidazol-1-yl, diazabicyclo[3.1.1]heptan-6 ...7-yl, dihydro-5H-pyrrolo[3,4-b]pyridin-5-yl, tetrahydropyrrolo[3,4-d]imidazol-2-yl, dihydro-2H-benzo[b][1,4]oxazin-6-yl, dihydro-2H-benzo[b][1,4]oxazin-7-yl, dihydro-4H-pyrrolo[3,4-d]imidazol-1-yl, diazabicyclo[3.1.1]heptan-6-yl, diazabicyclo[3.1.1]heptan-7-yl, dihydro-5H-pyrrolo[3,4-b]pyridin-5-yl, tetrahydropyrrolo[3,4-d]imidazol-2-yl, dihydro-2H-benzo[b][1,4]oxazin-7-yl, dihydro-4H-pyrrolo[3,4-d]imidazol-1-yl, diazabicyclo[3.1.1]heptan-6-yl, diazabicyclo[3.1.1]heptan-7-yl, dihydro-5H-pyrrolo[3,4-b]pyridin-5-yl, tetrahydropyrrolo[3,4-d]imi Cyclo[3.2.1]octan-8-yl, diazabicyclo[2.2.1]heptan-2-yl, dihydro-1H-pyrrolo[3,4-c]pyridin-6-yl, dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-yl, dihydro-4H-pyrrolo[3,4-d]thiazol-2-yl, dihydro-4H-pyrrolo[3,4-d]oxazo-2-yl, tetrahydropyrrolo[3,4 -c]pyrazol-3-yl, diazaspiro[3.3]heptan-6-yl, tetrahydroimidazo[1,2-a]pyridin-6-yl, tetrahydroimidazo[1,2-a]pyridin-7-yl, or spiro[azetidine-3,5'-imidazo[1,2-a]pyrazine]-7'(8'H)-yl), or a heteroaryl ring (e.g. pyridyl or pyrimidinyl). wherein the carbocyclyl, heterocyclyl, or heteroaryl group is selected from the group consisting of halogen (e.g., fluorine); one or more halogens (e.g., -CF 3 or -CHF 2 ), hydroxy (e.g., -CH 2 -OH), or cyano (e.g., -CH 2 C optionally substituted with a -CN) group 1-6 Alkyl (e.g., methyl or ethyl); hydroxy; C 1-6 Alkoxy (e.g., methoxy and -CH 2 -OMe); -CO-C 1-6 Alkyl (e.g., -CO-Me); oxo; C 1-6 Alkylamino (e.g., -N(Me)-(CH 2 ) 2 -N(Me) 2 ; or cyano); In particular, A but, -(CH) optionally substituted with halogen groups 2 ) m -CO-C 2-6 Alkyl (e.g., -CO-CH 2 -Cl); One or more halogen, hydroxy, CO, or -NR x R y Optionally substituted with -(CH 2 ) m -CO-C 2-6 Alkenyl (e.g., -COCH=CH 2 , -CO-C(=CH 2 )-Me, -CO-CH=CH-CH 2 -N(Me) 2 , -CO-C(=CH 2 )-CH 2 -N(Me) 2 , -CO-C(=CH-Me)-CH 2 -N(Me) 2 , -CO-C(=CH 2 )-CH 2 -N(Me) 2 , -CO-C(Cl)=CH-CH 2 -N(Me) 2 , -CO-C(=CH 2 )-CH 2 -OH, -CO-C(=CH 2 )-CH 2 -OC(=O)-Me), -CO-CH=CH-CHF 2 , -CO-C(=CH 2 )-CH 2 -NEt 2 ; -NR x R y Optionally substituted with -(CH 2 ) m -NHCO-C 2-6 Alkenyl (e.g., -NH-CO-CH=CH 2 , -NH-CO-C(=CH 2 )-CH 2 -N(Me) 2 , -NH-CO-C(=CH-Me)-CH 2 -N(Me) 2 , -NH-CO-CH=CH-CH 2 -N(Me) 2 , -CH 2 -NH-CO-CH=CH 2 -, -CH 2 -NH-CO-CH=CH-CH 2 -N(Me) 2 , -CH 2 -NH-CO-C(=CH 2 )-CH 2 -N(Me) 2 ); -(CH 2 ) m -CO-C 2-6 Alkynyl (e.g., -CO-ethynyl or -CO-ethynyl-Me); or -(CH 2 ) m -NHCO-C 2-6 Alkynyl groups (e.g., -NH-CO-ethynyl) heterocyclyl rings (e.g., azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, isoindolin-1-yl, isoindolin-5-yl, tetrahydroisoquinolin-6-yl, diazaspiro[3.4]octan-6-yl, octahydro-2H-pyrazino[1,2-a]pyrazin-2-yl, octahydro-5H-pyrrolo[3,4-c]pyridin-5-yl, 5-oxa-2,8-diazaspiro[3.5]nonan-8-yl, 2,6-diazaspiro[3.4]octane, 9-oxa-3,7-diazabis(2,6-diamino-1,2-diphenyl-2,4-diphenyl ... chloro[3.3.1]nonan-3-yl, tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl, tetrahydro-1'H-spiro[azetidine-3,4'-pyrrolo[1,2-a]pyrazine]-2'(3'H)-yl, tetrahydro-1'H-spiro[azetidine-3,6'-pyrazino[2,1-c][1,4]oxazine]-8'(7'H)-yl, tetrahydro-3H-imidazo[4,5-c]pyridin-3-yl, tetrahydro-[1,2,4]triazolo[1,5-a]pyrazin-2-yl, tetrahydroimidazo[1,2-a]pi 2-yl, tetrahydropyrazolo[1,5-a]pyrazin-2-yl, octahydro-2H-pyrazino[1,2-a]pyrazin-3-yl, tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3-yl, 2,5,8-triazaspiro[3.5]nonan-8-yl, spiro[azetidin-3,3'-imidazo[1,2-a]imidazol]-1'(2'H)-yl, dihydro-5H-pyrrolo[3,4-b]pyrazin-2-yl, dihydro-5H-pyrrolo[3,4-b]pyridin-3-yl, dihydro-5H-pyrrolo[3,4 -b]pyridin-2-yl, dihydro-5H-pyrrolo[3,4-b]pyridin-7-yl, dihydro-5H-pyrrolo[3,4-b]pyridin-5-yl, tetrahydropyrrolo[3,4-d]imidazol-2-yl, dihydro-2H-benzo[b][1,4]oxazin-6-yl, dihydro-2H-benzo[b][1,4]oxazin-7-yl, dihydro-4H-pyrrolo[3,4-d]imidazol-1-yl, diazabicyclo[3.1.1]heptan-6-yl, diazabicyclo[3.2.1]octan-8-yl, diazabicyclo[2.2.1]heptan-2-yl, dihydro-1H-pyrrolo[3,4-c]pyridin-6-yl, dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-yl, dihydro-4H-pyrrolo[3,4-d]thiazol-2-yl, dihydro-4H-pyrrolo[3,4-d]oxazo-2-yl, tetrahydropyrrolo[3,4-c]pyrazol-3-yl, diazaspiro[3.3]heptan-6-yl, tetrahydroimidazo[1,2-a]pyridin-6-yl, tetrahydroimidazo[1,2-a]pyridin-7-yl, or spiro[azetidin-3,5'-imidazo[1,2-a]pyrazine]-7'(8'H)-yl). wherein the heterocyclyl or heteroaryl group is selected from the group consisting of halogen (e.g., fluorine); one or more halogens (e.g., -CF 3 or -CHF 2 ), hydroxy (e.g., -CH 2 -OH), or cyano (e.g., -CH 2 C optionally substituted with a -CN) group 1-6 Alkyl (e.g., methyl or ethyl), hydroxy, C 1-6 Alkoxy (e.g., methoxy and -CH 2 -OMe), -CO-C 1-6 Alkyl (e.g., -CO-Me), oxo, C 1-6 Alkylamino (e.g., -N(Me)-(CH 2 ) 2 -N(Me) 2 ), or cyano); More particularly, the ring A but, One or more halogen, hydroxy, CO, or -NR x R y Optionally substituted with -(CH 2 ) m -CO-C 2-6 Alkenyl (e.g., -COCH=CH 2 , -CO-C(=CH 2 )-Me, -CO-CH=CH-CH 2 -N(Me) 2 , -CO-C(=CH 2 )-CH 2 -N(Me) 2 , -CO-C(=CH-Me)-CH 2 -N(Me) 2 , -CO-C(=CH 2 )-CH 2 -N(Me) 2 , -CO-C(Cl)=CH-CH 2 -N(Me) 2 , -CO-C(=CH 2 )-CH 2 -OH, -CO-C(=CH 2 )-CH 2 -OC(=O)-Me), -CO-CH=CH-CHF 2 , -CO-C(=CH 2 )-CH 2 -NEt 2 dihydro-5H-pyrrolo[3,4-b]pyridinyl, for example dihydro-5H-pyrrolo[3,4-b]pyridin-3-yl, dihydro-5H-pyrrolo[3,4-b]pyridin-2-yl, dihydro-5H-pyrrolo[3,4-b]pyridin-7-yl or dihydro-5H-pyrrolo[3,4-b]pyridin-5-yl, each of which is substituted by wherein the heterocyclyl group is selected from the group consisting of halogen (e.g., fluorine); one or more halogens (e.g., -CF 3 or -CHF 2 ), hydroxy (e.g., -CH 2 -OH), or cyano (e.g., -CH 2 C optionally substituted with a -CN) group 1-6 Alkyl (e.g., methyl or ethyl), hydroxy, C 1-6 Alkoxy (e.g., methoxy and -CH 2 -OMe), -CO-C 1-6 Alkyl (e.g., -CO-Me), oxo, C 1-6 Alkylamino (e.g., -N(Me)-(CH 2 ) 2 -N(Me) 2 ), or cyano); In particular, A But -COCH=CH 2 dihydro-5H-pyrrolo[3,4-b]pyridinyl, for example dihydro-5H-pyrrolo[3,4-b]pyridin-3-yl, dihydro-5H-pyrrolo[3,4-b]pyridin-2-yl, dihydro-5H-pyrrolo[3,4-b]pyridin-7-yl or dihydro-5H-pyrrolo[3,4-b]pyridin-5-yl, each of which is substituted by More particularly, the ring A -COCH=CH 2 represents dihydro-5H-pyrrolo[3,4-b]pyridin-2-yl substituted by More particularly, the ring A -COCH=CH 2 represents 6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-2-yl substituted by The compound of claim 4.

6. R 2 Ga-ring B -Y-ring C The compound according to any one of claims 1 to 3, which represents

7. ring B However, each of them is hydroxy, oxo, C 1-6 Alkyl (e.g., methyl), haloC 1-6 Alkyl (e.g., -CH 2 7. The compound according to claim 6, wherein the aryl group represents a carbocyclyl (e.g. cyclohexyl or phenyl), a heterocyclyl (e.g. azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, diazepanyl or hexahydropyrrolo[3,4-b][1,4]oxazin-6(2H)-yl), or a heteroaryl (e.g. imidazolyl, pyrazolyl, triazolyl, pyridinyl, pyrimidinyl, oxazolyl or oxadiazolyl), which may be optionally substituted by one or more (e.g. one, two or three) substituents selected from: -F), cyano, or halogen (e.g. fluorine).

8. Y is a bond, -O-, -NHCO-, CO, or one or more C 1-6 Alkyl, C 2-6 Alkenyl, -NR x , C optionally substituted with O, hydroxy, or CO groups; 1 -C 6 Alkylene groups (e.g., -CO-C(=CH 2 )-CH 2 - or -NHCO-CH=CH-CH 2 8. The compound of claim 1, wherein Y represents a bond or Y represents -O-.

9. ring C represents a monocyclic heterocyclyl ring having at least one nitrogen atom, in a further embodiment, the ring C each of which is a halogen (e.g., fluorine), C 1-6 Alkyl (e.g., methyl), -CO-C 1-6 Alkyl (e.g., -CO-methyl), and / or -NR x R y Optionally substituted with -(CH 2 ) m -CO-C 2-6 Alkenyl (e.g., -COCH=CH 2 , -CO-C(=CH 2 )-CH 2 -N(Me) 2 , -CO-C(=CH-Me)-CH 2 -N(Me) 2 or -CO-CH=CH-CH 2 -N(Me) 2 9. The compound according to claim 1, wherein the aryl group is azetidinyl, pyrrolidinyl, piperazinyl or tetrahydropyridinyl, each of which is substituted by .

10. X is a bond or one or more C 1-6 Alkyl (e.g., methyl), -NR x (e.g., -NH or -N-methyl), O, hydroxy, halogen (e.g., fluorine), or C0 groups optionally substituted. 1 -C 4 10. The compound according to any one of claims 1 to 9, which represents an alkylene group.

11. X is -CH 2 10. The compound according to any one of claims 1 to 9, wherein

12. X is 1 or more C 1-6 Alkyl (e.g., -(CH 2 )-C(Me)-), O(e.g., -(CH 2 ) 2 -O-, -(CH 2 ) 3 -O- or -(CH 2 ) 2 -O-CH 2 -), or CO (e.g., -(CH 2 )-CO- or -(CH 2 ) 2 -CO-), -NR x (For example, -(CH 2 ) 2 -NH-, -(CH 2 ) 3 -NH-, -(CH 2 ) 2 -N(Me)- or -(CH 2 ) 3 -N(Me)-) groups, or CO and -NR x Groups (e.g., -(CH 2 ) 2 -N(Me)-CO-), or hydroxy and -NR x Groups (e.g., -(CH 2 )-CH(OH)-CH 2 -N(Me)-, or halogen (e.g., -(CH 2 ) 3 -CHF-, -(CH 2 ) 2 -CHF-CH 2 - or -CH 2 -CHF-(CH 2 ) 2 C optionally replaced by -) 1 -C 4 Alkylene groups (e.g., -CH 2 -, -(CH 2 ) 2 -, -(CH 2 ) 3 - or -(CH 2 ) 4 10. The compound according to any one of claims 1 to 9, wherein:

13. X is a bond, -CH 2 -, -(CH 2 ) 2 -, -(CH 2 ) 3 -, -(CH 2 ) 4 -, -(CH 2 )-C(Me)-, -(CH 2 ) 2 -O-, -(CH 2 ) 3 -O-, -(CH 2 ) 2 -O-CH 2 -, -(CH 2 )-CO-, -(CH 2 ) 2 -CO-, -(CH 2 ) 2 -NH-, -(CH 2 ) 3 -NH-, -(CH 2 ) 2 -N(Me)-, -(CH 2 ) 3 -N(Me)-, -(CH 2 ) 2 -N(Me)-CO-, -(CH 2 )-CH(OH)-CH 2 -N(Me)-, -(CH 2 ) 3 -CHF-, -(CH 2 ) 2 -CHF-CH 2 - or -CH 2 -CHF-(CH 2 ) 2 10. The compound according to any one of claims 1 to 9, wherein

14. -XR 2 But -C 1 -C 10 Alkylene-NR x R y A group, wherein the alkylene group is one or more C 2-6 Alkenyl, NR x , O, or CO groups), for example, -(CH 2 ) 2 -O-(CH 2 ) 2 -NH-CO-C(=CH 2 )-CH 2 -N(Me) 2 , -(CH 2 ) 5 -NH-CO-CH=CH-CH 2 -N(Me) 2 , -(CH 2 ) 5 -NH-CO-C(=CH 2 )-CH 2 -N(Me) 2 , -(CH 2 ) 4 -NHCOCH=CH-CH 2 -NMe 2 , or -CH 2 -CHF-(CH 2 ) 3- NHCO-CH=CHCH 2 NMe 2 , -(CH 2 ) 3 -CHF-CH 2 NHCO-CH=CHCH 2 NMe 2 , or -(CH 2 ) 3 -CF 2 -CH 2 NHCO-CH=CHCH 2 NMe 2 The compound according to any one of claims 1 to 13, wherein

15. R 3 is hydrogen or C 1-6 alkyl (e.g., methyl or ethyl), e.g., R 3 is hydrogen or C 1-6 alkyl (e.g., methyl), in particular R 3 C 1-6 alkyl (e.g., methyl), in particular R 3 15. The compound according to any one of claims 1 to 14, wherein represents methyl.

16. R 4 but, hydrogen; C 1-6 alkyl (e.g., methyl or ethyl); C 2-6 Alkenyl (e.g., ethenyl); 1-6 Alkoxy (e.g., methoxy); halogens (e.g., chlorine); or -NR x R y (For example, -N(Me) 2 or -N(Me)(Et) : stands for For example, R 4 C 1-6 alkyl (e.g., methyl), in particular R 4 represents methyl, 16. The compound according to any one of claims 1 to 15.

17. R 5 but, hydrogen; halogens (e.g., chlorine); or C 1-6 Alkyl (e.g., methyl) represents For example, R 5 represents hydrogen, 17. The compound according to any one of claims 1 to 16.

18. R 6 but, C 1-6 Alkyl (e.g., methyl, ethyl, or isopropyl); C 2-6 Alkenyl (e.g., -C(=CH 2 )(Me)); halogens (e.g. bromine); HaroC 1-6 Alkyl (e.g., trifluoromethyl or -C(H)(Me)-CF 3 ); or HaroC 1-6 Alkoxy (e.g., difluoromethoxy) represents For example, R 6 HaroC 1-6 alkyl (e.g. trifluoromethyl), in particular R 6 represents trifluoromethyl; A compound according to any one of claims 1 to 17.

19. R 7 19. The compound according to any one of claims 1 to 18, wherein represents hydrogen or cyano, e.g. hydrogen.

20. R x and R y are independently hydrogen or C 1-6 alkyl (e.g., methyl or ethyl), e.g., R x and R y C independently 1-6 alkyl (e.g., methyl), in particular R x and R y Both are C 1-6 20. The compound according to any one of claims 1 to 19, which represents alkyl (e.g. methyl).

21. Formula (I) a or a tautomeric or stereochemically isomeric form, a pharma- ceutically acceptable salt, or solvate thereof: 【Chemistry 2】 (where n, R 1 , X, R 2 , and R 3 is as defined in claim 1) 2. The compound of claim 1, wherein

22. 2. The compound of claim 1, wherein the compound is a free base of a compound of Examples 1-332, or a pharma- ceutically acceptable salt or solvate thereof.

23. A pharmaceutical composition comprising a compound of formula (I) according to any one of claims 1 to 22.

24. 23. A pharmaceutical composition comprising a compound of formula (I) as defined in any one of claims 1 to 22 in combination with one or more therapeutic agents.

25. A compound according to any one of claims 1 to 22 for use in therapy.

26. A compound according to any one of claims 1 to 22 for use in the prevention or treatment of cancer.

27. A process for preparing a compound of formula (I) as defined herein, comprising: (a) a compound of formula (II); 【Chemistry 3】 (In the formula, R 1 , n, X, R 3 , R 4 , R 5 , R 6 , R 7 ,ring A , and ring C is as defined in claim 1, and P 1 represents a suitable protecting group, e.g., Boc) Deprotection of; (b) A compound of formula (III): 【Chemistry 4】 (R in the formula 1 , n, R 3 , R 4 , R 5 , R 6 , and R 7 is as defined in claim 1) with the formula L 1 -XR 2 wherein X and R 2 is as defined in claim 1, and L 1 represents a suitable leaving group, for example a halogen (i.e., chlorine) or a hydroxy group. reacting with; (c) deprotection of a protected derivative of a compound of formula (I); (d) interconversion of a compound of formula (I) or a protected derivative thereof to a further compound of formula (I) or a protected derivative thereof; and (e) the optional formation of a pharma- ceutically acceptable salt of a compound of formula (I). The method comprising: